================================================================================
COLLECTED CLINICAL TRIALS REPORT
================================================================================
Collection Date: 2025-07-17 11:26:23
Total Studies: 305
Filter Criteria: Studies with publications AND posted results
--------------------------------------------------------------------------------

1. Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy
   NCT ID: NCT02731729
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma
   Intervention: ipilimumab; nivolumab
   Sponsor: Parker Institute for Cancer Immunotherapy
   Start Date: 2016-06-21
   Completion Date: 2019-02-13
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02731729
   Summary: The purpose of this research study is to learn whether patients whose disease grows after being treated with nivolumab or pembrolizumab respond to ipilimumab (Yervoy®) alone or in combination with nivolumab (Opdivo®).
   Locations: University of California, Los Angeles, Los Angeles, United States; University of California, San Francisco, San Francisco, United States; Memorial Sloan Kettering Basking Ridge, Basking Ridge, United States
              ... and 4 more locations
----------------------------------------

2. Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)
   NCT ID: NCT02362594
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE3
   Condition: Melanoma
   Intervention: pembrolizumab; placebo
   Sponsor: Merck Sharp & Dohme LLC
   Start Date: 2015-07-16
   Completion Date: 2026-07-31
   Has Posted Results: True
   Publications Count: 7
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02362594
   Summary: This study will assess whether post-surgery therapy with pembrolizumab improves recurrence-free survival (RFS) as compared to placebo for high-risk participants with melanoma (Stage IIIA \[\> 1 mm metastasis\], IIIB and IIIC). The study will also assess whether pembrolizumab improves RFS versus plac...
----------------------------------------

3. Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous Melanoma
   NCT ID: NCT00896480
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma
   Intervention: Immunotherapeutic GSK2132231A
   Sponsor: GlaxoSmithKline
   Start Date: 2009-05-19
   Completion Date: 2014-11-03
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00896480
   Summary: The clinical objective of this clinical trial is to examine the clinical activity in terms of tumor response and time to treatment failure of the immunotherapeutic product GSK2132231A when given to patients with unresectable and progressive metastatic cutaneous melanoma. The safety of the treatment ...
   Locations: GSK Investigational Site, Brussels, Belgium; GSK Investigational Site, Brussel, Belgium; GSK Investigational Site, Wilrijk, Belgium
              ... and 5 more locations
----------------------------------------

4. Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma
   NCT ID: NCT01967576
   Status: COMPLETED
   Phase: PHASE2
   Condition: Pheochromocytoma; Paraganglioma
   Intervention: Axitinib (AG-013736)
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2013-10-19
   Completion Date: 2020-12-01
   Has Posted Results: True
   Publications Count: 4
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01967576
   Summary: Background:

* Most treatments for malignant pheochromocytomas/paragangliomas (PHEO/PGL) are palliative and multidisciplinary. Chemotherapy using the combination of cyclophosphamide, vincristine, and dacarbazine has been successfully utilized in the management of rapidly progressive metastatic PHEO,...
   Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, United States
----------------------------------------

5. A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma
   NCT ID: NCT01069627
   Status: COMPLETED
   Phase: PHASE2
   Condition: Malignant Melanoma
   Intervention: bevacizumab [Avastin]; fotemustine
   Sponsor: Hoffmann-La Roche
   Start Date: 2006-12
   Completion Date: 2009-07
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01069627
   Summary: This study will investigate the efficacy and safety of bevacizumab + fotemustine in patients with stage IV melanoma, previously untreated with chemo- or immunotherapy for metastatic disease. Patients will receive Avastin (15mg/kg intravenously\[IV\]) on Day 1 of every 3 week cycle, in combination wi...
----------------------------------------

6. Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
   NCT ID: NCT00019682
   Status: COMPLETED
   Phase: PHASE3
   Condition: Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma
   Intervention: Aldesleukin; gp100 Antigen; Montanide ISA 51 VG; Quality-of-Life Assessment; Questionnaire Administration; Laboratory Biomarker Analysis
   Sponsor: National Cancer Institute (NCI)
   Start Date: 1999-12
   Completion Date: 2011-05
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00019682
   Summary: This randomized phase III trial studies aldesleukin with vaccine therapy to see how well it works compared to aldesleukin alone in treating patients with melanoma that has spread from where it started to nearby tissue or lymph nodes or to other places in the body. Aldesleukin may stimulate a person'...
   Locations: University of Alabama at Birmingham, Birmingham, United States; Mayo Clinic in Arizona, Scottsdale, United States; Kaiser Permanente Medical Center, Riverside, United States
              ... and 16 more locations
----------------------------------------

7. 68Ga-DOTATATE PET Scan in Neuroendocrine Cancer
   NCT ID: NCT01396382
   Status: COMPLETED
   Phase: PHASE2
   Condition: Neuroendocrine Carcinoma
   Intervention: 68Ga-DOTATATE PET scan
   Sponsor: Vanderbilt-Ingram Cancer Center
   Start Date: 2010-03
   Completion Date: 2014-12
   Has Posted Results: True
   Publications Count: 2
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01396382
   Summary: Neuroendocrine cancer is an unusual disease and often goes undetected by routine imaging. The 68Ga-DOTATATE PET scan is a new generation of scans that might have improved sensitivity and resolution specifically for neuroendocrine tumors. The investigators will scan people with this cancer and compar...
   Locations: Vanderbilt University Medical Center, Nashville, United States
----------------------------------------

8. QUILT-3.006 for Recurrent Medullary Thyroid Cancer
   NCT ID: NCT01856920
   Status: COMPLETED
   Phase: PHASE2
   Condition: Medullary Thyroid Cancer (MTC)
   Intervention: GI-6207 [Recombinant Saccharomyces cerevisiae-CEA (610D)]
   Sponsor: NantCell, Inc.
   Start Date: 2013-03-26
   Completion Date: 2018-05-08
   Has Posted Results: True
   Publications Count: 4
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01856920
   Summary: Background:

- GI-6207 is an experimental cancer vaccine made with baker's yeast. The yeast has been modified to help the immune system target a protein called CEA. CEA is found on the surface of some kinds of tumor cells, including thyroid cancer cells. Researchers want to see if GI-6207 can encour...
   Locations: NIH Clinical Center, Bethesda, United States
----------------------------------------

9. Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery
   NCT ID: NCT00700882
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma (Skin)
   Intervention: dasatinib
   Sponsor: Eastern Cooperative Oncology Group
   Start Date: 2009-07-02
   Completion Date: 2020-12-28
   Has Posted Results: True
   Publications Count: 2
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00700882
   Summary: RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

PURPOSE: This phase II trial is studying how well dasatinib works in treating patients with locally advanced or metastatic mucosal melanoma or acral melanoma.
   Locations: Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, United States; Stanford Cancer Center, Stanford, United States; Michael and Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital, Fort Lauderdale, United States
              ... and 148 more locations
----------------------------------------

10. Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors
   NCT ID: NCT01560260
   Status: COMPLETED
   Phase: PHASE2
   Condition: Carney Complex; Chondrosarcoma; Gastrointestinal Stromal Tumor; Paraganglioma
   Intervention: Laboratory Biomarker Analysis; Linsitinib; Pharmacological Study
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2012-03
   Completion Date: 2015-10
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01560260
   Summary: This phase II trial studies how well linsitinib works in treating younger and adult patients with gastrointestinal stromal tumors. Linsitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
   Locations: Stanford Cancer Institute, Palo Alto, United States; University of Iowa/Holden Comprehensive Cancer Center, Iowa City, United States; National Institutes of Health Clinical Center, Bethesda, United States
              ... and 5 more locations
----------------------------------------

11. RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma
   NCT ID: NCT00113360
   Status: COMPLETED
   Phase: PHASE2
   Condition: Neuroendocrine Carcinoma; Islet Cell Carcinoma
   Intervention: RAD001; Octreotide Depot
   Sponsor: M.D. Anderson Cancer Center
   Start Date: 2005-01
   Completion Date: 2009-07
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00113360
   Summary: Objectives:

Primary endpoint:

-Assess the clinical activity of RAD 001 plus depot octreotide as defined by progression free survival (PFS) duration defined by RECIST criteria in treated and untreated patients with metastatic, unresectable low grade neuroendocrine carcinoma.

Secondary endpoints:

...
   Locations: UT MD Anderson Cancer Center, Houston, United States
----------------------------------------

12. Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma
   NCT ID: NCT02211131
   Status: COMPLETED
   Phase: PHASE2
   Condition: Completely Resectable Stage IIIB, IIIC, or IVM1a Melanoma
   Intervention: Talimogene Laherparepvec; Immediate surgical resection of melanoma lesion(s)
   Sponsor: Amgen
   Start Date: 2015-02-03
   Completion Date: 2022-04-28
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02211131
   Summary: This is a phase 2, multicenter, randomized, open-label study to estimate the efficacy of talimogene laherparepvec as a neoadjuvant treatment followed by surgery compared to surgery alone in subjects with completely resectable stage IIIB, IIIC, or IVM1a melanoma.
   Locations: Research Site, Birmingham, United States; Research Site, Duarte, United States; Research Site, Orange, United States
              ... and 43 more locations
----------------------------------------

13. Trametinib With GSK2141795 in BRAF Wild-type Melanoma
   NCT ID: NCT01941927
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma
   Intervention: Trametinib (GSK1120212); GSK2141795
   Sponsor: Adil Daud
   Start Date: 2013-09-10
   Completion Date: 2017-05-03
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01941927
   Summary: This is a multicenter phase II clinical study of trametinib in combination with GSK2141795 in patients with BRAF wild-type mutation melanoma. All patients will receive continuous dosing of trametinib (2 mg) in combination with GSK2141795 (25 mg) oral daily until progression of disease, withdrawal of...
   Locations: University of California, San Francisco, San Francisco, United States; Memorial Sloan-Kettering Cancer Center, New York, United States
----------------------------------------

14. Survivorship Promotion In Reducing IGF-1 Trial
   NCT ID: NCT02431676
   Status: COMPLETED
   Phase: PHASE2
   Condition: Breast Cancer; Prostate Cancer; Lung Cancer; Colon Cancer; Melanoma of Skin; Endometrial Cancer; Liver Cancer; Pancreatic Cancer; Rectal Cancer; Kidney Cancer; Other Solid Malignant Tumors
   Intervention: Metformin; Coach Directed Behavioral Weight Loss; Self-control weight loss
   Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
   Start Date: 2015-05
   Completion Date: 2018-12
   Has Posted Results: True
   Publications Count: 5
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02431676
   Summary: This is a prospective, single-center randomized trial with three arms, and an allocation ratio of 1:1:1. The study design is an efficacy study to evaluate the effect of metformin and coach-directed behavioral weight loss versus self-directed weight loss on insulin-like growth factor (IGF)-1 and IGF-...
   Locations: Johns Hopkins ProHealth, Baltimore, United States
----------------------------------------

15. Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor
   NCT ID: NCT01037127
   Status: COMPLETED
   Phase: PHASE2
   Condition: Cancer
   Intervention: GSK1120212
   Sponsor: GlaxoSmithKline
   Start Date: 2009-11
   Completion Date: 2013-01
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01037127
   Summary: MEK113583 is a Phase II open-label, multi-site study to investigate the objective response rate, safety, and pharmacokinetics of GSK1120212 in subjects with BRAF mutation-positive melanoma who were previously treated with or without a BRAF inhibitor. GSK1120212 is a potent and highly selective inhib...
   Locations: GSK Investigational Site, Los Angeles, United States; GSK Investigational Site, Aurora, United States; GSK Investigational Site, New York, United States
              ... and 7 more locations
----------------------------------------

16. An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma
   NCT ID: NCT01368276
   Status: COMPLETED
   Phase: PHASE3
   Condition: Melanoma
   Intervention: Talimogene Laherparepvec; Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)
   Sponsor: BioVex Limited
   Start Date: 2010-10
   Completion Date: 2014-09
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01368276
   Summary: The purpose of this study is to learn about the safety and the risks of using talimogene laherparepvec in patients who already received treatment with talimogene laherparepvec in study 005/05 (NCT00769704), and to see if extended treatment with talimogene laherparepvec can destroy melanoma tumors.
   Locations: Rush University Medical Center, Chicago, United States; Indiana University, Indianapolis, United States; University of Iowa Hospitals & Clinics, Iowa City, United States
              ... and 7 more locations
----------------------------------------

17. Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
   NCT ID: NCT00569127
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE3
   Condition: Colorectal Neuroendocrine Tumor G1; Gastric Neuroendocrine Tumor G1; Neuroendocrine Neoplasm; Neuroendocrine Tumor; Neuroendocrine Tumor G2
   Intervention: Bevacizumab; Laboratory Biomarker Analysis; Octreotide Acetate; Recombinant Interferon Alfa-2b
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2007-12-01
   Completion Date: 2026-01-31
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00569127
   Summary: This randomized phase III trial studies octreotide acetate and recombinant interferon alfa-2b to see how well it works compared to octreotide acetate and bevacizumab in treating patients with high-risk neuroendocrine tumors that have spread to other places in the body (metastatic) or spread from whe...
   Locations: Providence Hospital, Mobile, United States; Fairbanks Memorial Hospital, Fairbanks, United States; Mercy Hospital Fort Smith, Fort Smith, United States
              ... and 493 more locations
----------------------------------------

18. Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma
   NCT ID: NCT02500576
   Status: COMPLETED
   Phase: PHASE2
   Condition: Metastatic Melanoma; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7
   Intervention: Aldesleukin; Cyclophosphamide; Fludarabine Phosphate; Laboratory Biomarker Analysis; Pembrolizumab; Quality-of-Life Assessment; Therapeutic Tumor Infiltrating Lymphocytes
   Sponsor: M.D. Anderson Cancer Center
   Start Date: 2015-08-07
   Completion Date: 2022-10-12
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02500576
   Summary: This randomized phase II trial studies how well giving pembrolizumab with standard chemotherapy, tumor infiltrating lymphocytes (TIL), and aldesleukin works in treating patients with melanoma that has spread to other areas of the body. Immunotherapy with monoclonal antibodies, such as pembrolizumab,...
   Locations: M D Anderson Cancer Center, Houston, United States
----------------------------------------

19. Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut
   NCT ID: NCT00171873
   Status: COMPLETED
   Phase: PHASE3
   Condition: Neuroendocrine Tumors
   Intervention: Octreotide LAR (Long-acting release); Placebo
   Sponsor: Carmen Schade-Brittinger
   Start Date: 2001-09
   Completion Date: 2013-12
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00171873
   Summary: Placebo-controlled prospective randomized phase III study to investigate the antiproliferative effect of octreotide in patients with metastasized neuroendocrine tumors of the midgut
   Locations: Novartis Investigative Site, Bochum, Germany; Novartis Investigative Site, Dresden, Germany; Novartis Investigative Site, Halle, Germany
              ... and 7 more locations
----------------------------------------

20. A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain
   NCT ID: NCT02308020
   Status: COMPLETED
   Phase: PHASE2
   Condition: Breast Cancer; Non-small Cell Lung Cancer; Melanoma; Brain Metastases
   Intervention: Abemaciclib
   Sponsor: Eli Lilly and Company
   Start Date: 2015-04-20
   Completion Date: 2019-11-08
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02308020
   Summary: The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as abemaciclib in participants with hormone receptor positive breast cancer, non-small cell lung cancer (NSCLC), or melanoma that has spread to the brain.
   Locations: City of Hope National Medical Center, Duarte, United States; University of California - San Diego, La Jolla, United States; Univ of California San Francisco, San Francisco, United States
              ... and 41 more locations
----------------------------------------

21. Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma
   NCT ID: NCT00256282
   Status: COMPLETED
   Phase: PHASE2
   Condition: Metastatic Melanoma
   Intervention: Vinorelbine; Docetaxel; Sargramostim
   Sponsor: John P. Fruehauf
   Start Date: 2003-04
   Completion Date: 2012-08
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00256282
   Summary: This is a Phase II Evaluation of Docetaxel and Vinorelbine Plus Sargramostim in subjects who have metastatic melanoma which has advanced beyond the point at which local therapies such as surgery or radiation therapy would be helpful. Without effective treatment, metastatic melanoma is usually a seve...
   Locations: Chao Family Comprehensive Cancer Center, Orange, United States
----------------------------------------

22. CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext)
   NCT ID: NCT01636882
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma
   Intervention: CVA21
   Sponsor: Viralytics
   Start Date: 2012-07-03
   Completion Date: 2016-04-06
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01636882
   Summary: This is an extended use study for patients who have received 10 doses of CAVATAK™ in the VLA 007 trial. There may be patients who have benefitted from the study drug and who might benefit from further treatment. In order to accommodate those patients further treatment to complete 48 weeks of CVA21 i...
   Locations: Oncology Specialists, Park Ridge, United States; Providence Medical Centre, Portland, United States; Mary Crowley Medical Center, Dallas, United States
              ... and 1 more locations
----------------------------------------

23. A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours
   NCT ID: NCT02402062
   Status: COMPLETED
   Phase: PHASE2
   Condition: Neuroendocrine Tumors; Pancreatic Neoplasms
   Intervention: TH-302 + Sunitinib
   Sponsor: Grupo Espanol de Tumores Neuroendocrinos
   Start Date: 2015-05-11
   Completion Date: 2020-01-10
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02402062
   Summary: The purpose of this study is to determine the safety and the efficacy of the combination of the drugs TH-302 and sunitinib in metastatic neuroendocrine tumours.
   Locations: Institut Catalá d'Oncologia L'Hospitalet, L'Hospitalet de Llobregat, Spain; Hospital Universitario Marqués de Valdecilla, Santander, Spain; Hospital Provincial de Castellón, Castelló, Spain
              ... and 7 more locations
----------------------------------------

24. GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma
   NCT ID: NCT01245062
   Status: COMPLETED
   Phase: PHASE3
   Condition: Melanoma
   Intervention: GSK1120212; Chemotherapy
   Sponsor: GlaxoSmithKline
   Start Date: 2010-11-22
   Completion Date: 2016-12-16
   Has Posted Results: True
   Publications Count: 6
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01245062
   Summary: This is a two-arm, open-label, randomized Phase III study comparing single agent GSK1120212 to chemotherapy (either dacarbazine or paclitaxel) in subjects with Stage IIIc or Stage IV malignant cutaneous melanoma. All subjects must have a BRAF mutation-positive tumour sample. Subjects who have receiv...
   Locations: GSK Investigational Site, Tucson, United States; GSK Investigational Site, Fort Myers, United States; GSK Investigational Site, Athens, United States
              ... and 109 more locations
----------------------------------------

25. Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma
   NCT ID: NCT00539591
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Malignant Melanoma
   Intervention: Peginterferon alfa-2b; Temozolomide; Recombinant interferon alfa-2b
   Sponsor: St. Jude Children's Research Hospital
   Start Date: 2008-05-09
   Completion Date: 2026-05
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00539591
   Summary: The main goal of this study is to estimate the tumor response rate of temozolomide administered in combination with peginterferon alfa-2b to pediatric patients with unresectable Stage III, metastatic, or recurrent cutaneous melanoma.
   Locations: Rady Children's Hospital, San Diego, United States; St. Jude Children's Research Hospital, Memphis, United States; The Children's Cancer Hospital at UT M.D. Anderson Cancer Center, Houston, United States
----------------------------------------

26. Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
   NCT ID: NCT03070392
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Uveal Melanoma
   Intervention: IMCgp100; Dacarbazine; Ipilimumab; Pembrolizumab
   Sponsor: Immunocore Ltd
   Start Date: 2017-10-16
   Completion Date: 2025-07
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03070392
   Summary: To evaluate the overall survival of HLA-A\*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investigator's Choice of dacarbazine, ipilimumab, or pembrolizumab.
   Locations: UCLA Medical Center, Los Angeles, United States; The Angeles Clinic and Research Institute, Los Angeles, United States; Byers Eye Institute, Stanford University, Palo Alto, United States
              ... and 54 more locations
----------------------------------------

27. A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
   NCT ID: NCT01227889
   Status: COMPLETED
   Phase: PHASE3
   Condition: Cancer
   Intervention: GSK2118436; Dacarbazine (DTIC)
   Sponsor: GlaxoSmithKline
   Start Date: 2010-12-23
   Completion Date: 2016-09-16
   Has Posted Results: True
   Publications Count: 6
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01227889
   Summary: BRF113683 is a Phase III, randomized, open-label study comparing the efficacy, safety, and tolerability of GSK2118436 to dacarbazine (DTIC), in subjects with BRAF mutant advanced (Stage III) or metastatic (Stage IV) melanoma. Subjects will be randomized to receive 150 mg of GSK2118436 twice daily or...
   Locations: GSK Investigational Site, Birmingham, United States; GSK Investigational Site, Mobile, United States; GSK Investigational Site, La Jolla, United States
              ... and 91 more locations
----------------------------------------

28. Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
   NCT ID: NCT02867592
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Adrenal Cortical Carcinoma; Alveolar Soft Part Sarcoma; Central Nervous System Neoplasm; Childhood Clear Cell Sarcoma of Soft Tissue; Clear Cell Sarcoma of Soft Tissue; Ewing Sarcoma; Hepatoblastoma; Hepatocellular Carcinoma; Osteosarcoma; Recurrent Adrenal Cortical Carcinoma; Recurrent Alveolar Soft Part Sarcoma; Recurrent Clear Cell Sarcoma of Soft Tissue; Recurrent Ewing Sarcoma; Recurrent Hepatoblastoma; Recurrent Hepatocellular Carcinoma; Recurrent Kidney Wilms Tumor; Recurrent Malignant Solid Neoplasm; Recurrent Osteosarcoma; Recurrent Primary Malignant Central Nervous System Neoplasm; Recurrent Renal Cell Carcinoma; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Recurrent Thyroid Gland Medullary Carcinoma; Refractory Adrenal Cortical Carcinoma; Refractory Alveolar Soft Part Sarcoma; Refractory Clear Cell Sarcoma of Soft Tissue; Refractory Ewing Sarcoma; Refractory Hepatoblastoma; Refractory Hepatocellular Carcinoma; Refractory Malignant Solid Neoplasm; Refractory Osteosarcoma; Refractory Primary Central Nervous System Neoplasm; Refractory Primary Malignant Central Nervous System Neoplasm; Refractory Renal Cell Carcinoma; Refractory Rhabdomyosarcoma; Refractory Soft Tissue Sarcoma; Refractory Thyroid Gland Medullary Carcinoma; Refractory Wilms Tumor; Renal Cell Carcinoma; Rhabdomyosarcoma; Soft Tissue Sarcoma; Solid Neoplasm; Thyroid Gland Medullary Carcinoma; Wilms Tumor
   Intervention: Cabozantinib; Cabozantinib S-malate; Pharmacological Study
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2017-05-18
   Completion Date: 2026-06-27
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02867592
   Summary: This phase II trial studies how well cabozantinib-s-malate works in treating younger patients with sarcomas, Wilms tumor, or other rare tumors that have come back, do not respond to therapy, or are newly diagnosed. Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzy...
   Locations: Children's Hospital of Alabama, Birmingham, United States; Providence Alaska Medical Center, Anchorage, United States; Arkansas Children's Hospital, Little Rock, United States
              ... and 139 more locations
----------------------------------------

29. Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)
   NCT ID: NCT02299089
   Status: COMPLETED
   Phase: PHASE2
   Condition: Acromegaly; Neuroendocrine Tumors
   Intervention: octreotide FluidCrystal® injection depot
   Sponsor: Camurus AB
   Start Date: 2015-01
   Completion Date: 2016-06
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02299089
   Summary: This is a Phase II, open-label multicentre, randomised study to assess the PK, PD, efficacy, and safety of two dosing regimens of CAM2029 in adult patients with acromegaly or a functional, well-differentiated NET, with carcinoid symptoms.
   Locations: Hospices Civils de Lyon, Bron, France; CHU Rouen, Hôpital Charles Nicolle, Rouen cedex, France; Abteilung: Klinische Studien, Bad Berka, Germany
              ... and 7 more locations
----------------------------------------

30. Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
   NCT ID: NCT01121562
   Status: COMPLETED
   Phase: PHASE2
   Condition: Pancreatic Neuroendocrine Tumors
   Intervention: Sunitinib
   Sponsor: Pfizer
   Start Date: 2010-07
   Completion Date: 2013-11
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01121562
   Summary: The purpose of the study is to evaluate the effect of Sunitinib on the clinical benefit response rate.
   Locations: Aichi Cancer Center Central Hospital, Nagoya, Japan; National Cancer Center Hospital, Chuo-ku, Japan; Kyushu University Hospital, Fukuoka, Japan
              ... and 1 more locations
----------------------------------------

31. Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab
   NCT ID: NCT01515189
   Status: COMPLETED
   Phase: PHASE3
   Condition: Melanoma
   Intervention: Ipilimumab
   Sponsor: Bristol-Myers Squibb
   Start Date: 2012-02-17
   Completion Date: 2017-08-17
   Has Posted Results: True
   Publications Count: 3
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01515189
   Summary: The purpose of this study is to determine whether giving Ipilimumab at a dose of 10mg/kg will extend the lives of subjects with unresectable or metastatic melanoma more than giving Ipilimumab at a dose of 3 mg/kg
   Locations: The Angeles Clinic And Research Institute, Los Angeles, United States; University Of California Los Angeles, Los Angeles, United States; Baptist Cancer Institute, Jacksonville, United States
              ... and 85 more locations
----------------------------------------

32. Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma
   NCT ID: NCT00679289
   Status: COMPLETED
   Phase: PHASE2
   Condition: Metastatic Melanoma; Cutaneous Melanoma
   Intervention: HDI; KW2871; KW2871; KW2871
   Sponsor: Ludwig Institute for Cancer Research
   Start Date: 2008-03-28
   Completion Date: 2014-02-03
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00679289
   Summary: This was a Phase 2, open-label study of KW2871 (ecromeximab) in combination with high-dose interferon-α2b (HDI) in patients with metastatic melanoma. The primary objectives of this study were to assess progression-free survival (PFS) and safety. The secondary objectives were to assess the objective ...
   Locations: University of Chicago Hospital, Chicago, United States; University of Pittsburgh Cancer Institute, Pittsburgh, United States
----------------------------------------

33. Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
   NCT ID: NCT02441062
   Status: COMPLETED
   Phase: PHASE2
   Condition: Neuroendocrine Tumors; Carcinoid Tumors; Neuroblastoma; Medulloblastoma
   Intervention: 68Ga-DOTATOC PET/CT
   Sponsor: Sue O'Dorisio
   Start Date: 2015-09
   Completion Date: 2020-01-20
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02441062
   Summary: Participants in this study have been diagnosed with a tumor such as a carcinoid, neuroendocrine tumor, neuroblastoma, Ewing's sarcoma, or brain tumor that has cells which carry somatostatin receptors.

The purpose of this research study is to see if the tumor can be identified using a special proced...
   Locations: University of Iowa Hospitals and Clinics, Iowa City, United States
----------------------------------------

34. PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
   NCT ID: NCT03365791
   Status: COMPLETED
   Phase: PHASE2
   Condition: Small Cell Lung Cancer; Gastric Adenocarcinoma; Esophageal Adenocarcinoma; Castration Resistant Prostate Adenocarcinoma; Soft Tissue Sarcoma; Ovarian Adenocarcinoma; Advanced Well-differentiated Neuroendocrine Tumors; Diffuse Large B Cell Lymphoma
   Intervention: PDR001; LAG525
   Sponsor: Novartis Pharmaceuticals
   Start Date: 2018-01-24
   Completion Date: 2020-09-17
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03365791
   Summary: The purpose of this signal seeking study is to determine whether treatment with PDR001 and LAG525 demonstrates sufficient efficacy in advanced malignancies to warrant further study.
   Locations: California Pacific Medical Center Drug Shipment (2), San Francisco, United States; Hematology Oncology Associates of the Treasure Coast, Port Saint Lucie, United States; University Cancer and Blood Center, LLC, Athens, United States
              ... and 17 more locations
----------------------------------------

35. A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma
   NCT ID: NCT00942162
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma
   Intervention: Immunotherapeutic GSK2132231A
   Sponsor: GlaxoSmithKline
   Start Date: 2009-08-14
   Completion Date: 2015-04-01
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00942162
   Summary: The objective of this study is to evaluate the clinical activity of the GSK2132231A immunotherapeutic in patients with MAGE-A3 positive unresectable metastatic melanoma presenting with the predictive gene signature.
   Locations: GSK Investigational Site, Los Angeles, United States; GSK Investigational Site, Los Angeles, United States; GSK Investigational Site, Orange, United States
              ... and 60 more locations
----------------------------------------

36. Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M...
   NCT ID: NCT01118091
   Status: COMPLETED
   Phase: PHASE2
   Condition: Skin Cancer; Melanoma; Metastatic Melanoma
   Intervention: Aldesleukin; CD8 enriched Young TIL
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2010-04
   Completion Date: 2012-04
   Has Posted Results: True
   Publications Count: 3
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01118091
   Summary: Background:

- Adoptive cell therapy involves taking white blood cells called lymphocytes from patients' tumors, growing them in the laboratory in large numbers, and then giving the cells back to the patient to allow the cells to attack the tumor. Because this process is lengthy and difficult to per...
   Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, United States
----------------------------------------

37. Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
   NCT ID: NCT00610129
   Status: COMPLETED
   Phase: PHASE2
   Condition: Neuroendocrine Tumors; Metastatic Neuroendocrine Tumors
   Intervention: MK-0646
   Sponsor: Memorial Sloan Kettering Cancer Center
   Start Date: 2008-01
   Completion Date: 2010-01
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00610129
   Summary: The purpose of this study is to test a new drug for neuroendocrine tumors. We think that this new drug may help control your tumor.

MK-0646 is a monoclonal antibody. An antibody is a protein that is able to attach to specific target on cancer cells. This target helps the cancer cells grow and divid...
   Locations: Memorial Sloan-Kettering at Basking Ridge, Basking Ridge, United States; Memorial Sloan-Kettering Cancer Center @ Suffolk, Commack, United States; Memorial Sloan-Kettering Cancer Center, New York, United States
              ... and 2 more locations
----------------------------------------

38. Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye
   NCT ID: NCT01413191
   Status: COMPLETED
   Phase: PHASE2
   Condition: Ciliary Body and Choroid Melanoma, Medium/Large Size; Ciliary Body and Choroid Melanoma, Small Size; Iris Melanoma; Metastatic Intraocular Melanoma; Recurrent Intraocular Melanoma; Stage IV Intraocular Melanoma
   Intervention: Cixutumumab; Laboratory biomarker analysis
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2011-08
   Completion Date: 2014-06
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01413191
   Summary: This phase II trial studies how well giving cixutumumab works in treating patients with metastatic melanoma of the eye. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kil...
   Locations: Thomas Jefferson University Hospital, Philadelphia, United States; M D Anderson Cancer Center, Houston, United States
----------------------------------------

39. Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
   NCT ID: NCT01585194
   Status: COMPLETED
   Phase: PHASE2
   Condition: Metastatic Uveal Melanoma; Stage IV Uveal Melanoma AJCC v7
   Intervention: Ipilimumab; Laboratory Biomarker Analysis; Nivolumab
   Sponsor: M.D. Anderson Cancer Center
   Start Date: 2012-11-29
   Completion Date: 2024-05-14
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01585194
   Summary: This phase II trial studies how well nivolumab and ipilimumab work in treating patients with uveal melanoma that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and m...
   Locations: M D Anderson Cancer Center, Houston, United States
----------------------------------------

40. Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin
   NCT ID: NCT02420691
   Status: COMPLETED
   Phase: PHASE2
   Condition: Advanced Digestive System Neuroendocrine Neoplasm; Duodenal Neuroendocrine Tumor G1; Functional Pancreatic Neuroendocrine Tumor; Gastric Neuroendocrine Tumor; Intermediate Grade Lung Neuroendocrine Neoplasm; Low Grade Lung Neuroendocrine Neoplasm; Nonfunctional Pancreatic Neuroendocrine Tumor; Thymus Neoplasm
   Intervention: Laboratory Biomarker Analysis; Pharmacological Study; Ribociclib
   Sponsor: M.D. Anderson Cancer Center
   Start Date: 2015-08-25
   Completion Date: 2019-06-05
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02420691
   Summary: This phase II trial studies how well ribociclib works in treating patients with neuroendocrine tumors of the foregut, which includes the thymus, lung, stomach, and pancreas, that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced tumors). Riboc...
   Locations: M D Anderson Cancer Center, Houston, United States
----------------------------------------

41. Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma
   NCT ID: NCT00273910
   Status: COMPLETED
   Phase: PHASE2
   Condition: High-Risk Melanoma
   Intervention: gp100:209-217 (210M); Montanide ISA-51; Imiquimod
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2006-01
   Completion Date: 2010-05
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00273910
   Summary: This study will evaluate the immunization effects of a vaccine for patients who are at risk for recurrence of their skin cancer. That is, the risk of cancer is higher if melanoma has invaded deep into the skin or lymph nodes. Currently, the only therapy that the U.S. Food and Drug Administration (FD...
   Locations: National Cancer Institute (NCI), Bethesda, United States
----------------------------------------

42. Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma
   NCT ID: NCT01876212
   Status: COMPLETED
   Phase: PHASE2
   Condition: Metastatic Melanoma
   Intervention: DC vaccine; Dasatinib
   Sponsor: Walter J. Storkus
   Start Date: 2014-05-16
   Completion Date: 2019-07-31
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01876212
   Summary: Current therapeutic approaches available for patients with advanced-stage melanoma remain inadequate, and existing approaches including those involving immunotherapy with cytokines and/or targeted strategies have resulted in disappointingly low rates of durable and complete responses. Correcting imm...
   Locations: Hillman Cancer Center, Pittsburgh, United States
----------------------------------------

43. TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)
   NCT ID: NCT01677910
   Status: COMPLETED
   Phase: PHASE3
   Condition: Carcinoid Syndrome
   Intervention: Telotristat etiprate; Placebo-matching telotristat etiprate
   Sponsor: Lexicon Pharmaceuticals
   Start Date: 2013-01-08
   Completion Date: 2016-03-21
   Has Posted Results: True
   Publications Count: 6
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01677910
   Summary: The primary objective of the study is to confirm that at least 1 or more doses of telotristat etiprate compared to placebo is effective in reducing the number of daily bowel movements (BMs) from baseline averaged over the 12-week double-blind portion (Treatment Period) of the trial in patients not a...
   Locations: Lexicon Investigational Site, Mobile, United States; Lexicon Investigational Site, Palo Alto, United States; Lexicon Investigational Site, San Francisco, United States
              ... and 72 more locations
----------------------------------------

44. A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...
   NCT ID: NCT00923481
   Status: COMPLETED
   Phase: PHASE2
   Condition: Head and Neck Neoplasms; Pheochromocytoma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell
   Intervention: Fostamatinib disodium
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2009-04
   Completion Date: 2012-01
   Has Posted Results: True
   Publications Count: 3
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00923481
   Summary: Background:

* The drug R935788 (fostamatanib disodium) is a kinase inhibitor (i.e., it interferes with cell communication and growth and may prevent tumor growth).
* R935788 has shown promising activity in NCI-60 (a panel of 60 diverse human cancer cell lines) against colon cancer, non-small cell l...
   Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, United States
----------------------------------------

45. An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma
   NCT ID: NCT03068455
   Status: COMPLETED
   Phase: PHASE3
   Condition: Melanoma
   Intervention: nivolumab; ipilimumab
   Sponsor: Bristol-Myers Squibb
   Start Date: 2017-04-11
   Completion Date: 2021-02-02
   Has Posted Results: True
   Publications Count: 2
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03068455
   Summary: The purpose of this study is to determine whether an investigational immunotherapy Nivolumab, when combined with Ipilimumab, is more effective than Nivolumab by itself, in delaying the return of cancer in patients who have had a complete surgical removal of stage IIIb/c/d or stage IV Melanoma
   Locations: University of Arizona Cancer Center, Tucson, United States; The Angeles Clinic & Research Institute, Los Angeles, United States; California Pacific Medical Center, San Francisco, United States
              ... and 121 more locations
----------------------------------------

46. Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
   NCT ID: NCT00324155
   Status: COMPLETED
   Phase: PHASE3
   Condition: Melanoma
   Intervention: Ipilimumab; Placebo; Dacarbazine
   Sponsor: Bristol-Myers Squibb
   Start Date: 2006-08
   Completion Date: 2013-10
   Has Posted Results: True
   Publications Count: 3
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00324155
   Summary: The purpose of this clinical research study is to examine the safety and effectiveness (how well the drug works) of two different treatments for patients with melanoma. One treatment is an investigational compound (a drug that is not currently approved by the United States Food and Drug Administrati...
   Locations: Pacific Cancer Medical Center, Anaheim, United States; Wilshire Oncology Medical Group Inc, La Verne, United States; The Angeles Clinic And Research Institute, Los Angeles, United States
              ... and 124 more locations
----------------------------------------

47. Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy
   NCT ID: NCT00965250
   Status: COMPLETED
   Phase: PHASE2
   Condition: Thymoma; Thymic Carcinoma; Thymic Carcinoid; Thymic Neuroendocrine Tumors
   Intervention: IMC-12
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2009-08
   Completion Date: 2016-06
   Has Posted Results: True
   Publications Count: 4
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00965250
   Summary: Background:

* Cisplatin-containing chemotherapy is the standard of care for advanced thymoma and thymic carcinoma that cannot be treated with surgery. New options for treatment are necessary in patients with advanced thymoma and thymic carcinoma that have progressed on cisplatin-containing therapy....
   Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, United States; Memorial Sloan Kettering Cancer Center, New York, United States
----------------------------------------

48. Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267)
   NCT ID: NCT00091572
   Status: COMPLETED
   Phase: PHASE3
   Condition: Melanoma
   Intervention: Temozolomide; Dacarbazine
   Sponsor: Merck Sharp & Dohme LLC
   Start Date: 2004-10-20
   Completion Date: 2007-12-31
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00091572
   Summary: The purpose of this study is to ascertain if the extended schedule of Temozolomide, which allows increased doses and potential depletion of the enzyme underlaying resistance, is a more effective treatment of metastatic melanoma than single agent dacarbazine.
----------------------------------------

49. Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
   NCT ID: NCT00636168
   Status: COMPLETED
   Phase: PHASE3
   Condition: High Risk Stage III Melanoma
   Intervention: ipilimumab; Placebo
   Sponsor: Bristol-Myers Squibb
   Start Date: 2008-06-30
   Completion Date: 2018-11-26
   Has Posted Results: True
   Publications Count: 4
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00636168
   Summary: The purpose of the study is to determine if ipilimumab is effective in preventing or delaying recurrence and prolongs survival after complete resection of high risk stage III melanoma
   Locations: The Angeles Clinic & Research Institute, Los Angeles, United States; Sharp Memorial Hospital, San Diego, United States; California Pacific Medical Center, San Francisco, United States
              ... and 94 more locations
----------------------------------------

50. Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery
   NCT ID: NCT03008369
   Status: COMPLETED
   Phase: PHASE2
   Condition: Malignant Adrenal Gland Pheochromocytoma; Malignant Paraganglioma; Metastatic Adrenal Gland Pheochromocytoma
   Intervention: Laboratory Biomarker Analysis; Lenvatinib; Quality-of-Life Assessment
   Sponsor: Mayo Clinic
   Start Date: 2017-05-31
   Completion Date: 2022-09-28
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03008369
   Summary: This phase II trial studies how well lenvatinib works in treating patients with pheochromocytoma or paraganglioma that has spread to other places in the body or cannot be removed by surgery. Lenvatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
   Locations: Mayo Clinic, Rochester, United States
----------------------------------------

51. An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma
   NCT ID: NCT03329846
   Status: COMPLETED
   Phase: PHASE3
   Condition: Melanoma; Skin Cancer
   Intervention: BMS-986205; Nivolumab; Placebo
   Sponsor: Bristol-Myers Squibb
   Start Date: 2017-11-30
   Completion Date: 2020-07-02
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03329846
   Summary: The purpose of this study is to see if BMS-986205 combined with nivolumab, compared to nivolumab by itself, is more effective in treating Melanoma that has spread or is unable to be removed by surgery, and has not previously been treated
   Locations: Angeles Clinic and Research Institute, Los Angeles, United States; University Of Colorado, Aurora, United States; Mount Sinai Comprehensive Cancer Center, Miami Beach, United States
              ... and 60 more locations
----------------------------------------

52. Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma
   NCT ID: NCT01681212
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma
   Intervention: Ipilimumab; Dacarbazine
   Sponsor: Bristol-Myers Squibb
   Start Date: 2012-10
   Completion Date: 2014-05
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01681212
   Summary: The purpose of this study is to determine the survival rate after 1 year of treatment with ipilimumab plus dacarbazine in patients with previously untreated Stage III (unresectable) or Stage IV melanoma.
   Locations: Local Institution, Fukuoka-shi, Japan; Local Institution, Kumamoto-shi, Japan; Local Institution, Matsumoto-shi, Japan
              ... and 3 more locations
----------------------------------------

53. Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).
   NCT ID: NCT04068181
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma
   Intervention: Talimogene laherparepvec; Pembrolizumab
   Sponsor: Amgen
   Start Date: 2020-01-22
   Completion Date: 2024-02-26
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04068181
   Summary: This is a phase 2, open-label, single-arm, multicenter clinical trial designed to evaluate the efficacy and safety of talimogene laherparepvec in combination with pembrolizumab following disease progression on prior anti-programmed cell death protein (anti-PD-1) therapy in unresectable/metastatic me...
   Locations: Sansum Clinic, Santa Barbara, United States; Medical Oncology Hematology Consultants Helen F Graham Cancer Center, Newark, United States; University of Florida Health Cancer Center at Orlando Health, Orlando, United States
              ... and 43 more locations
----------------------------------------

54. Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma
   NCT ID: NCT02366195
   Status: COMPLETED
   Phase: PHASE2
   Condition: Unresected Stage IIIb to IVM1c Melanoma
   Intervention: Talimogene Laherparepvec
   Sponsor: Amgen
   Start Date: 2015-04-07
   Completion Date: 2020-12-25
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02366195
   Summary: The study is a phase 2, multi centered, single arm study designed to evaluate the correlation between cluster of differentiation 8-positive (CD8+) cell density and objective response rate in adults with unresected stage IIIB to IVM1c melanoma. This study will also evaluate the safety and tolerabilit...
   Locations: Research Site, Salt Lake City, United States; Research Site, Salzburg, Austria; Research Site, Wien, Austria
              ... and 39 more locations
----------------------------------------

55. Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
   NCT ID: NCT00118274
   Status: COMPLETED
   Phase: PHASE1
   Condition: Melanoma (Skin)
   Intervention: incomplete Freund's adjuvant; melanoma helper peptide vaccine; multi-epitope melanoma peptide vaccine; tetanus toxoid helper peptide; cyclophosphamide
   Sponsor: Craig L Slingluff, Jr
   Start Date: 2005-03
   Completion Date: 2010-02
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00118274
   Summary: RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cyclophospha...
   Locations: Fox Chase Cancer Center - Philadelphia, Philadelphia, United States; M. D. Anderson Cancer Center at University of Texas, Houston, United States; University of Virginia Cancer Center, Charlottesville, United States
----------------------------------------

56. Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
   NCT ID: NCT03375320
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE3
   Condition: Carcinoid Tumor; Functioning Pancreatic Neuroendocrine Tumor; Intermediate Grade Lung Neuroendocrine Neoplasm; Locally Advanced Digestive System Neuroendocrine Neoplasm; Locally Advanced Digestive System Neuroendocrine Tumor G1; Locally Advanced Lung Neuroendocrine Neoplasm; Locally Advanced Pancreatic Neuroendocrine Tumor; Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm; Low Grade Lung Neuroendocrine Neoplasm; Lung Neuroendocrine Tumor; Lung Neuroendocrine Tumor G2; Metastatic Digestive System Neuroendocrine Neoplasm; Metastatic Digestive System Neuroendocrine Tumor G1; Metastatic Lung Neuroendocrine Neoplasm; Metastatic Lung Neuroendocrine Tumor; Metastatic Pancreatic Neuroendocrine Neoplasm; Metastatic Pancreatic Neuroendocrine Tumor; Metastatic Thymus Neuroendocrine Neoplasm; Neuroendocrine Neoplasm; Neuroendocrine Tumor G2; Non-Functioning Pancreatic Neuroendocrine Tumor; Pancreatic Serotonin-Producing Neuroendocrine Tumor; Thymus Neuroendocrine Tumor; Unresectable Digestive System Neuroendocrine Neoplasm; Unresectable Digestive System Neuroendocrine Tumor G1; Unresectable Lung Neuroendocrine Neoplasm; Unresectable Pancreatic Neuroendocrine Neoplasm; Unresectable Thymus Neuroendocrine Neoplasm
   Intervention: Biospecimen Collection; Cabozantinib S-malate; Computed Tomography; Magnetic Resonance Imaging; Placebo Administration; Quality-of-Life Assessment; X-Ray Imaging
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2018-10-26
   Completion Date: 2025-11-22
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03375320
   Summary: This phase III trial studies cabozantinib to see how well it works compared with placebo in treating patients with neuroendocrine or carcinoid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Cabozantinib is a chemotherap...
   Locations: Katmai Oncology Group, Anchorage, United States; Kingman Regional Medical Center, Kingman, United States; Mayo Clinic Hospital in Arizona, Phoenix, United States
              ... and 433 more locations
----------------------------------------

57. Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma
   NCT ID: NCT00976573
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma (Skin)
   Intervention: bevacizumab; carboplatin; everolimus; paclitaxel
   Sponsor: Alliance for Clinical Trials in Oncology
   Start Date: 2010-04
   Completion Date: 2015-09
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00976573
   Summary: This randomized phase II trial is studying how well carboplatin, paclitaxel, and bevacizumab work when given with or without everolimus in treating patients with malignant melanoma that has spread from where it started to other places in the body. Drugs used in chemotherapy, such as carboplatin and ...
   Locations: Mayo Clinic Scottsdale, Scottsdale, United States; Contra Costa Regional Medical Center, Martinez, United States; El Camino Hospital Cancer Center, Mountain View, United States
              ... and 305 more locations
----------------------------------------

58. Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer
   NCT ID: NCT00514046
   Status: COMPLETED
   Phase: PHASE1
   Condition: Medullary Thyroid Carcinoma; Multiple Endocrine Neoplasia Type 2A; Multiple Endocrine Neoplasia Type 2B
   Intervention: Vandetanib
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2007-07-20
   Completion Date: 2020-11-01
   Has Posted Results: True
   Publications Count: 7
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00514046
   Summary: Background:

* Medullary thyroid carcinoma (MTC) is common in people with a genetic disorder called multiple endocrine neoplasia (MEN).
* Vandetanib is an experimental drug that blocks a defective protein receptor (rearranged during transfection (RET) receptor) found on the surface of cancer cells i...
   Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, United States
----------------------------------------

59. An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor
   NCT ID: NCT01619774
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma
   Intervention: GSK2118436; GSK1120212
   Sponsor: M.D. Anderson Cancer Center
   Start Date: 2012-09
   Completion Date: 2015-08
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01619774
   Summary: The goal of this clinical research study is to learn if the combination of 2 drugs dabrafenib and trametinib can help to control melanoma that has or has not spread to the brain. The safety of this drug combination will also be studied.

Dabrafenib is designed to block the mutated BRAF protein. This...
   Locations: University of Texas MD Anderson Cancer Center, Houston, United States
----------------------------------------

60. A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma
   NCT ID: NCT02908672
   Status: COMPLETED
   Phase: PHASE3
   Condition: Melanoma
   Intervention: Atezolizumab; Atezolizumab Placebo; Cobimetinib; Vemurafenib; Vemurafenib Placebo
   Sponsor: Hoffmann-La Roche
   Start Date: 2017-01-13
   Completion Date: 2024-07-01
   Has Posted Results: True
   Publications Count: 3
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02908672
   Summary: This is a Phase III, double-blinded, placebo-controlled, randomized, multicenter study designed to evaluate the efficacy, safety, and pharmacokinetics of atezolizumab + cobimetinib + vemurafenib compared with placebo + cobimetinib + vemurafenib in patients with previously untreated BRAFv600 mutation...
   Locations: University of Alabama at Birmingham, Birmingham, United States; Arizona Oncology Associates, PC - HAL, Tempe, United States; Highlands Oncology Group, Springdale, United States
              ... and 113 more locations
----------------------------------------

61. Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery
   NCT ID: NCT01989572
   Status: COMPLETED
   Phase: PHASE3
   Condition: Iris Melanoma; Medium/Large Size Posterior Uveal Melanoma; Mucosal Melanoma; Ocular Melanoma With Extraocular Extension; Recurrent Melanoma; Recurrent Uveal Melanoma; Small Size Posterior Uveal Melanoma; Stage IIA Cutaneous Melanoma AJCC v6 and v7; Stage IIA Uveal Melanoma AJCC v7; Stage IIB Cutaneous Melanoma AJCC v6 and v7; Stage IIB Uveal Melanoma AJCC v7; Stage IIC Cutaneous Melanoma AJCC v6 and v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIA Uveal Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIB Uveal Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IIIC Uveal Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Stage IV Uveal Melanoma AJCC v7
   Intervention: Laboratory Biomarker Analysis; Placebo; Placebo; Sargramostim; Tyrosinase Peptide
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2000-02-23
   Completion Date: 2013-01-31
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01989572
   Summary: This randomized phase III trial studies sargramostim or vaccine therapy alone to see how well they work compared to sargramostim and vaccine therapy together in preventing disease recurrence in patients with melanoma that has been removed by surgery. Sargramostim may stimulate the immune system in d...
   Locations: University of Alabama at Birmingham Cancer Center, Birmingham, United States; Mobile Infirmary Medical Center, Mobile, United States; Mayo Clinic in Arizona, Scottsdale, United States
              ... and 145 more locations
----------------------------------------

62. Lithium for Low-Grade Neuroendocrine Tumors
   NCT ID: NCT00501540
   Status: COMPLETED
   Phase: PHASE2
   Condition: Neuroendocrine Tumors
   Intervention: Lithium Carbonate
   Sponsor: University of Wisconsin, Madison
   Start Date: 2007-07
   Completion Date: 2009-06
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00501540
   Summary: The purpose of this study is to learn more about the effectiveness and side effects of lithium treatment for subjects with low-grade neuroendocrine tumors.
   Locations: University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, United States
----------------------------------------

63. BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation
   NCT ID: NCT01894672
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma
   Intervention: LGX818
   Sponsor: Memorial Sloan Kettering Cancer Center
   Start Date: 2013-07
   Completion Date: 2016-03-17
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01894672
   Summary: The purpose of this phase II study is to find out if an investigational drug called LGX818 can stop the melanoma from growing.
   Locations: Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge, United States; Memorial Sloan Kettering Cancer Center at Commack, Commack, United States; Memorial Sloan Kettering Cancer Center, New York, United States
              ... and 2 more locations
----------------------------------------

64. A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours
   NCT ID: NCT01578239
   Status: COMPLETED
   Phase: PHASE3
   Condition: Carcinoid Tumor of the Small Bowel; Neuroendocrine Tumour
   Intervention: Octreotide LAR; 177Lu-DOTA0-Tyr3-Octreotate
   Sponsor: Advanced Accelerator Applications
   Start Date: 2012-09-06
   Completion Date: 2021-01-18
   Has Posted Results: True
   Publications Count: 4
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01578239
   Summary: This was a multicenter, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with Lutathera plus best supportive care (30 mg Octreotide LAR) to treatment with high dose (60 mg) Octreotide LAR in participants with metastasized or locally advanced, in...
   Locations: Cedars-Sinai Medical Center Samuel Oschin Cancer Center, Los Angeles, United States; Stanford Cancer Center, Palo Alto, United States; Moffitt Cancer Center, Tampa, United States
              ... and 36 more locations
----------------------------------------

65. Evaluation of Pigmented Skin Lesions With MelaFind(R) System
   NCT ID: NCT00434057
   Status: COMPLETED
   Phase: PHASE3
   Condition: Melanoma
   Intervention: MelaFind(R)
   Sponsor: MELA Sciences, Inc.
   Start Date: 2007-01
   Completion Date: 2008-07
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00434057
   Summary: The purpose of this clinical trial is to demonstrate that MelaFind®, a new instrument that uses machine vision for non-invasive early detection of cutaneous pigmented malignant melanoma, is safe and effective. MelaFind® acquires digital images of the lesion with illumination in different spectral ba...
   Locations: Skin and Cancer Associates, Plantation, United States; Dermatology Associates of Tallahassee, Tallahassee, United States
----------------------------------------

66. A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)
   NCT ID: NCT02752074
   Status: COMPLETED
   Phase: PHASE3
   Condition: Melanoma
   Intervention: pembrolizumab + epacadostat; pembrolizumab + placebo
   Sponsor: Incyte Corporation
   Start Date: 2016-06-21
   Completion Date: 2019-08-16
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02752074
   Summary: The purpose of the study is to assess the efficacy, safety, and tolerability when combining pembrolizumab with epacadostat or placebo in participants with unresectable or metastatic melanoma
----------------------------------------

67. Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors
   NCT ID: NCT01619865
   Status: COMPLETED
   Phase: PHASE1
   Condition: Neuroendocrine Tumors; Carcinoid Tumors; Neuroblastoma; Medulloblastoma
   Intervention: 68Ga-DOTATOC PET/CT
   Sponsor: Sue O'Dorisio
   Start Date: 2012-02-21
   Completion Date: 2017-08-27
   Has Posted Results: True
   Publications Count: 2
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01619865
   Summary: This protocol is designed to test the efficacy of 68Ga-DOTATOC PET/CT in diagnosis, staging, and measurement of response to treatment in patients with somatostatin receptor positive tumors. Goals are to 1) compare this unique PET/CT scan with the current standard of care which is a combination of Oc...
   Locations: University of Iowa Health Care, Iowa City, United States
----------------------------------------

68. Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma
   NCT ID: NCT01107665
   Status: COMPLETED
   Phase: PHASE2
   Condition: Stage III Melanoma; Stage IV Melanoma; Unresectable Melanoma
   Intervention: Pazopanib and Paclitaxel
   Sponsor: University of California, Irvine
   Start Date: 2010-08
   Completion Date: 2018-02
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01107665
   Summary: This is a Phase II single-arm, open-label, clinical trial evaluating the efficacy and safety of pazopanib in combination with paclitaxel as first line therapy for subjects with unresectable Stage III and Stage IV melanoma. Previous cytokine therapy is permitted. Subjects must have measurable disease...
   Locations: Chao Family Comprehensive Cancer Center, Orange, United States
----------------------------------------

69. Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
   NCT ID: NCT00623766
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma
   Intervention: Ipilimumab; Corticosteroid: Betamethasone; Corticosteroid: Dexamethasone; Corticosteroid: Fludrocortisone; Corticosteroid: Hydrocortisone; Corticosteroid: Meprednisone; Corticosteroid: Methylprednisolone; Corticosteroid: Prednisolone; Corticosteroid: Prednisone; Corticosteroid: Triamcinolone
   Sponsor: Bristol-Myers Squibb
   Start Date: 2008-07
   Completion Date: 2012-10
   Has Posted Results: True
   Publications Count: 4
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00623766
   Summary: To assess the response of melanoma with brain metastases to ipilimumab treatment while maintaining acceptable tolerability.
   Locations: Mayo Clinic Arizona, Scottsdale, United States; City Of Hope, Duarte, United States; The Angeles Clinic & Research Institute, Los Angeles, United States
              ... and 11 more locations
----------------------------------------

70. A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection
   NCT ID: NCT05297565
   Status: COMPLETED
   Phase: PHASE3
   Condition: Melanoma
   Intervention: Nivolumab/rHuPH20; Nivolumab
   Sponsor: Bristol-Myers Squibb
   Start Date: 2022-08-02
   Completion Date: 2024-02-08
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT05297565
   Summary: The purpose of this study is to assess the safety and tolerability of subcutaneous nivolumab vs intravenous nivolumab in participants with completely resected Stage IIIA/B/C/D or Stage IV melanoma.
   Locations: Local Institution - 0004, Fort Wayne, United States; Local Institution - 0044, Knoxville, United States; Local Institution - 0038, Coffs Harbour, Australia
              ... and 13 more locations
----------------------------------------

71. Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
   NCT ID: NCT00866840
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma (Skin)
   Intervention: riluzole
   Sponsor: Rutgers, The State University of New Jersey
   Start Date: 2009-04
   Completion Date: 2013-07
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00866840
   Summary: RATIONALE: Riluzole may stop or slow the growth of tumor cells and may be an effective treatment for melanoma.

PURPOSE: This phase II trial is studying how well riluzole works in treating patients with stage III or stage IV melanoma that cannot be removed by surgery.
   Locations: Rutgers Cancer Institute of New Jersey, New Brunswick, United States
----------------------------------------

72. Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
   NCT ID: NCT01106040
   Status: COMPLETED
   Phase: PHASE3
   Condition: Breast Cancer; Melanoma
   Intervention: Lymphoseek
   Sponsor: Navidea Biopharmaceuticals
   Start Date: 2010-06
   Completion Date: 2011-04
   Has Posted Results: True
   Publications Count: 2
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01106040
   Summary: Data from this pivotal clinical trial will be used to support a marketing application (i.e., NDA) of Navidea's Lymphoseek for use in anatomical delineation of lymphoid tissue (nodes) in the lymphatic pathway draining the primary site of a tumor.

Multicenter, open-label, within-patient comparative s...
   Locations: University of Alabama, Birmingham, Birmingham, United States; UCSD Moores Cancer Center, La Jolla, United States; Califonia Pacific Medical Center, San Francisco, United States
              ... and 5 more locations
----------------------------------------

73. Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery
   NCT ID: NCT00450372
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma (Skin)
   Intervention: ADI-PEG-20; Pharmacology Studies
   Sponsor: University of Miami
   Start Date: 2004-06
   Completion Date: 2012-02
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00450372
   Summary: RATIONALE: Pegylated arginine deiminase may stop the growth of tumor cells by taking away an amino acid needed for cell growth.

PURPOSE: This phase II trial is studying how well pegylated arginine deiminase works in treating patients with metastatic melanoma that cannot be removed by surgery.
   Locations: University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, United States
----------------------------------------

74. An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma
   NCT ID: NCT03765229
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma
   Intervention: Entinostat; Pembrolizumab
   Sponsor: UNC Lineberger Comprehensive Cancer Center
   Start Date: 2019-03-22
   Completion Date: 2023-07-31
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03765229
   Summary: Cancers develop in two different ways. First, cancer cells can become invisible to the immune system by stop having proteins on their surface that are required for the immune system to recognize them. In this scenario, tumors do not attract any immune cells (e.g. white blood cells) whatsoever or the...
   Locations: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, United States
----------------------------------------

75. Intratumoral Injections of LL37 for Melanoma
   NCT ID: NCT02225366
   Status: COMPLETED
   Phase: PHASE1
   Condition: Melanoma
   Intervention: LL37; Photographs
   Sponsor: M.D. Anderson Cancer Center
   Start Date: 2015-07-08
   Completion Date: 2020-11-24
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02225366
   Summary: The goal of this clinical research study is to find the appropriate dose of LL37 that can be given to patients with melanoma. Researchers also want to learn if LL37 can stimulate the immune system to help control the disease.
   Locations: University of Texas MD Anderson Cancer Center, Houston, United States
----------------------------------------

76. A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)
   NCT ID: NCT02130466
   Status: COMPLETED
   Phase: PHASE1
   Condition: Melanoma; Solid Tumors
   Intervention: Pembrolizumab; Dabrafenib; Trametinib; Placebo
   Sponsor: Merck Sharp & Dohme LLC
   Start Date: 2014-05-29
   Completion Date: 2021-07-14
   Has Posted Results: True
   Publications Count: 3
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02130466
   Summary: This is a 5-part dose-finding and preliminary efficacy study of pembrolizumab (Pembro) + dabrafenib (D) + trametinib (T) for participants with advanced melanoma and solid tumors.

Parts 1 and 2 are open-label to find and confirm the maximum tolerated dose (MTD)/maximum administered dose (MAD) for Pe...
----------------------------------------

77. LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma
   NCT ID: NCT02159066
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma
   Intervention: LGX818; MEK162; LEE011; BGJ398; BKM120; INC280
   Sponsor: Pfizer
   Start Date: 2014-07-23
   Completion Date: 2023-01-10
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02159066
   Summary: The primary purpose of this study is to assess the anti-tumor activity of LGX818/MEK162 in combination with targeted agents after progression on LGX818/MEK162 combination therapy, as well as the safety and tolerability of the novel triple combinations.
   Locations: University of California Los Angeles, Los Angeles, United States; Cancer Care Center, Los Angeles, United States; Doris Stein Research Center Building, Los Angeles, United States
              ... and 29 more locations
----------------------------------------

78. Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
   NCT ID: NCT01010126
   Status: COMPLETED
   Phase: PHASE2
   Condition: Adult Hepatocellular Carcinoma; Advanced Adult Hepatocellular Carcinoma; Endometrial Serous Adenocarcinoma; Localized Non-Resectable Adult Liver Carcinoma; Lung Carcinoid Tumor; Malignant Pancreatic Gastrinoma; Malignant Pancreatic Glucagonoma; Malignant Pancreatic Insulinoma; Malignant Pancreatic Somatostatinoma; Metastatic Digestive System Neuroendocrine Tumor G1; Ovarian Carcinosarcoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Seromucinous Carcinoma; Ovarian Serous Surface Papillary Adenocarcinoma; Pancreatic Alpha Cell Adenoma; Pancreatic Beta Cell Adenoma; Pancreatic Delta Cell Adenoma; Pancreatic G-Cell Adenoma; Pancreatic Polypeptide Tumor; Recurrent Adult Liver Carcinoma; Recurrent Digestive System Neuroendocrine Tumor G1; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Pancreatic Neuroendocrine Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Uterine Corpus Carcinoma; Regional Digestive System Neuroendocrine Tumor G1; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIA Uterine Corpus Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IIIC Uterine Corpus Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer; Uterine Carcinosarcoma
   Intervention: Bevacizumab; Temsirolimus
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2009-09-08
   Completion Date: 2017-03-13
   Has Posted Results: True
   Publications Count: 2
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01010126
   Summary: This phase II trial studies how well temsirolimus and bevacizumab work in treating patients with advanced endometrial, ovarian, liver, carcinoid, or islet cell cancer. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such ...
   Locations: Mayo Clinic in Arizona, Scottsdale, United States; Tower Cancer Research Foundation, Beverly Hills, United States; City of Hope Comprehensive Cancer Center, Duarte, United States
              ... and 58 more locations
----------------------------------------

79. Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma
   NCT ID: NCT01721772
   Status: COMPLETED
   Phase: PHASE3
   Condition: Melanoma
   Intervention: BMS-936558 (Nivolumab); Placebo matching BMS-936558 (Nivolumab); Dacarbazine; Placebo matching Dacarbazine
   Sponsor: Bristol-Myers Squibb
   Start Date: 2013-01-18
   Completion Date: 2021-05-14
   Has Posted Results: True
   Publications Count: 5
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01721772
   Summary: The purpose of this study is to compare the clinical benefit, as measured by overall survival, of nivolumab with that of. dacarbazine in patients with previously untreated, unresectable, or metastatic melanoma
   Locations: Fundacion Cidea, Buenos Aires, Argentina; Instituto Medico Especialazado Alexander Fleming, Buenos Aires, Argentina; Instituto Oncologico De Cordoba, Cordoba, Argentina
              ... and 72 more locations
----------------------------------------

80. Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
   NCT ID: NCT01693068
   Status: COMPLETED
   Phase: PHASE2
   Condition: N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma
   Intervention: Pimasertib; Dacarbazine
   Sponsor: EMD Serono
   Start Date: 2012-12-05
   Completion Date: 2016-10-24
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01693068
   Summary: This is a Phase 2, multicenter, randomized, controlled, open-label trial of pimasertib versus dacarbazine aimed to confirm the activity of pimasertib in previously untreated subjects with N-Ras mutated locally advanced or metastatic malignant cutaneous melanoma by comparing the progression-free surv...
   Locations: Research Site, Birmingham, United States; Research Site, Tucson, United States; Research Site, San Francisco, United States
              ... and 99 more locations
----------------------------------------

81. A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
   NCT ID: NCT01721746
   Status: COMPLETED
   Phase: PHASE3
   Condition: Unresectable or Metastatic Melanoma
   Intervention: BMS-936558; Dacarbazine; Carboplatin; Paclitaxel
   Sponsor: Bristol-Myers Squibb
   Start Date: 2012-12-21
   Completion Date: 2020-12-29
   Has Posted Results: True
   Publications Count: 2
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01721746
   Summary: The purpose of the study is to estimate the response rate and compare overall survival of patients taking BMS-936558 to those taking study physician's choice of either Dacarbazine or Carboplatin and Paclitaxel
   Locations: Mayo Clinic, Phoenix, United States; UCSD Moores Cancer Center, La Jolla, United States; The Angeles Clinic & Research Institute, Los Angeles, United States
              ... and 92 more locations
----------------------------------------

82. Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer
   NCT ID: NCT00625846
   Status: COMPLETED
   Phase: PHASE2
   Condition: Recurrent Thyroid Gland Carcinoma; Stage III Differentiated Thyroid Gland Carcinoma AJCC v7; Stage III Thyroid Gland Medullary Carcinoma AJCC v7; Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7; Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v7; Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7; Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7; Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v7; Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7; Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7; Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v7; Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7; Thyroid Gland Anaplastic Carcinoma
   Intervention: Laboratory Biomarker Analysis; Pazopanib Hydrochloride
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2008-02-22
   Completion Date: 2019-08-13
   Has Posted Results: True
   Publications Count: 2
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00625846
   Summary: This phase II trial studies the side effects and how well pazopanib hydrochloride works in treating patients with advanced thyroid cancer. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by stopping blood flow to the tumor.
   Locations: Mayo Clinic in Arizona, Scottsdale, United States; University of Colorado Hospital, Aurora, United States; Mayo Clinic in Florida, Jacksonville, United States
              ... and 19 more locations
----------------------------------------

83. A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain
   NCT ID: NCT01266967
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma and Brain Metastases
   Intervention: GSK2118436
   Sponsor: GlaxoSmithKline
   Start Date: 2011-02
   Completion Date: 2012-11
   Has Posted Results: True
   Publications Count: 3
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01266967
   Summary: This study is designed to assess the efficacy, pharmacokinetics, safety, and tolerability of an oral, twice daily dose of 150 mg GSK2118436 administered to subjects with BRAF V600E or V600K mutation-positive metastatic melanoma to the brain. Subjects in Cohort A will not have received any local brai...
   Locations: GSK Investigational Site, Los Angeles, United States; GSK Investigational Site, San Francisco, United States; GSK Investigational Site, San Francisco, United States
              ... and 21 more locations
----------------------------------------

84. Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma
   NCT ID: NCT00513604
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma; Malignant Melanoma; Melanoma, Experimental; Experimental Melanomas
   Intervention: aldesleukin; therapeutic autologous lymphocytes; Cyclophosphamide; Fludarabine phosphate; Total body irradiation
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2007-06
   Completion Date: 2012-11
   Has Posted Results: True
   Publications Count: 5
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00513604
   Summary: Background:

* Most therapeutic therapies for metastatic melanoma have focused on the ability of T-cell lymphocytes to kill cells of tumors.
* An adaptive cell transfer therapy has been pioneered, in which cells are grown for a short time in the laboratory. The way they are grown may have a better e...
   Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, United States
----------------------------------------

85. A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors
   NCT ID: NCT03070301
   Status: COMPLETED
   Phase: PHASE2
   Condition: Neuroendocrine Tumors
   Intervention: LEE011; everolimus
   Sponsor: Memorial Sloan Kettering Cancer Center
   Start Date: 2017-02-27
   Completion Date: 2024-01-31
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03070301
   Summary: The purpose of this study is to test any good and bad effects of the combination of LEE011 with everolimus on the participant and the cancer.
   Locations: Massachusetts General Hospital, Boston, United States; Dana Farber Cancer Institute, Boston, United States; Beth Israel Deaconess Medical Center, Boston, United States
              ... and 2 more locations
----------------------------------------

86. Pazopanib as Single Agent in Advanced NETs
   NCT ID: NCT01280201
   Status: COMPLETED
   Phase: PHASE2
   Condition: Advanced/Metastatic Neuroendocrine Tumors
   Intervention: Pazopanib
   Sponsor: Grupo Espanol de Tumores Neuroendocrinos
   Start Date: 2011-01-26
   Completion Date: 2015-03-15
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01280201
   Summary: The incidence of new diagnosed patients with NET of the digestive tract including carcinoid and pancreatic islet cells tumors ranges from 2 to 10 per 100,000 in the western Countries (Kulke M, Mayer R. N Engl J Med 340:858-868, 1999). Despite of the low incidence, the prevalence of these tumors is h...
   Locations: Institut Català d'Oncologia L'Hospitalet, L'Hospitalet de Llobregat, Spain; Hospital Universitari Vall d'Hebron, Barcelona, Spain; Centro Integral Oncológico Clara Campal, Madrid, Spain
              ... and 7 more locations
----------------------------------------

87. Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors
   NCT ID: NCT00510068
   Status: COMPLETED
   Phase: PHASE3
   Condition: Advanced Neuroendocrine Tumors of Pancreatic Origin
   Intervention: Everolimus; Everolimus Placebo
   Sponsor: Novartis Pharmaceuticals
   Start Date: 2007-07
   Completion Date: 2014-03
   Has Posted Results: True
   Publications Count: 5
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00510068
   Summary: The purpose of this study was to evaluate progression free survival in those participants assigned everolimus 10 mg/day plus Best Supportive Care versus those assigned to placebo plus Best Supportive Care in Advanced Neuroendocrine Tumors of pancreatic origin.
   Locations: University of South Alabama / Mitchell Cancer Institute Deptof Mitchell Cancer Inst(2), Mobile, United States; Pacific Cancer Medical Center, Inc., Anaheim, United States; Cedars Sinai Medical Center SC-2, Los Angeles, United States
              ... and 79 more locations
----------------------------------------

88. A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma
   NCT ID: NCT01781572
   Status: COMPLETED
   Phase: PHASE1
   Condition: Locally Advanced or Metastatic NRAS Mutant Melanoma
   Intervention: LEE011; MEK162
   Sponsor: Pfizer
   Start Date: 2013-06
   Completion Date: 2018-02-20
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01781572
   Summary: In the phase Ib, the primary purpose is to establish the maximum tolerated dose (MTD)(s)/recommended phase ll dose (RP2D) and schedule of LEE011 and MEK162 orally administered combination. Once the MTD(s)/RP2D have been determined for each tested schedule, additional patients will be enrolled in the...
   Locations: University of California, Dept of Oncology, San Francisco, United States; California Pacific Medical Center Onc Dept, San Francisco, United States; Karmanos Cancer Institute Dept of Oncology, Detroit, United States
              ... and 14 more locations
----------------------------------------

89. An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself
   NCT ID: NCT02320058
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma
   Intervention: Ipilimumab; Nivolumab
   Sponsor: Bristol-Myers Squibb
   Start Date: 2015-03-05
   Completion Date: 2020-09-08
   Has Posted Results: True
   Publications Count: 4
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02320058
   Summary: This is a study of Nivolumab combined with Ipilimumab followed by Nivolumab by itself for the treatment of patients with Melanoma that has spread to the brain. Patients with histologically confirmed Malignant Melanoma and asymptomatic brain metastases are eligible for the study.
   Locations: City of Hope, Duarte, United States; Angeles Clinic and Research Institute, Los Angeles, United States; UCLA Medical Hematology and Oncology, Los Angeles, United States
              ... and 33 more locations
----------------------------------------

90. A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma
   NCT ID: NCT01667419
   Status: COMPLETED
   Phase: PHASE3
   Condition: Melanoma
   Intervention: Vemurafenib; Placebo
   Sponsor: Hoffmann-La Roche
   Start Date: 2012-09-24
   Completion Date: 2018-07-13
   Has Posted Results: True
   Publications Count: 2
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01667419
   Summary: This multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of vemurafenib in participants with completely resected, cutaneous BRAF mutation-positive melanoma at high risk for recurrence. Participants will be enrolled in two separate cohorts: Cohort 1 w...
   Locations: University of Alabama at Birmingham, Birmingham, United States; UCLA Department of Medicine; Division of Hematology / Oncology, California City, United States; Kaiser Permanente - Hayward, Hayward, United States
              ... and 204 more locations
----------------------------------------

91. A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases
   NCT ID: NCT03625141
   Status: COMPLETED
   Phase: PHASE2
   Condition: Metastatic Melanoma
   Intervention: Cobimetinib; Atezolizumab; Vemurafenib
   Sponsor: Hoffmann-La Roche
   Start Date: 2018-12-13
   Completion Date: 2023-04-13
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03625141
   Summary: This study will evaluate the efficacy and safety of cobimetinib plus atezolizumab in participants with BRAFV600 wild-type melanoma with central nervous system (CNS) metastases and of cobimetinib plus atezolizumab and vemurafenib in BRAFV600 mutation-positive melanoma patients with CNS metastases.
   Locations: Instituto Nacional de Cancer - INCa; Oncologia, Rio de Janeiro, Brazil; Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda, Ijui, Brazil; Hospital das Clinicas - UFRGS, Porto Alegre, Brazil
              ... and 19 more locations
----------------------------------------

92. Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
   NCT ID: NCT00110019
   Status: COMPLETED
   Phase: PHASE3
   Condition: Mucosal Melanoma; Recurrent Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma
   Intervention: Carboplatin; Laboratory Biomarker Analysis; Paclitaxel; Pharmacological Study; Placebo; Sorafenib Tosylate
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2005-06
   Completion Date: 2012-08
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00110019
   Summary: This randomized phase III trial studies carboplatin, paclitaxel, and sorafenib tosylate to see how well they work compared to carboplatin and paclitaxel in treating patients with stage III or stage IV melanoma that cannot be removed by surgery. Drugs used in chemotherapy, such as carboplatin and pac...
   Locations: University of Alabama at Birmingham Cancer Center, Birmingham, United States; Mercy Hospital Fort Smith, Ft. Smith, United States; University of Arkansas for Medical Sciences, Little Rock, United States
              ... and 216 more locations
----------------------------------------

93. Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma
   NCT ID: NCT01927419
   Status: COMPLETED
   Phase: PHASE2
   Condition: Unresectable Melanoma; Metastatic Melanoma
   Intervention: Nivolumab; Ipilimumab; Placebo
   Sponsor: Bristol-Myers Squibb
   Start Date: 2013-08-23
   Completion Date: 2021-02-26
   Has Posted Results: True
   Publications Count: 3
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01927419
   Summary: The primary purpose of this study is to compare the objective response rate, as determined by investigators, of Nivolumab combined with Ipilimumab versus Ipilimumab monotherapy in patients with untreated, unresectable, or metastatic melanoma
   Locations: San Francisco Oncology Associates, San Francisco, United States; Orlando Health Inc, Orlando, United States; University Of Louisville Medical Center, Inc., Dba, Louisville, United States
              ... and 18 more locations
----------------------------------------

94. Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study
   NCT ID: NCT04889118
   Status: COMPLETED
   Phase: PHASE3
   Condition: Malignant Melanoma
   Intervention: Pembrolizumab; Lenvatinib; Placebo for lenvatinib
   Sponsor: Merck Sharp & Dohme LLC
   Start Date: 2020-07-14
   Completion Date: 2024-11-01
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04889118
   Summary: The purpose of the China Extension study is to assess the safety and efficacy of pembrolizumab (MK-3475) combined with lenvatinib (MK-7902/E7080) compared to pembrolizumab alone (with placebo for lenvatinib) as first-line treatment in Chinese participants with no prior systemic therapy for their adv...
   Locations: Beijing Cancer Hospital (0601), Beijing, China; Fujian Provincial Cancer Hospital ( Site 0612), Fuzhou, China; Sun Yat-Sen University Cancer Center (0602), Guangzhou, China
              ... and 8 more locations
----------------------------------------

95. Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma
   NCT ID: NCT00671918
   Status: COMPLETED
   Phase: PHASE3
   Condition: Breast Cancer; Melanoma
   Intervention: Lymphoseek
   Sponsor: Navidea Biopharmaceuticals
   Start Date: 2008-04
   Completion Date: 2009-07
   Has Posted Results: True
   Publications Count: 50
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00671918
   Summary: Data from this pivotal clinical trial will be used to support a marketing application (i.e., NDA) for Navidea's Lymphoseek for use in intraoperative localization of lymph tissue (nodes) in the lymphatic pathway draining the primary site of a tumor.
   Locations: Barbara Michna, M.D, Alexander City, United States; Helen Krontiras, M.D., Birmingham, United States; Anne Wallace, M.D., La Jolla, United States
              ... and 12 more locations
----------------------------------------

96. Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye
   NCT ID: NCT00329641
   Status: COMPLETED
   Phase: PHASE2
   Condition: Ciliary Body and Choroid Melanoma, Medium/Large Size; Extraocular Extension Melanoma; Iris Melanoma; Metastatic Intraocular Melanoma; Recurrent Intraocular Melanoma
   Intervention: carboplatin; paclitaxel; sorafenib tosylate
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2011-02
   Completion Date: 2012-11
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00329641
   Summary: This phase II trial is studying how well sorafenib works when given together with carboplatin and paclitaxel in treating patients with stage IV melanoma of the eye. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by kil...
   Locations: Southwest Oncology Group, San Antonio, United States
----------------------------------------

97. CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma
   NCT ID: NCT02027935
   Status: COMPLETED
   Phase: PHASE2
   Condition: Metastatic Melanoma; Stage IV Cutaneous Melanoma AJCC v6 and v7
   Intervention: Aldesleukin; Autologous CD8+ Melanoma Specific T Cells; Cyclophosphamide; Ipilimumab; Laboratory Biomarker Analysis
   Sponsor: M.D. Anderson Cancer Center
   Start Date: 2015-01-22
   Completion Date: 2024-04-12
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02027935
   Summary: This phase II trial studies the side effects and how well white blood cells taken from person's own (autologous) cluster of differentiation (CD)8+ antigen-specific T cells, cyclophosphamide, aldesleukin, and ipilimumab work in treating patients with melanoma that has spread to another place in the b...
   Locations: M D Anderson Cancer Center, Houston, United States
----------------------------------------

98. Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma
   NCT ID: NCT00885534
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma; Skin Cancer
   Intervention: Cisplatin, Vinblastine, Temozolomide
   Sponsor: Memorial Sloan Kettering Cancer Center
   Start Date: 2009-04
   Completion Date: 2013-10
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00885534
   Summary: The investigators want to learn to predict which tumors will respond to CVT chemotherapy. CVT is a combination of three drugs - cisplatin, vinblastine, and temozolomide. We and other investigators have used CVT in melanoma patients and found that tumors got significantly smaller in 30-40% of cases. ...
   Locations: Memorial Sloan Kettering Cancer Center, New York, United States
----------------------------------------

99. Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma
   NCT ID: NCT00590824
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma
   Intervention: hu14.18-IL2; hu14.18-IL2
   Sponsor: University of Wisconsin, Madison
   Start Date: 2007-12-17
   Completion Date: 2018-09-20
   Has Posted Results: True
   Publications Count: 2
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00590824
   Summary: Evaluate the antitumor activity of hu14.18-IL2 in the minimal residual disease setting. Evaluate the time to recurrence and overall survival of patients treated with hu14.18-IL2.
   Locations: University of Wisconsin Hospitals and Clinics, Madison, United States
----------------------------------------

100. A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition
   NCT ID: NCT05061134
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Melanoma
   Intervention: Ceralasertib; Durvalumab
   Sponsor: AstraZeneca
   Start Date: 2022-08-31
   Completion Date: 2026-11-02
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT05061134
   Summary: Main study: This is an open-label, phase 2 study that aims to evaluate the efficacy and safety/tolerability of ceralasertib, when administered as monotherapy and in combination with durvalumab in participants with unresectable or advanced melanoma and primary or secondary resistance to PD-(L)1 inhib...
   Locations: Research Site, Los Angeles, United States; Research Site, Sacramento, United States; Research Site, San Francisco, United States
              ... and 63 more locations
----------------------------------------

101. RAD001 Plus Bevacizumab in Metastatic Melanoma
   NCT ID: NCT00591734
   Status: COMPLETED
   Phase: PHASE2
   Condition: Metastatic Melanoma
   Intervention: Bevacizumab; Everolimus
   Sponsor: SCRI Development Innovations, LLC
   Start Date: 2008-01
   Completion Date: 2011-10
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00591734
   Summary: This is a non-randomized, open label Phase II study comparing bevacizumab and everolimus in the treatment of metastatic melanoma.
   Locations: Florida Cancer Specialists, Fort Myers, United States; Watson Clinic Center for Cancer Care and Research, Lakeland, United States; Florida Hospital Cancer Institute, Orlando, United States
              ... and 12 more locations
----------------------------------------

102. CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease
   NCT ID: NCT03618641
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma; Lymph Node Cancer
   Intervention: CMP-001; Nivolumab
   Sponsor: Diwakar Davar
   Start Date: 2018-08-08
   Completion Date: 2023-12-31
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03618641
   Summary: The purpose this research study is to determine if the combination of nivolumab and CMP-001 improves the likelihood of eradicating (destroying) disease in the lymph node (pathologic response rate).
   Locations: UPMC Hillman Cancer Center, Pittsburgh, United States
----------------------------------------

103. A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma
   NCT ID: NCT02714218
   Status: COMPLETED
   Phase: PHASE3
   Condition: Melanoma
   Intervention: Nivolumab 3 mg/kg IV; Ipilimumab 1 mg/kg IV; Nivolumab 1 mg/kg IV; Ipilimumab 3 mg/kg IV; Nivolumab 6 mg/kg IV
   Sponsor: Bristol-Myers Squibb
   Start Date: 2016-04-04
   Completion Date: 2021-05-28
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02714218
   Summary: The purpose of this study is to evaluate two different dose combinations of nivolumab and ipilimumab in the treatment of melanoma.
   Locations: University Of Colorado Cancer Center, Aurora, United States; H. Lee Moffitt Cancer Center, Tampa, United States; Allina Health, Fridley, United States
              ... and 54 more locations
----------------------------------------

104. Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma
   NCT ID: NCT00607113
   Status: COMPLETED
   Phase: PHASE2
   Condition: Neuroendocrine Carcinoma
   Intervention: Avastin; RAD001
   Sponsor: M.D. Anderson Cancer Center
   Start Date: 2008-01
   Completion Date: 2011-10
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00607113
   Summary: Primary Objectives:

* To determine the effect of Avastin on tumor blood flow as determined by functional computed tomography (CT) in patients with low or intermediate grade neuroendocrine carcinoma.
* To determine the effect of RAD001 on tumor blood flow as determined by functional CT in patients w...
   Locations: U.T.M.D. Anderson Cancer Center, Houston, United States
----------------------------------------

105. Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation
   NCT ID: NCT01682213
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma
   Intervention: Dabrafenib
   Sponsor: Memorial Sloan Kettering Cancer Center
   Start Date: 2012-09
   Completion Date: 2019-05
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01682213
   Summary: In this study, the investigator's want to find out if dabrafenib can stop stage IIIC melanoma from coming back after surgery.
   Locations: Memorial Sloan Kettering Cancer Center, New York, United States
----------------------------------------

106. Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
   NCT ID: NCT02223819
   Status: COMPLETED
   Phase: PHASE2
   Condition: Uveal Melanoma
   Intervention: Crizotinib
   Sponsor: Columbia University
   Start Date: 2015-03
   Completion Date: 2019-07-03
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02223819
   Summary: The study is designed to determine the 32 month rate of distant relapse in patients with uveal melanoma who are at high risk of recurrence following definitive therapy with surgery or radiation who receive adjuvant crizotinib; and secondarily, the overall survival and disease specific survival in th...
   Locations: Mount Sinai Comprehensive Cancer Center, Miami Beach, United States; Columbia Univeristy Medical Center, New York, United States; Memorial Sloan Kettering Cancer Center, New York, United States
              ... and 1 more locations
----------------------------------------

107. Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
   NCT ID: NCT01993719
   Status: COMPLETED
   Phase: PHASE2
   Condition: Metastatic Melanoma
   Intervention: Aldesleukin; Fludarabine; Fludarabine; Cyclophosphamide; Cyclophosphamide; Cyclophosphamide; Young TIL; Pembrolizumab
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2013-12-12
   Completion Date: 2022-07-06
   Has Posted Results: True
   Publications Count: 2
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01993719
   Summary: Background:

* The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the laboratory in large numbers, and then giving the cells back to the patient. These cells are called Tumor Infiltrat...
   Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, United States
----------------------------------------

108. Pembrolizumab TX-naive Distant Mets Melanoma and Use of (C11-AMT) PET at Baseline as Imaging Biomarker
   NCT ID: NCT03089606
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma
   Intervention: FDG PET/CT scan; C11-AMT PET scan; Pembrolizumab; CT scan
   Sponsor: UNC Lineberger Comprehensive Cancer Center
   Start Date: 2017-04-19
   Completion Date: 2023-07-01
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03089606
   Summary: Explore the association between intensity of 11C-methyl-L-tryptophan (C11-AMT) positron emission tomography (PET) at baseline, as measured by mean standardized uptake value (SUVmax) at each lesion, total tumor metabolic volume, measurement of intra-tumoral and inter-lesional heterogeneity, with obje...
   Locations: Lineberger Comprehensive Cancer Center, Chapel Hill, United States; UNC Rex Healthcare, Raleigh, United States
----------------------------------------

109. Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma
   NCT ID: NCT03071406
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Merkel Cell Carcinoma; Skin Cancer
   Intervention: Nivolumab; Ipilimumab; Stereotactic Body Radiation Therapy (SBRT)
   Sponsor: H. Lee Moffitt Cancer Center and Research Institute
   Start Date: 2017-03-14
   Completion Date: 2025-10
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03071406
   Summary: The purpose of this study is to test the effectiveness, safety, and tolerability of the drugs nivolumab plus ipilimumab with or without the addition of stereotactic body radiation therapy (SBRT). Nivolumab is an antibody (a type of human protein) that is being tested to see if it will stimulate the ...
   Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, United States; Ohio State University Comprehensive Cancer Center, Columbus, United States
----------------------------------------

110. Phase II Study of Tesetaxel in Metastatic Melanoma
   NCT ID: NCT01064713
   Status: COMPLETED
   Phase: PHASE2
   Condition: Advanced Melanoma; Cancer
   Intervention: Tesetaxel
   Sponsor: M.D. Anderson Cancer Center
   Start Date: 2010-02
   Completion Date: 2014-10
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01064713
   Summary: The goal of this clinical research study is to learn if tesetaxel can help to control metastatic melanoma. The safety of this drug will also be studied.
   Locations: University of Texas MD Anderson Cancer Center, Houston, United States
----------------------------------------

111. A Study of RO5185426 in Patients With Metastatic Melanoma
   NCT ID: NCT01248936
   Status: COMPLETED
   Phase: PHASE2
   Condition: Malignant Melanoma
   Intervention: RO5185426
   Sponsor: Hoffmann-La Roche
   Start Date: 2010-12
   Completion Date: 2011-10
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01248936
   Summary: This is an open-label, non-comparative, multicenter, expanded access study of RO5185426 in patients who have received prior systemic therapy for metastatic melanoma and who have no other satisfactory treatment options.
----------------------------------------

112. BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.
   NCT ID: NCT01658436
   Status: COMPLETED
   Phase: PHASE2
   Condition: Pancreatic Neuroendocrine Tumors (pNET)
   Intervention: BEZ235 (Stage 1)
   Sponsor: Novartis Pharmaceuticals
   Start Date: 2012-11
   Completion Date: 2015-07
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01658436
   Summary: This is a Phase II study in 2 stages, evaluating BEZ235 plus best supportive care (BSC) versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (pNET) after failure of mTOR inhibitor therapy.

Study design: This was a Phase II, two-stage, multicenter study, where Stage 1 w...
   Locations: Indiana University SC, Indianapolis, United States; Dana Farber Cancer Institute GastrointestionalCancer Clinic, Boston, United States; Montefiore Medical Center SC-2, Bronx, United States
              ... and 14 more locations
----------------------------------------

113. Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)
   NCT ID: NCT02437136
   Status: COMPLETED
   Phase: PHASE1
   Condition: Non-Small Cell Lung Cancer; Melanoma; Mismatch Repair-Proficient Colorectal Cancer
   Intervention: entinostat; pembrolizumab
   Sponsor: Syndax Pharmaceuticals
   Start Date: 2015-08-26
   Completion Date: 2022-09-29
   Has Posted Results: True
   Publications Count: 2
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02437136
   Summary: The purpose of this study is to determine the safety and tolerability of entinostat used in combination with pembrolizumab in participants with NSCLC. Additionally, the purpose of the study is to assess how effective entinostat and pembrolizumab are in combination in participants with NSCLC, Melanom...
   Locations: Yale University, New Haven, United States; Emory University, Atlanta, United States; University of Maryland, Marlene and Stewart Greenbaum Cancer Center, Baltimore, United States
              ... and 8 more locations
----------------------------------------

114. Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)
   NCT ID: NCT03776136
   Status: COMPLETED
   Phase: PHASE2
   Condition: Advanced Melanoma
   Intervention: lenvatinib; pembrolizumab
   Sponsor: Merck Sharp & Dohme LLC
   Start Date: 2019-01-30
   Completion Date: 2023-10-11
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03776136
   Summary: This study will evaluate the safety and efficacy of combination therapy of lenvatinib (E7080/MK-7902) and pembrolizumab following approximately 2 years of pembrolizumab therapy and approximately 2 years or more lenvatinib therapy in adult participants with unresectable or advanced melanoma who have ...
   Locations: Ironwood Cancer & Research Centers ( Site 0312), Chandler, United States; John Wayne Cancer Institute ( Site 0301), Santa Monica, United States; Advocate Medical Group-Park Ridge ( Site 0313), Park Ridge, United States
              ... and 20 more locations
----------------------------------------

115. Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma
   NCT ID: NCT00518206
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma
   Intervention: NY-ESO-1 ISCOMATRIX® vaccine; Cyclophosphamide
   Sponsor: Ludwig Institute for Cancer Research
   Start Date: 2003-11-28
   Completion Date: 2010-01-22
   Has Posted Results: True
   Publications Count: 2
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00518206
   Summary: This was a Phase 2, open-label study of the NY-ESO-1 ISCOMATRIX® (ISCOM) vaccine administered as an intramuscular injection given every 4 weeks to subjects with measurable advanced malignant melanoma. Study objectives included determination of the anticancer activity, cellular and humoral immunogeni...
   Locations: Peter MacCallum Cancer Institute, East Melbourne, Australia; Austin Health (Ludwig Institute Oncology Unit), Heidelberg, Australia
----------------------------------------

116. A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma
   NCT ID: NCT01689519
   Status: COMPLETED
   Phase: PHASE3
   Condition: Malignant Melanoma
   Intervention: Placebo; Vemurafenib; Cobimetinib
   Sponsor: Hoffmann-La Roche
   Start Date: 2013-01-08
   Completion Date: 2019-07-21
   Has Posted Results: True
   Publications Count: 7
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01689519
   Summary: To evaluate the efficacy of vemurafenib in combination with cobimetinib (GDC-0973), compared with vemurafenib and placebo, in previously untreated BRAF V600 mutation-positive patients with unresectable locally advanced or metastatic melanoma, as measured by progression-free survival (PFS), assessed ...
   Locations: University of Alabama at Birmingham, Birmingham, United States; The Angeles Clinic and Research Institute - W LA Office, Los Angeles, United States; University of California Davis Health System, Sacramento, United States
              ... and 153 more locations
----------------------------------------

117. Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma
   NCT ID: NCT03620019
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma Stage Iii; Melanoma Stage Iv; Melanoma; Melanoma (Skin); Cutaneous Melanoma
   Intervention: Denosumab; Pembrolizumab; Nivolumab
   Sponsor: UNC Lineberger Comprehensive Cancer Center
   Start Date: 2018-09-10
   Completion Date: 2023-08-15
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03620019
   Summary: This is a multicenter open-label, single-arm, phase II study designed to investigate the pharmacodynamic and antitumor effects of denosumab alone and in combination with an anti-Programmed death-1 or Programmed death ligand 1 (PD1) agent (pembrolizumab or nivolumab) in patients with unresectable Pro...
   Locations: Dartmouth-Hitchcock Medical Center, Manchester, United States; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, United States
----------------------------------------

118. Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)
   NCT ID: NCT01866319
   Status: COMPLETED
   Phase: PHASE3
   Condition: Melanoma
   Intervention: Pembrolizumab; Ipilimumab
   Sponsor: Merck Sharp & Dohme LLC
   Start Date: 2013-08-28
   Completion Date: 2019-06-03
   Has Posted Results: True
   Publications Count: 12
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01866319
   Summary: This study will evaluate the safety and efficacy of 2 different dosing schedules of pembrolizumab (MK-3475), every 2 weeks (Q2W) and every 3 weeks (Q3W), and compare the 2 schedules to treatment with ipilimumab in ipilimumab-naïve participants with unresectable or metastatic melanoma. The primary hy...
----------------------------------------

119. Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection
   NCT ID: NCT00588341
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma; Skin Cancer; Cancer
   Intervention: Temozolomide
   Sponsor: Memorial Sloan Kettering Cancer Center
   Start Date: 2005-09
   Completion Date: 2009-03
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00588341
   Summary: In this study, we want to find out how likely it is for temozolomide to shrink melanoma tumors that have spread only to areas that could be removed by surgery. We also want to study the melanoma before and after temozolomide treatment to learn why some tumors respond and others do not. This is a Pha...
   Locations: Memorial Sloan-Kettering Cancer Center, New York, United States
----------------------------------------

120. Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)
   NCT ID: NCT01169649
   Status: COMPLETED
   Phase: PHASE2
   Condition: PANCREAS; Neuroendocrine
   Intervention: MK-2206
   Sponsor: Memorial Sloan Kettering Cancer Center
   Start Date: 2010-07
   Completion Date: 2014-02
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01169649
   Summary: The purpose of this study is to test a new drug called MK-2206. This study is a phase II study. In cancer studies, a phase II study is to find out what effects, good and/or bad, a new treatment has against a certain type of cancer.

MK-2206 is an oral medication known as a targeted therapy. By attac...
   Locations: Memorial Sloan Kettering Cancer Center, New York, United States
----------------------------------------

121. AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
   NCT ID: NCT00427349
   Status: COMPLETED
   Phase: PHASE2
   Condition: Gastrointestinal Carcinoid Tumor; Islet Cell Tumor; Neoplastic Syndrome
   Intervention: AMG 706; octreotide
   Sponsor: Eastern Cooperative Oncology Group
   Start Date: 2008-11-07
   Completion Date: 2015-04
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00427349
   Summary: RATIONALE: AMG 706 and octreotide may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

PURPOSE: This phase II trial is studying how well AMG 706 and octreotide work in treating patients with low-grade neuroendocrine tumor...
   Locations: Hematology Oncology Associates of Illinois - Berwyn, Berwyn, United States; Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, United States; Hematology and Oncology Associates, Chicago, United States
              ... and 109 more locations
----------------------------------------

122. Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
   NCT ID: NCT03553836
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE3
   Condition: Melanoma
   Intervention: Pembrolizumab; Placebo
   Sponsor: Merck Sharp & Dohme LLC
   Start Date: 2018-09-12
   Completion Date: 2033-10-12
   Has Posted Results: True
   Publications Count: 4
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03553836
   Summary: This 2-part study will evaluate the safety and efficacy of pembrolizumab (MK-3475) compared to placebo in participants with surgically resected high-risk Stage II melanoma. Participants in Part 1 will receive either pembrolizumab or placebo in a double-blind design every 3 weeks (Q3W) for up to 17 c...
   Locations: University of Arizona Cancer Center ( Site 0121), Tucson, United States; UCSD Moores Cancer Center ( Site 0133), La Jolla, United States; The Angeles Clinic and Research Institute ( Site 0029), Los Angeles, United States
              ... and 156 more locations
----------------------------------------

123. A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma
   NCT ID: NCT00533702
   Status: COMPLETED
   Phase: PHASE2
   Condition: Metastatic Malignant Melanoma
   Intervention: IMC-1121B (ramucirumab); Dacarbazine
   Sponsor: Eli Lilly and Company
   Start Date: 2007-11
   Completion Date: 2011-05
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00533702
   Summary: The primary objective of this study is to determine the progression-free survival (PFS) of participants with previously untreated metastatic malignant melanoma when treated with IMC-1121B (ramucirumab) alone or in combination with dacarbazine.
   Locations: ImClone Investigational Site, Decatur, United States; ImClone Investigational Site, Scottsdale, United States; ImClone Investigational Site, Scottsdale, United States
              ... and 14 more locations
----------------------------------------

124. Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
   NCT ID: NCT01143402
   Status: COMPLETED
   Phase: PHASE2
   Condition: Iris Melanoma; Medium/Large Size Posterior Uveal Melanoma; Ocular Melanoma With Extraocular Extension; Recurrent Uveal Melanoma; Small Size Posterior Uveal Melanoma; Stage IV Uveal Melanoma
   Intervention: Dacarbazine; Laboratory Biomarker Analysis; Quality-of-Life Assessment; Selumetinib; Temozolomide
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2010-06
   Completion Date: 2016-05
   Has Posted Results: True
   Publications Count: 3
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01143402
   Summary: This randomized phase II trial studies temozolomide to see how well it works compared to selumetinib in treating patients with melanoma of the eye that has spread to other places in the body. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, ...
   Locations: University of Colorado Cancer Center - Anschutz Cancer Pavilion, Aurora, United States; Mount Sinai Medical Center, Miami Beach, United States; Moffitt Cancer Center, Tampa, United States
              ... and 30 more locations
----------------------------------------

125. A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma
   NCT ID: NCT00949702
   Status: COMPLETED
   Phase: PHASE2
   Condition: Malignant Melanoma
   Intervention: vemurafenib
   Sponsor: Hoffmann-La Roche
   Start Date: 2009-09-30
   Completion Date: 2014-06-03
   Has Posted Results: True
   Publications Count: 5
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00949702
   Summary: This open-label single arm study will assess the efficacy, safety and tolerability of Vemurafenib in previously treated patients with metastatic melanoma. Patients will receive oral Vemurafenib \[RG7204; PLEXXIKON: PLX4032\] at a dose of 960 mg b.i.d. continuously until disease progression or withdr...
   Locations: UCLA - School of Medicine; Division of Hematology/Oncology, Los Angeles, United States; University of Colorado, Denver, United States; Moffitt Cancer Center, Tampa, United States
              ... and 12 more locations
----------------------------------------

126. Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors
   NCT ID: NCT01678664
   Status: COMPLETED
   Phase: PHASE2
   Condition: Neuroendocrine Tumors; Hepatic Metastases; Metastases
   Intervention: Everolimus; embolization; Doxorubicin
   Sponsor: Federation Francophone de Cancerologie Digestive
   Start Date: 2012-12
   Completion Date: 2019-04
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01678664
   Summary: Determine wether 24 months treatment with everolimus prolongs progression free survival rate (based on a central assessment) after embolisation ou chemoembolisation for liver metastases.

* H0 a 24 months progression free survival rate less than 35% is unacceptable
* H1 a 24 months progression free ...
   Locations: CHU - Hôtel Dieu, Angers, France; Hôpital Avicenne, Bobigny, France; Hôpital Saint André, Bordeaux, France
              ... and 15 more locations
----------------------------------------

127. Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients
   NCT ID: NCT00936221
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma
   Intervention: AZD6244; Dacarbazine; Placebo
   Sponsor: AstraZeneca
   Start Date: 2009-07
   Completion Date: 2014-11
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00936221
   Summary: To assess the efficacy in terms of overall survival of AZD6244 in combination with dacarbazine, compared with dacarbazine alone, in first line patients with BRAF mutation positive advanced cutaneous or unknown primary melanoma
   Locations: Research Site, Aurora, United States; Research Site, Boston, United States; Research Site, Belo Horizonte, Brazil
              ... and 35 more locations
----------------------------------------

128. High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI
   NCT ID: NCT01266603
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma
   Intervention: HDIL-2; recMAGE-A3 + AS15
   Sponsor: M.D. Anderson Cancer Center
   Start Date: 2011-02-22
   Completion Date: 2018-11-01
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01266603
   Summary: The goal of this clinical research study is to learn if high-dose interleukin-2 (HDIL-2), when given in combination with recMAGE-A3 + AS15 ASCI (Antigen-Specific Cancer Immunotherapeutic), can help to control unresectable or metastatic melanoma in patients whose tumor tissue has the MAGE-A3 protein....
   Locations: University of Texas MD Anderson Cancer Center, Houston, United States
----------------------------------------

129. RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
   NCT ID: NCT02489903
   Status: COMPLETED
   Phase: PHASE2
   Condition: Small Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Neuroendocrine Tumors; Ovarian Epithelial Cancer
   Intervention: RRx-001; Cisplatin; Etoposide; Carboplatin; Irinotecan; Vinorelbine; Doxil; Gemcitabine; Taxane; Paclitaxel; Nab-Paclitaxel; Pemetrexed
   Sponsor: EpicentRx, Inc.
   Start Date: 2015-06
   Completion Date: 2021-12-06
   Has Posted Results: True
   Publications Count: 2
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02489903
   Summary: This study is designed to explore the potential of the epigenetic agent RRx-001 to sensitize patients who previously received and now have failed a platinum based doublet regimen. RRx-001 is administered with autologous blood once weekly followed by or in combination with reintroduction of platinum-...
   Locations: Stanford University, Palo Alto, United States; VA Connecticut Cancer Center, West Haven, United States; Memorial Hospital of South Bend, South Bend, United States
              ... and 7 more locations
----------------------------------------

130. Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma
   NCT ID: NCT02599402
   Status: COMPLETED
   Phase: PHASE3
   Condition: Melanoma
   Intervention: Nivolumab; Ipilimumab
   Sponsor: Bristol-Myers Squibb
   Start Date: 2015-12-20
   Completion Date: 2020-02-10
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02599402
   Summary: The purpose of this study is to determine the effects of combination treatment of Nivolumab with Ipilimumab followed by Nivolumab monotherapy in patients with previously untreated advanced Melanoma.
   Locations: Local Institution, Garran, Australia; Local Institution, Camperdown, Australia; Local Institution, Coffs Harbour, Australia
              ... and 108 more locations
----------------------------------------

131. Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
   NCT ID: NCT01763164
   Status: COMPLETED
   Phase: PHASE3
   Condition: Metastatic or Unresectable Cutaneous Melanoma
   Intervention: MEK162; Dacarbazine
   Sponsor: Pfizer
   Start Date: 2013-07-12
   Completion Date: 2019-06-04
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01763164
   Summary: Two-arm, randomized, prospective, open-label, multi-center, phase III study to compare the efficacy and safety of MEK162 (45 mg BID) versus dacarbazine (1000 mg/m2 IV every 3 weeks) in patients with advanced (Stage IIIC) unresectable or metastatic (Stage IV) NRAS Q61 mutation-positive cutaneous or u...
   Locations: Highlands Oncology Group, Fayetteville, United States; Highlands Oncology Group, Rogers, United States; Florida Cancer Specialists, Altamonte Springs, United States
              ... and 226 more locations
----------------------------------------

132. Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer
   NCT ID: NCT02981303
   Status: COMPLETED
   Phase: PHASE2
   Condition: Advanced Melanoma; Triple-Negative Breast Cancer
   Intervention: Imprime PGG; Pembrolizumab
   Sponsor: HiberCell, Inc.
   Start Date: 2017-02-22
   Completion Date: 2020-12-31
   Has Posted Results: True
   Publications Count: 6
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02981303
   Summary: Objective: To determine the Overall Response Rate (ORR) to Imprime PGG + pembrolizumab in subjects with advanced melanoma or metastatic TNBC

Safety: To characterize the safety of Imprime PGG + pembrolizumab given in combination

Hypothesis: Restore (for melanoma) or enhance (for TNBC) sensitivity t...
   Locations: Arizona Center for Cancer Care, Avondale, United States; John Wayne Cancer Institute, Santa Monica, United States; University of Colorado Cancer Center, Aurora, United States
              ... and 7 more locations
----------------------------------------

133. Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
   NCT ID: NCT01962103
   Status: COMPLETED
   Phase: PHASE1
   Condition: Neuroblastoma; Rhabdomyosarcoma; Ewing's Sarcoma; Ewing's Tumor; Sarcoma, Ewing's; Sarcomas, Epitheliod; Sarcoma, Soft Tissue; Sarcoma, Spindle Cell; Melanoma; Malignant Melanoma; Clinical Oncology; Oncology, Medical; Pediatrics, Osteosarcoma; Osteogenic Sarcoma; Osteosarcoma Tumor; Sarcoma, Osteogenic; Tumors; Cancer; Neoplasia; Neoplasm; Histiocytoma; Fibrosarcoma; Dermatofibrosarcoma
   Intervention: nab-paclitaxel; nab-paclitaxel
   Sponsor: Celgene
   Start Date: 2013-12-04
   Completion Date: 2018-11-06
   Has Posted Results: True
   Publications Count: 3
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01962103
   Summary: The purpose of this study is to find the safe dose of nab-paclitaxel in children with solid tumors, and to see if it works to treat these solid tumors in children and young adults (in Phase 1 ≤ 18 years old and in Phase 2 ≤ 24 years old). After the final dose has been chosen, patients will be enroll...
   Locations: Phoenix Childrens Hospital, Phoenix, United States; Columbia University Medical Center, New York, United States; The Hospital for Sick Children, Toronto, Canada
              ... and 17 more locations
----------------------------------------

134. Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma
   NCT ID: NCT01661179
   Status: COMPLETED
   Phase: PHASE1
   Condition: Unresectable Locally Advanced or Metastatic, Medullary Thyroid Carcinoma
   Intervention: Vandetanib 300mg
   Sponsor: Genzyme, a Sanofi Company
   Start Date: 2012-11
   Completion Date: 2014-07
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01661179
   Summary: Open-label Study to Evaluate the Safety and Tolerability of Vandetanib 300 mg/day in Japanese Patients with Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma.
   Locations: Research Site, Fukuoka-shi, Japan; Research Site, Kobe-shi, Japan; Research Site, Koto-ku, Japan
              ... and 1 more locations
----------------------------------------

135. Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy
   NCT ID: NCT01449279
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma
   Intervention: Ipilimumab; Radiation Therapy
   Sponsor: Stanford University
   Start Date: 2011-10
   Completion Date: 2016-12-01
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01449279
   Summary: To determine the safety of local palliative radiation therapy used in combination with anti-CTLA-4 immunotherapy.
   Locations: Stanford University School of Medicine, Stanford, United States
----------------------------------------

136. A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors
   NCT ID: NCT01413503
   Status: COMPLETED
   Phase: PHASE2
   Condition: Pheochromocytoma; Paraganglioma
   Intervention: 131I-MIBG
   Sponsor: University of California, San Francisco
   Start Date: 1991-05
   Completion Date: 2009-05
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01413503
   Summary: This is an ongoing prospective Phase II clinical trial evaluating the efficacy of 131I-MIBG for the treatment of patients with metastatic or unresectable pheochromocytoma and related tumors.
   Locations: UCSF, San Francisco, United States
----------------------------------------

137. Vemurafenib and TIL Therapy for Metastatic Melanoma
   NCT ID: NCT02354690
   Status: COMPLETED
   Phase: PHASE1
   Condition: Metastatic Melanoma
   Intervention: Vemurafenib; Lymphodepleting chemotherapy; TIL infusion; Interleukin-2
   Sponsor: Inge Marie Svane
   Start Date: 2014-11
   Completion Date: 2018-12-31
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02354690
   Summary: Background:

Adoptive T cell therapy with tumor infiltrating lymphocytes (TILs) has been reported to induce durable clinical responses in patients with metastatic melanoma. From patients own tumor material T cells are extracted, expanded and activated in vitro in a 4-6 weeks culture period. Before T...
   Locations: Center for Cancer Immune Therapy, Dept. of Haematology/Oncology, Copenhagen, Denmark
----------------------------------------

138. A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
   NCT ID: NCT02819843
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma; Merkel Cell Carcinoma; Other Solid Tumors
   Intervention: TALIMOGENE LAHERPAREPVEC (TVEC); Hypofractionated Radiotherapy
   Sponsor: Memorial Sloan Kettering Cancer Center
   Start Date: 2016-06-21
   Completion Date: 2024-02-22
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02819843
   Summary: The purpose of this phase II clinical study is to test the good and bad effects of T-VEC (talimogene laherparepvec) with or without hypofractionated radiotherapy on people with melanoma, Merkel cell carcinoma, or other solid tumors with skin metastasis.
   Locations: Memorial Sloan Kettering Monmouth, Middletown, United States; Memorial Sloan Kettering Westchester, Harrison, United States; Memorial Sloan Kettering Cancer Center, New York, United States
----------------------------------------

139. Fecal Microbiota Transplant (FMT) in Melanoma Patients
   NCT ID: NCT03341143
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma
   Intervention: Fecal Microbiota Transplant with Pembrolizumab
   Sponsor: Zarour, Hassane, MD
   Start Date: 2018-03-19
   Completion Date: 2024-09-30
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03341143
   Summary: The main goal of this research study is to determine if the fecal microbiota transplant (FMT) improves the body's ability to fight your cancer.
   Locations: UPMC Hillman Cancer Center, Pittsburgh, United States
----------------------------------------

140. Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer
   NCT ID: NCT00134043
   Status: COMPLETED
   Phase: PHASE2
   Condition: Insular Thyroid Cancer; Recurrent Thyroid Cancer; Stage II Follicular Thyroid Cancer; Stage II Papillary Thyroid Cancer; Stage IV Follicular Thyroid Cancer; Stage IV Papillary Thyroid Cancer; Thyroid Gland Medullary Carcinoma
   Intervention: vorinostat
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2005-12
   Completion Date: 2009-03
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00134043
   Summary: This phase II trial is studying how well suberoylanilide hydroxamic acid works in treating patients with metastatic and/or locally advanced or locally recurrent thyroid cancer. Drugs used in chemotherapy, such as suberoylanilide hydroxamic acid, work in different ways to stop the growth of tumor cel...
   Locations: Ohio State University Medical Center, Columbus, United States
----------------------------------------

141. Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer
   NCT ID: NCT02267603
   Status: COMPLETED
   Phase: PHASE2
   Condition: Recurrent Merkel Cell Carcinoma; Stage III Merkel Cell Carcinoma AJCC v7; Stage IIIA Merkel Cell Carcinoma AJCC v7; Stage IIIB Merkel Cell Carcinoma AJCC v7; Stage IV Merkel Cell Carcinoma AJCC v7
   Intervention: Laboratory Biomarker Analysis; Pembrolizumab
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2014-11-25
   Completion Date: 2021-12-15
   Has Posted Results: True
   Publications Count: 3
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02267603
   Summary: This phase II trial studies how well pembrolizumab works in treating patients with Merkel cell cancer that cannot be removed by surgery or controlled with treatment, or has spread to other parts of the body. Pembrolizumab may stimulate the immune system to identify and destroy cancer cells.
   Locations: Stanford Cancer Institute Palo Alto, Palo Alto, United States; UCSF Medical Center-Mount Zion, San Francisco, United States; Yale University, New Haven, United States
              ... and 10 more locations
----------------------------------------

142. Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II Study
   NCT ID: NCT00462423
   Status: COMPLETED
   Phase: PHASE2
   Condition: Metastatic Malignant Melanoma
   Intervention: Avastin; Abraxane
   Sponsor: Lynn E. Spitler, MD
   Start Date: 2007-04
   Completion Date: 2012-01
   Has Posted Results: True
   Publications Count: 2
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00462423
   Summary: The study is an open-label, single arm multicenter Phase II study to evaluate the safety and efficacy of the combination of Abraxane and Avastin as first-line therapy for patients with unresectable metastatic malignant melanoma. The patient sample will be approximately 50 individuals, males and fema...
   Locations: Northern California Melanoma Center, San Francisco, United States; The Angeles Clinic and Research Institute, Santa Monica, United States
----------------------------------------

143. Evaluation of [18F]Fluoroethyl Triazole Labelled [Tyr3]-Octreotate Analogues for the Imaging of Neuroendocrine Tumours.
   NCT ID: NCT06456723
   Status: COMPLETED
   Phase: PHASE1
   Condition: Neuroendocrine Tumors
   Intervention: [18F]-FET-βAG-TOCA
   Sponsor: Imperial College London
   Start Date: 2014-05-14
   Completion Date: 2018-10-17
   Has Posted Results: True
   Publications Count: 2
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT06456723
   Summary: Radiolabelled somatostatin analogs are invaluable in the diagnosis and treatment of neuroendocrine tumours (NET). The most common positron emission tomography (PET) radiotracers used for the visualisation of NET are radiolabelled somatostatin analogs (SSAs) labelled with \[68Ga\]Ga-DOTA-peptides. Ho...
----------------------------------------

144. Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma
   NCT ID: NCT00085423
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma (Skin)
   Intervention: aldesleukin; sargramostim; cyclophosphamide; fludarabine phosphate
   Sponsor: Dartmouth-Hitchcock Medical Center
   Start Date: 2004-02
   Completion Date: 2010-02
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00085423
   Summary: RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide and fludarabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells and may help a person's immune system recover from the s...
   Locations: Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, United States
----------------------------------------

145. Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
   NCT ID: NCT01597908
   Status: COMPLETED
   Phase: PHASE3
   Condition: Melanoma
   Intervention: Dabrafenib; Vemurafenib; Trametinib
   Sponsor: Novartis Pharmaceuticals
   Start Date: 2012-06-04
   Completion Date: 2019-04-25
   Has Posted Results: True
   Publications Count: 5
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01597908
   Summary: This was a two-arm, open-label, randomized, Phase III study comparing dabrafenib (GSK2118436) and trametinib (GSK1120212) combination therapy with vemurafenib.
   Locations: Novartis Investigative Site, Birmingham, United States; Novartis Investigative Site, Gilbert, United States; Novartis Investigative Site, Beverly Hills, United States
              ... and 202 more locations
----------------------------------------

146. T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
   NCT ID: NCT01967823
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma; Meningioma; Breast Cancer; Non-Small Cell Lung Cancer; Hepatocellular Cancer
   Intervention: Anti-NY ESO-1 mTCR PBL; Cyclophosphamide; Fludarabine; Aldesleukin
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2013-10-24
   Completion Date: 2020-04-06
   Has Posted Results: True
   Publications Count: 3
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01967823
   Summary: Background:

The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for treating patients with cancer that involves taking white blood cells from the patient, growing them in the laboratory in large numbers, genetically modifying them, and then giving the cells back...
   Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, United States
----------------------------------------

147. Ipilimumab + Temozolomide in Metastatic Melanoma
   NCT ID: NCT01119508
   Status: COMPLETED
   Phase: PHASE2
   Condition: Metastatic Melanoma
   Intervention: Ipilimumab; Temozolomide
   Sponsor: M.D. Anderson Cancer Center
   Start Date: 2010-05
   Completion Date: 2016-08
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01119508
   Summary: The goal of this clinical research study is to learn if combining ipilimumab and temozolomide can help to control metastatic melanoma. The safety of this drug combination will be studied. Researchers would also like to study how this therapy affects the levels of certain chemicals in the blood that ...
   Locations: University of Texas MD Anderson Cancer Center, Houston, United States
----------------------------------------

148. Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment
   NCT ID: NCT01298323
   Status: COMPLETED
   Phase: PHASE3
   Condition: Locally Advanced or Metastatic Medullary Thyroid Cancer; Medullary Thyroid Cancer
   Intervention: Patient outreach; Vandetanib
   Sponsor: Sanofi
   Start Date: 2011-02-25
   Completion Date: 2025-03-13
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01298323
   Summary: The purpose of this study is to evaluate the effect of patient outreach program on the proportion of time patients with MTC experience moderate or severe AEs during first 12 months of treatment with vandetanib
   Locations: Investigational Site Number : 301, St Leonards, Australia; Investigational Site Number 301, St Leonards, Australia; Investigational Site Number 401, Wien, Austria
              ... and 63 more locations
----------------------------------------

149. A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
   NCT ID: NCT00804908
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma; Metastatic Melanoma; Skin Cancer
   Intervention: temozolomide; ABT-888; Placebo
   Sponsor: AbbVie (prior sponsor, Abbott)
   Start Date: 2009-02
   Completion Date: 2016-01
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00804908
   Summary: The purpose of this study is to evaluate the efficacy of ABT-888 in combination with temozolomide versus temozolomide alone in subjects with metastatic melanoma.
----------------------------------------

150. Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma
   NCT ID: NCT02107755
   Status: COMPLETED
   Phase: PHASE2
   Condition: Liver Metastases; Lung Metastases; Recurrent Melanoma; Stage IV Melanoma; Tumors Metastatic to Brain
   Intervention: ipilimumab; stereotactic radiosurgery; laboratory biomarker analysis
   Sponsor: Ohio State University Comprehensive Cancer Center
   Start Date: 2014-09-05
   Completion Date: 2021-08-16
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02107755
   Summary: This phase II trial studies the effectiveness of the combination of stereotactic radiation therapy and ipilimumab in patients with metastatic melanoma that has spread to four or fewer sites in the body (oligometastatic). Stereotactic radiation therapy is a type of external beam radiation therapy tha...
   Locations: Ohio State University Comprehensive Cancer Center, Columbus, United States
----------------------------------------

151. Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists
   NCT ID: NCT02126579
   Status: COMPLETED
   Phase: PHASE1
   Condition: Melanoma; Metastatic Melanoma; Mucosal Melanoma
   Intervention: Peptide Vaccine (LPV7) + Tetanus peptide; PolyICLC; Resiquimod; IFA
   Sponsor: Craig L Slingluff, Jr
   Start Date: 2014-05-01
   Completion Date: 2021-05-05
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02126579
   Summary: The purpose of this study is to learn what effects (good and bad) an experimental vaccine (LPV7) plus tetanus peptide and other substances called polyICLC, resiquimod, and Montanide ISA-51 have on you and your melanoma. We will also look at whether the experimental vaccine and these drugs cause any ...
   Locations: MDAnderson Cancer Center, Houston, United States; University of Virginia, Charlottesville, United States
----------------------------------------

152. LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations
   NCT ID: NCT01726738
   Status: COMPLETED
   Phase: PHASE2
   Condition: Stage III Melanoma; Stage IV Melanoma; Unresectable Melanoma; BRAF Mutant Melanoma
   Intervention: BRAF inhibitor dabrafenib and MEK inhibitor trametinib
   Sponsor: UNC Lineberger Comprehensive Cancer Center
   Start Date: 2013-04-04
   Completion Date: 2020-09-17
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01726738
   Summary: This phase II study in 20 patients with BRAFV600E mutant, unresectable stage III/IV melanoma is designed to explore the mechanisms by which tumors acquire resistance to the combination of a BRAF inhibitor (dabrafenib) and MEK inhibitor (trametinib). Tissue will be collected at baseline and at progre...
   Locations: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, United States
----------------------------------------

153. A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
   NCT ID: NCT00162123
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma
   Intervention: Ipilimumab
   Sponsor: Bristol-Myers Squibb
   Start Date: 2006-05
   Completion Date: 2014-04
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00162123
   Summary: The purpose of this study was to evaluate the continued use of ipilimumab in patients who had reinduction at the time of disease progression or to continue maintenance treatment. In addition, this study will continue to follow patients who have taken ipilimumab, but who are not eligible for maintena...
   Locations: University Of Arizona Cancer Center, Tucson, United States; Wilshire Oncology Medical Group Inc, Laverne, United States; The Angeles Clinic & Research Inst., Los Angeles, United States
              ... and 55 more locations
----------------------------------------

154. Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases
   NCT ID: NCT00587964
   Status: COMPLETED
   Phase: PHASE2
   Condition: Brain Metastasis; Bladder Cancer; Breast Cancer; Cervical Cancer; Colon Cancer; HEENT Cancer; Lung Cancer; Melanoma; Pancreatic Cancer; Prostate Cancer; Rectal Cancer; Sarcoma; Testicular Cancer
   Intervention: Stereotactic Radiosurgery
   Sponsor: Memorial Sloan Kettering Cancer Center
   Start Date: 2004-06
   Completion Date: 2009-01
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00587964
   Summary: For patients who have one or two metastases in the brain, the tumor(s) can often be removed with surgery to relieve symptoms from the tumor(s) and to improve survival. However, about half of all patients who have the tumor(s) removed with surgery will develop regrowth (recurrence) of the tumor. To p...
   Locations: Memorial Sloan-Kettering Cancer Center, New York, United States
----------------------------------------

155. Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)
   NCT ID: NCT01783938
   Status: COMPLETED
   Phase: PHASE2
   Condition: Advanced or Metastatic Melanoma
   Intervention: Nivolumab; Ipilimumab
   Sponsor: Bristol-Myers Squibb
   Start Date: 2013-04-30
   Completion Date: 2020-08-12
   Has Posted Results: True
   Publications Count: 2
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01783938
   Summary: The purpose of this study is to evaluate the safety and efficacy of a sequential combination therapy of Nivolumab and Ipilimumab
   Locations: H. Lee Moffitt Cancer Center & Research Institute, Tampa, United States; Indiana University Health Melvin And Bren Simon Cancer Center, Indianapolis, United States; Beth Israel Deaconess Medical Center, Boston, United States
              ... and 8 more locations
----------------------------------------

156. Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors
   NCT ID: NCT01782443
   Status: COMPLETED
   Phase: PHASE2
   Condition: Carcinoid Tumor
   Intervention: Ziv-aflibercept
   Sponsor: Dana-Farber Cancer Institute
   Start Date: 2013-02-13
   Completion Date: 2021-12-26
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01782443
   Summary: This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer. "Investigational" means that the drug, Ziv-aflibercept, is being studied. It also means that the FDA has not yet approv...
   Locations: Massachusetts General Hospital, Boston, United States; Brigham and Women's Hospital, Boston, United States; Dana-Farber Cancer Institute, Boston, United States
----------------------------------------

157. Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
   NCT ID: NCT03484923
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma
   Intervention: PDR001; LAG525; INC280; ACZ885; LEE011
   Sponsor: Novartis Pharmaceuticals
   Start Date: 2018-09-10
   Completion Date: 2022-12-30
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03484923
   Summary: The primary purpose of this study is to evaluate the efficacy of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma
   Locations: The Angeles Clinic and Research Institute, Los Angeles, United States; University of California Los Angeles, Los Angeles, United States; UCSF Medical Center ., San Francisco, United States
              ... and 27 more locations
----------------------------------------

158. Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE
   NCT ID: NCT03673943
   Status: COMPLETED
   Phase: PHASE3
   Condition: Neuroendocrine Tumors
   Intervention: 64Cu-DOTATATE
   Sponsor: Radiomedix, Inc.
   Start Date: 2018-08-23
   Completion Date: 2019-08-07
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03673943
   Summary: This is an open-label, single-dose, single-arm, single-center imaging study using DOTATATE peptide, labelled with the 64Cu tracer.
   Locations: Excel Diagnostics and Nuclear Oncology Center, Houston, United States
----------------------------------------

159. Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
   NCT ID: NCT01037790
   Status: COMPLETED
   Phase: PHASE2
   Condition: Adult Solid Tumor; Adenocarcinoma of the Colon; Adenocarcinoma of the Rectum; Adult Central Nervous System Germ Cell Tumor; Adult Teratoma; Benign Teratoma; Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; Familial Testicular Germ Cell Tumor; HER2-negative Breast Cancer; HER2-positive Breast Cancer; Male Breast Cancer; Ovarian Immature Teratoma; Ovarian Mature Teratoma; Ovarian Monodermal and Highly Specialized Teratoma; Progesterone Receptor-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Recurrent Colon Cancer; Recurrent Extragonadal Germ Cell Tumor; Recurrent Extragonadal Non-seminomatous Germ Cell Tumor; Recurrent Extragonadal Seminoma; Recurrent Malignant Testicular Germ Cell Tumor; Recurrent Melanoma; Recurrent Ovarian Germ Cell Tumor; Recurrent Rectal Cancer; Stage III Extragonadal Non-seminomatous Germ Cell Tumor; Stage III Extragonadal Seminoma; Stage III Malignant Testicular Germ Cell Tumor; Stage III Ovarian Germ Cell Tumor; Stage IV Breast Cancer; Stage IV Colon Cancer; Stage IV Extragonadal Non-seminomatous Germ Cell Tumor; Stage IV Extragonadal Seminoma; Stage IV Melanoma; Stage IV Ovarian Germ Cell Tumor; Stage IV Rectal Cancer; Testicular Immature Teratoma; Testicular Mature Teratoma
   Intervention: PD-0332991
   Sponsor: Abramson Cancer Center at Penn Medicine
   Start Date: 2009-10
   Completion Date: 2019-10
   Has Posted Results: True
   Publications Count: 2
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01037790
   Summary: RATIONALE: PD 0332991 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

PURPOSE: This phase II trial is studying the side effects and how well PD 0332991 works in treating patients with refractory solid tumors.
   Locations: Abramson Cancer Center of The University of Pennsylvania, Philadelphia, United States
----------------------------------------

160. A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)
   NCT ID: NCT05665595
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE3
   Condition: Melanoma
   Intervention: Pembrolizumab/Vibostolimab; Pembrolizumab
   Sponsor: Merck Sharp & Dohme LLC
   Start Date: 2023-01-19
   Completion Date: 2025-08-27
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT05665595
   Summary: The primary purpose of this study is to compare pembrolizumab/vibostolimab to pembrolizumab with respect to recurrence-free survival (RFS). The primary hypothesis is that pembrolizumab/vibostolimab is superior to pembrolizumab with respect to RFS as assessed by the investigator in participants with ...
   Locations: Moores Cancer Center ( Site 0116), La Jolla, United States; The Angeles Clinic and Research Institute - West Los Angeles Office ( Site 0123), Los Angeles, United States; UCLA Hematology/Oncology - Westwood (Building 100) ( Site 0131), Los Angeles, United States
              ... and 202 more locations
----------------------------------------

161. Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
   NCT ID: NCT01274338
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE3
   Condition: Melanoma of Unknown Primary; Recurrent Melanoma; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7
   Intervention: Ipilimumab; Quality-of-Life Assessment; Recombinant Interferon Alfa-2b
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2011-05-25
   Completion Date: 2026-03-19
   Has Posted Results: True
   Publications Count: 3
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01274338
   Summary: This randomized phase III trial studies ipilimumab to see how well it works compared to high-dose interferon alfa-2b in treating patients with high-risk stage III-IV melanoma that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as ipilimumab, may help the body's immune sy...
   Locations: University of Alabama at Birmingham Cancer Center, Birmingham, United States; Providence Hospital, Mobile, United States; University of South Alabama Mitchell Cancer Institute, Mobile, United States
              ... and 940 more locations
----------------------------------------

162. Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers
   NCT ID: NCT02487095
   Status: COMPLETED
   Phase: PHASE1
   Condition: Carcinoma, Non-Small -Cell Lung; Ovarian Neoplasms; Small Cell Lung Carcinoma; Uterine Cervical Neoplasms; Carcinoma, Neuroendocrine; Extrapulmonary Small Cell Cancer
   Intervention: Topotecan; VX-970 (M6620)
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2015-07-30
   Completion Date: 2024-12-26
   Has Posted Results: True
   Publications Count: 4
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02487095
   Summary: Background:

Chemotherapy damages cancer cell deoxyribonucleic acid (DNA) so the cells die, and the tumor shrinks. But it may stop working in some people over time. This is partly due to efficient DNA damage repair mechanisms used by tumor cells. VX-970 (M6620) may stop cancer cells from preventing ...
   Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, United States
----------------------------------------

163. A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma
   NCT ID: NCT02601950
   Status: COMPLETED
   Phase: PHASE2
   Condition: Malignant Rhabdoid Tumors (MRT); Rhabdoid Tumors of the Kidney (RTK); Atypical Teratoid Rhabdoid Tumors (ATRT); Selected Tumors With Rhabdoid Features; Synovial Sarcoma; INI1-negative Tumors; Malignant Rhabdoid Tumor of Ovary; Renal Medullary Carcinoma; Epithelioid Sarcoma; Poorly Differentiated Chordoma (or Other Chordoma With Sponsor Approval); Any Solid Tumor With an EZH2 GOF Mutation
   Intervention: Tazemetostat
   Sponsor: Epizyme, Inc.
   Start Date: 2015-12-22
   Completion Date: 2024-02-26
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02601950
   Summary: This study will include participants with various types of cancer known as soft-tissue sarcomas.

Tissues that can be affected by soft tissue sarcomas include fat, muscle, blood vessels, deep skin tissues, tendons and ligaments.

Soft tissue cancers are rare and can occur almost anywhere in the body...
   Locations: University of California San Francisco, San Francisco, United States; University of Colorado Denver, Aurora, United States; Mayo Clinic - Jacksonville, Jacksonville, United States
              ... and 29 more locations
----------------------------------------

164. Study of Gene Modified Immune Cells in Patients With Advanced Melanoma
   NCT ID: NCT00910650
   Status: COMPLETED
   Phase: PHASE2
   Condition: Metastatic Melanoma
   Intervention: F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells; non-myeloablative conditioning chemotherapy
   Sponsor: Jonsson Comprehensive Cancer Center
   Start Date: 2009-10-13
   Completion Date: 2019-05-30
   Has Posted Results: True
   Publications Count: 3
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00910650
   Summary: The purpose of this phase 2 study is to find the best way to give this new experimental regimen and determine if it can treat metastatic melanoma in humans. In this phase 2 study, the experimental products are given initially to a group of 8 people. If safe and found to have significant anti-tumor a...
   Locations: University of California Los Angeles, David Geffen School of Medicine, Los Angeles, United States
----------------------------------------

165. Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma
   NCT ID: NCT00923195
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma; Skin Cancer
   Intervention: MART-1: 26-35(27L) Peptide; Montanide ISA 51 VG; gp100:154-162 Peptide; Radiation; Aldesleukin; Fludarabine; Cyclophosphamide; Anti-gp 100:154 TCR PBL; Anti-MART-1 F5 TCR PBL
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2008-12
   Completion Date: 2011-08
   Has Posted Results: True
   Publications Count: 4
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00923195
   Summary: Background:

* Melanoma antigen recognized by T-cells (MART-1) and gp100 are two genes found in melanoma cells. An experimental procedure developed for treating patients with advanced melanoma uses these genes and a type of virus to make special cells called anti-MART-1 and anti-gp100 cells, which a...
   Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, United States
----------------------------------------

166. Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma
   NCT ID: NCT02306850
   Status: COMPLETED
   Phase: PHASE2
   Condition: Unresectable Malignant Neoplasm; Melanoma; Metastatic Melanoma; Stage IV Melanoma; Stage III Melanoma
   Intervention: Pembrolizumab
   Sponsor: St. Louis University
   Start Date: 2015-01
   Completion Date: 2018-06-08
   Has Posted Results: True
   Publications Count: 4
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02306850
   Summary: This study is being done to see if using the study drug, pembrolizumab, can shrink down melanoma tumors enough so that they will be small enough to cut out, so that there will be no cancer left in the body.

Eligible participants include those who have not received any systemic melanoma therapies (i...
   Locations: Saint Louis University Hospital, Saint Louis, United States
----------------------------------------

167. Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)
   NCT ID: NCT01327612
   Status: COMPLETED
   Phase: PHASE2
   Condition: Advanced Solid Tumors; Carcinoid; Colorectal Cancer; Locally Advanced; Lymphoma; Metastatic Cancer; Non-Small Cell Lung Cancer; Sarcoma; Solid Tumors
   Intervention: Modified FOLFOX6; Conatumumab; Ganitumab; Bevacizumab
   Sponsor: Amgen
   Start Date: 2011-03-03
   Completion Date: 2020-02-05
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01327612
   Summary: The purpose of this protocol is to allow continued treatment with conatumumab and/or ganitumab, with or without chemotherapy, to participants who completed a separate Amgen-sponsored conatumumab or ganitumab study without disease progression whose previous studies were closed.
   Locations: Research Site, Duarte, United States; Research Site, La Jolla, United States; Research Site, Denver, United States
              ... and 9 more locations
----------------------------------------

168. Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations
   NCT ID: NCT02296112
   Status: COMPLETED
   Phase: PHASE2
   Condition: Recurrent Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma
   Intervention: trametinib; laboratory biomarker analysis; pharmacological study
   Sponsor: Vanderbilt-Ingram Cancer Center
   Start Date: 2015-01
   Completion Date: 2021-04-16
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02296112
   Summary: This phase II trial studies trametinib in treating patients with melanoma with v-Raf murine sarcoma viral oncogene homolog B (BRAF) non-V600 mutations that has spread to other places in the body. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
   Locations: Georgetown University Medical Center, Washington, United States; Dana-Farber Cancer Institute, Boston, United States; Vanderbilt-Ingram Cancer Center, Nashville, United States
              ... and 1 more locations
----------------------------------------

169. A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation
   NCT ID: NCT04280081
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Solid Tumor; Medullary Thyroid Cancer
   Intervention: Selpercatinib
   Sponsor: Eli Lilly and Company
   Start Date: 2020-03-16
   Completion Date: 2027-11
   Has Posted Results: True
   Publications Count: 2
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04280081
   Summary: The reason for this study is to see if the study drug selpercatinib is safe and effective in participants in China with rearranged during transfection (RET) fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.
   Locations: Beijing Cancer Hospital, Beijing, China; The First Affiated Hospital Of Guangzhou Medical University, Guangzhou, China; Southern Medical University Nanfang Hospital, Guangzhou, China
              ... and 10 more locations
----------------------------------------

170. A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
   NCT ID: NCT02643303
   Status: COMPLETED
   Phase: PHASE1
   Condition: Head and Neck Squamous Cell Carcinoma; Breast Cancer; Sarcoma; Merkel Cell Carcinoma; Cutaneous T-Cell Lymphoma; Melanoma; Renal Cancer; Bladder Cancer; Prostate Cancer; Testicular Cancer; Solid Tumor
   Intervention: Durvalumab; Tremelimumab; Poly-ICLC
   Sponsor: Ludwig Institute for Cancer Research
   Start Date: 2016-12-28
   Completion Date: 2022-02-23
   Has Posted Results: True
   Publications Count: 2
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02643303
   Summary: This is an open-label, multicenter, Phase 1/2 study of the CTLA-4 antibody, tremelimumab, and the PD-L1 antibody, durvalumab (MEDI4736), in combination with the tumor microenvironment (TME) modulator poly-ICLC, a TLR3 agonist, in subjects with advanced, measurable, biopsy-accessible cancers.
   Locations: Research Facility, Atlanta, United States; Research Facility, Lebanon, United States; Research Facility, Buffalo, United States
              ... and 4 more locations
----------------------------------------

171. RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA
   NCT ID: NCT01497808
   Status: COMPLETED
   Phase: PHASE1
   Condition: Metastatic Melanoma
   Intervention: Ipilimumab; Stereotactic Body Radiation Therapy
   Sponsor: Abramson Cancer Center at Penn Medicine
   Start Date: 2011-11-29
   Completion Date: 2015-10-12
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01497808
   Summary: The primary objective is to determine the maximum tolerated hypofractionated radiotherapy dose (MTD) to a solitary metastatic focus ('index lesion') when followed by ipilimumab, in metastatic melanoma patients without brain involvement The secondary objectives are to determine late toxicity, immune-...
   Locations: Abramson Cancer Center of the Universirty of Pennsylvania, Philadelphia, United States
----------------------------------------

172. Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
   NCT ID: NCT01134614
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Advanced Melanoma; Metastatic Melanoma; Recurrent Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Melanoma
   Intervention: Ipilimumab; Sargramostim
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2010-12-28
   Completion Date: 2026-03-19
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01134614
   Summary: This randomized phase II trial is studying how well giving ipilimumab with or without sargramostim (GM-CSF) works in treating patients with stage III or stage IV melanoma that cannot be removed by surgery (unresectable). Ipilimumab works by activating the patient's immune system to fight cancer. Col...
   Locations: University of Alabama at Birmingham Cancer Center, Birmingham, United States; Stanford Cancer Institute Palo Alto, Palo Alto, United States; VA Palo Alto Health Care System, Palo Alto, United States
              ... and 255 more locations
----------------------------------------

173. A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)
   NCT ID: NCT02156804
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma
   Intervention: Nivolumab (BMS-936558)
   Sponsor: Bristol-Myers Squibb
   Start Date: 2014-10-07
   Completion Date: 2019-01-18
   Has Posted Results: True
   Publications Count: 2
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02156804
   Summary: The purpose of this study is to determine the rate and frequency of high-grade (CTCAE v4.0 Grade 3 or higher), treatment-related, select adverse events in subjects with histologically confirmed stage III (unresectable) or stage IV melanoma and progression post prior treatment containing an anti-Cyto...
   Locations: Local Institution, Graz, Austria; Local Institution, Innsbruck, Austria; Local Institution, Salzburg, Austria
              ... and 167 more locations
----------------------------------------

174. Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
   NCT ID: NCT00769704
   Status: COMPLETED
   Phase: PHASE3
   Condition: Melanoma
   Intervention: Talimogene laherparepvec; GM-CSF
   Sponsor: BioVex Limited
   Start Date: 2009-04
   Completion Date: 2014-09
   Has Posted Results: True
   Publications Count: 3
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00769704
   Summary: The objective of this study is to evaluate the efficacy and safety of treatment with talimogene laherparepvec compared to subcutaneously administered GM-CSF in patients with unresectable Stage IIIb, IIIc and Stage IV melanoma. The efficacy endpoints of the study aim to demonstrate overall clinical b...
   Locations: University of Arizona Cancer Center, Tucson, United States; University of Arkansas for Medical Sciences, Little Rock, United States; University of California San Diego, Moores Cancer Center, La Jolla, United States
              ... and 80 more locations
----------------------------------------

175. Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
   NCT ID: NCT00521001
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma (Skin)
   Intervention: everolimus; temozolomide
   Sponsor: Alliance for Clinical Trials in Oncology
   Start Date: 2008-01
   Completion Date: 2010-12
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00521001
   Summary: RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everolimus may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes ...
   Locations: Aurora Presbyterian Hospital, Aurora, United States; Boulder Community Hospital, Boulder, United States; Penrose Cancer Center at Penrose Hospital, Colorado Springs, United States
              ... and 192 more locations
----------------------------------------

176. Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma
   NCT ID: NCT00506142
   Status: COMPLETED
   Phase: PHASE2
   Condition: Metastatic Malignant Uveal Melanoma
   Intervention: Marqibo® (vincristine sulfate liposomes injection)
   Sponsor: Spectrum Pharmaceuticals, Inc
   Start Date: 2007-11
   Completion Date: 2014-12
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00506142
   Summary: Marqibo (liposomal vincristine) is a form of vincristine preparation. Vincristine is designed to interfere with the multiplication of cancer cells, which may slow or stop their growing and spreading throughout the body. This may cause the cancer cells to die. Liposomal vincristine is formed when vin...
   Locations: University of California, Los Angeles, Los Angeles, United States; University of Colorado, Denver, Denver, United States; Thomas Jefferson University, Philadelphia, United States
              ... and 1 more locations
----------------------------------------

177. Study of ADI-PEG 20 in Patients With Advanced Melanoma
   NCT ID: NCT00520299
   Status: COMPLETED
   Phase: PHASE1
   Condition: Metastatic Melanoma; Skin Cancer; Neoplasm
   Intervention: ADI PEG 20
   Sponsor: Ludwig Institute for Cancer Research
   Start Date: 2007-07
   Completion Date: 2010-03
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00520299
   Summary: This was a phase 1/2, open-label, dose-escalation study of arginine deiminase linked via succinimidyl succinate to polyethylene glycol of 20,000 molecular weight (ADI-PEG 20) in subjects with advanced melanoma. ADI-PEG 20 was administered intramuscularly (IM) at escalating doses weekly for 9 weeks (...
   Locations: NYU Cancer Institute, New York, United States; Memorial Sloan-Kettering Cancer Center, New York, United States
----------------------------------------

178. Telotristat Etiprate for Carcinoid Syndrome Therapy
   NCT ID: NCT02063659
   Status: COMPLETED
   Phase: PHASE3
   Condition: Carcinoid Syndrome
   Intervention: Telotristat etiprate; Placebo
   Sponsor: Lexicon Pharmaceuticals
   Start Date: 2014-03-11
   Completion Date: 2016-03-29
   Has Posted Results: True
   Publications Count: 3
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02063659
   Summary: The purpose of the study is to evaluate the effect of telotristat etiprate versus placebo on the incidence of treatment-emergent adverse events and on 5-hydroxyindoleacetic acid (5-HIAA) levels.
   Locations: Lexicon Investigational Site, Stanford, United States; Lexicon Investigational Site, Orlando, United States; Lexicon Investigational Site, Iowa City, United States
              ... and 47 more locations
----------------------------------------

179. Phase 2 Study of ONC201 in Neuroendocrine Tumors
   NCT ID: NCT03034200
   Status: COMPLETED
   Phase: PHASE2
   Condition: Recurrent Neuroendocrine Tumor; Metastatic Neuroendocrine Tumor
   Intervention: ONC201
   Sponsor: Peter Anderson
   Start Date: 2017-08-02
   Completion Date: 2023-05-19
   Has Posted Results: True
   Publications Count: 8
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03034200
   Summary: The purpose of this study is to learn if a new drug, ONC201 can make tumors become smaller or go away completely. Investigators also want to learn if ONC201 can prevent new deposits of cancer from appearing in new places in participants (metastases). A phase 2 study of ONC201 in PC-PG (pheochromocyt...
   Locations: Cleveland Clinic Pediatric and Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, United States
----------------------------------------

180. Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma
   NCT ID: NCT00314106
   Status: COMPLETED
   Phase: PHASE2
   Condition: Metastatic Melanoma
   Intervention: Melanoma Reactive TIL; Cyclophosphamide; IL-2; Fludarabine; 1200 total body irradiation (TBI)
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2006-04
   Completion Date: 2009-03
   Has Posted Results: True
   Publications Count: 2
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00314106
   Summary: Background:

* In a study in humans with melanoma, patients given total body irradiation to suppress the immune system in conjunction with chemotherapy showed a significant clinical response.
* In previous studies, about one-half of patients given tumor-fighting cells (cells created from the patient...
   Locations: National Cancer Institute (NCI), Bethesda, United States
----------------------------------------

181. Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma
   NCT ID: NCT02388906
   Status: COMPLETED
   Phase: PHASE3
   Condition: Melanoma
   Intervention: Ipilimumab; Nivolumab; Placebo matching Ipilimumab; Placebo matching Nivolumab
   Sponsor: Bristol-Myers Squibb
   Start Date: 2015-03-16
   Completion Date: 2024-10-16
   Has Posted Results: True
   Publications Count: 5
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02388906
   Summary: The purpose of this study is to determine whether nivolumab is better than ipilimumab to prevent recurrence of melanoma.
   Locations: Local Institution - 0036, Little Rock, United States; Local Institution - 0117, La Jolla, United States; Local Institution - 0189, Los Angeles, United States
              ... and 133 more locations
----------------------------------------

182. A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine
   NCT ID: NCT02545075
   Status: COMPLETED
   Phase: PHASE3
   Condition: Melanoma
   Intervention: Ipilimumab; Dacarbazine
   Sponsor: Bristol-Myers Squibb
   Start Date: 2015-10-31
   Completion Date: 2019-04-19
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02545075
   Summary: The purpose of this study is to determine whether Ipilimumab will extend the life of chinese patients with Chemotherapy Naive Stage IV Melanoma more than Dacarbazine as well as to examine safety in this patient population.
   Locations: Local Institution, Nanjing, China; Local Institution, Changchun, China; Local Institution, Xi'an, China
              ... and 5 more locations
----------------------------------------

183. Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma
   NCT ID: NCT00788775
   Status: COMPLETED
   Phase: PHASE2
   Condition: Mucosal Lentiginous Melanoma; Acral Melanoma; Melanoma
   Intervention: Nilotinib
   Sponsor: Dana-Farber Cancer Institute
   Start Date: 2009-01-23
   Completion Date: 2014-03
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00788775
   Summary: Given the poor prognosis and limited treatment options available for patients with mucosal or acral/lentiginous melanomas who develop metastatic disease, genetic discoveries of KIT mutations in these cancers present the need to test multi-targeted kinase inhibitors with potent KIT inhibitory activit...
   Locations: The Angeles Clinic and Research Institute, Santa Monica, United States; University of Colorado, Aurora, United States; Moffitt Cancer Center, Tampa, United States
              ... and 5 more locations
----------------------------------------

184. A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma
   NCT ID: NCT02129075
   Status: COMPLETED
   Phase: PHASE2
   Condition: Cutaneous Melanoma; Melanoma; Melanoma of Unknown Primary; Mucosal Melanoma; Ocular Melanoma; Stage IIB Cutaneous Melanoma AJCC v6 and v7; Stage IIC Cutaneous Melanoma AJCC v6 and v7; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7
   Intervention: DEC-205/NY-ESO-1 Fusion Protein CDX-1401; Poly ICLC; Recombinant Flt3 Ligand
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2014-04-09
   Completion Date: 2018-05-18
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02129075
   Summary: This phase II trial studies the effect of a vaccine called CDX-1401 given with or without a biologic drug called CDX-301 in treating patients with stage IIB-IV melanoma. The cancer vaccine CDX-1401 attaches to a protein that is made in tumor cells. The vaccine helps the body recognize the tumor to f...
   Locations: University of Chicago Comprehensive Cancer Center, Chicago, United States; Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, United States; Mount Sinai Hospital, New York, United States
              ... and 4 more locations
----------------------------------------

185. Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic
   NCT ID: NCT02721732
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Advanced Malignant Solid Neoplasm; Carcinoma of Unknown Primary; Metastatic Adrenal Gland Pheochromocytoma; Metastatic Kidney Medullary Carcinoma; Metastatic Malignant Germ Cell Tumor; Metastatic Malignant Solid Neoplasm; Metastatic Paraganglioma; Metastatic Penile Carcinoma; Metastatic Skin Squamous Cell Carcinoma; Small Cell Carcinoma; Stage III Adrenal Cortex Carcinoma AJCC v7; Stage IV Adrenal Cortex Carcinoma AJCC v7; Stage IV Penile Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7; Unresectable Adrenal Gland Pheochromocytoma; Unresectable Paraganglioma; Unresectable Skin Squamous Cell Carcinoma; Unresectable Solid Neoplasm; Vascular Neoplasm
   Intervention: Laboratory Biomarker Analysis; Pembrolizumab; Questionnaire Administration
   Sponsor: M.D. Anderson Cancer Center
   Start Date: 2016-08-15
   Completion Date: 2025-12-31
   Has Posted Results: True
   Publications Count: 12
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02721732
   Summary: This phase II trial studies how well pembrolizumab works in treating patients with rare tumors that cannot be removed by surgery or have spread to other parts of the body. Monoclonal antibodies, such as pembrolizumab, may block specific proteins found on white blood cells which may strengthen the im...
   Locations: M D Anderson Cancer Center, Houston, United States
----------------------------------------

186. Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma
   NCT ID: NCT00001832
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma; Neoplasm Metastasis
   Intervention: gp100:209-217 (210M); Montanide ISA-51; IL-2; MART-1:26-35(27L); Abl cells; Fludarabine; Cyclophosphamide; GCSF (Growth colony stimulating factor); Apheresis
   Sponsor: National Cancer Institute (NCI)
   Start Date: 1999-08
   Completion Date: 2010-05
   Has Posted Results: True
   Publications Count: 2
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00001832
   Summary: This experiment will test the safety and effectiveness of a treatment for melanoma in which certain lymphocytes (a type of white blood cell) are taken from the patient, grown in the laboratory, and returned after the patient's immune system has been weakened with immune-suppressing drugs. Some patie...
   Locations: National Cancer Institute (NCI), Bethesda, United States
----------------------------------------

187. Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
   NCT ID: NCT00458952
   Status: COMPLETED
   Phase: PHASE1
   Condition: Pheochromocytoma; Paraganglioma
   Intervention: Ultratrace Iobenguane (MIBG) I 131
   Sponsor: Molecular Insight Pharmaceuticals, Inc.
   Start Date: 2007-04
   Completion Date: 2011-06
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00458952
   Summary: The purpose of this study is to determine whether iobenguane I 131 is safe and effective in patients with malignant pheochromocytoma or paraganglioma.
   Locations: New York Presbyterian Hospital-Weill Cornell Medical Center, New York, United States; Duke University Medical Center, Durham, United States; Rhode Island Hospital, Providence, United States
----------------------------------------

188. Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma
   NCT ID: NCT00665470
   Status: COMPLETED
   Phase: PHASE2
   Condition: Skin Cancer; Metastatic Melanoma
   Intervention: Aldesleukin
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2008-04
   Completion Date: 2012-04
   Has Posted Results: True
   Publications Count: 4
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00665470
   Summary: Background:

This study uses a new experimental procedure for treating melanoma that uses the patient's own lymphocytes (type of white blood cell), which are specially selected to target and destroy their tumor.

Objectives:

To determine whether this experimental treatment can cause the patient's t...
   Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, United States
----------------------------------------

189. Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
   NCT ID: NCT01824875
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Gastrinoma; Glucagonoma; Insulinoma; Islet Cell Carcinoma; Pancreatic Polypeptide Tumor; Recurrent Islet Cell Carcinoma; Somatostatinoma
   Intervention: temozolomide; capecitabine
   Sponsor: ECOG-ACRIN Cancer Research Group
   Start Date: 2013-08-08
   Completion Date: 2025-12
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01824875
   Summary: This randomized phase II trial studies how well giving temozolomide with or without capecitabine works in treating patients with advanced pancreatic neuroendocrine tumors. Drugs used in chemotherapy, such as temozolomide and capecitabine, work in different ways to stop the growth of tumor cells, eit...
   Locations: Kaiser Anaheim Medical Center, Anaheim, United States; Kaiser Permanente-Deer Valley Medical Center, Antioch, United States; Kaiser Permanente Medical Group - Baldwin Park, Baldwin Park, United States
              ... and 320 more locations
----------------------------------------

190. MK-3475 in Melanoma and NSCLC Patients With Brain Metastases
   NCT ID: NCT02085070
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma; Non-Small Cell Lung Cancer; Brain Metastases
   Intervention: MK-3475
   Sponsor: Yale University
   Start Date: 2014-03
   Completion Date: 2020-02-27
   Has Posted Results: True
   Publications Count: 5
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02085070
   Summary: The purpose of this trial is to study the activity of MK-3475 in untreated brain metastases from melanoma or non-small cell lung cancer.
   Locations: Smilow Cancer Center at Yale New Haven Hospital, New Haven, United States
----------------------------------------

191. Phase II Trial of Extended-Dosing Temozolomide in Patients With Melanoma
   NCT ID: NCT00591370
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma
   Intervention: Temozolomide (TMZ)
   Sponsor: Memorial Sloan Kettering Cancer Center
   Start Date: 2005-01
   Completion Date: 2008-06
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00591370
   Summary: Temozolomide (also known as TMZ) is a chemotherapy drug given by mouth. It is similar to DTIC, the only FDA-approved chemotherapy for melanoma, but because temozolomide is given by mouth, it can be given daily over a long period of time. We think that temozolomidemay work best if it is given every d...
   Locations: Memorial Sloan-Kettering Cancer Center, New York, United States
----------------------------------------

192. Peptide Vaccination for Patients at High Risk for Recurrent Melanoma
   NCT ID: NCT00059475
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma
   Intervention: Glycoprotein 100 (GP100): 209-217 (210M); Interleukin-2 (IL-2); Montanide ISA 51; Melanoma antigen recognized by T-cells (MART)-1: 27-35; 27-35 (27L): melanoma antigen recognized by T-cells (MART)-1; melanoma antigen recognized by T-cells (MART)-1: 26-35(27L)
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2003-04
   Completion Date: 2010-05
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00059475
   Summary: This study will examine the effectiveness and side effects of an experimental vaccine to prevent recurrence of melanoma. The likelihood of melanoma returning is higher in patients who have melanoma lesions deep in the skin, in patients who have had positive lymph nodes, and in patients who have had ...
   Locations: National Cancer Institute (NCI), Bethesda, United States
----------------------------------------

193. Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome
   NCT ID: NCT01104415
   Status: COMPLETED
   Phase: PHASE2
   Condition: Carcinoid Syndrome
   Intervention: Telotristat etiprate
   Sponsor: Lexicon Pharmaceuticals
   Start Date: 2010-06-15
   Completion Date: 2014-02-12
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01104415
   Summary: The purpose of the study is to evaluate the safety and tolerability of orally administered telotristat etiprate (LX1606) in participants with symptomatic carcinoid syndrome.
   Locations: Lexicon Investigational Site, Bad Berka, Germany; Lexicon Investigational Site, Berlin, Germany; Lexicon Investigational Site, Halle, Germany
              ... and 7 more locations
----------------------------------------

194. Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma Patients
   NCT ID: NCT01990859
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma
   Intervention: Ipilimumab
   Sponsor: Bristol-Myers Squibb
   Start Date: 2013-12
   Completion Date: 2015-02
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01990859
   Summary: The purpose of this study is to assess the safety of Ipilimumab monotherapy in Japanese subjects with advanced melanoma
   Locations: Local Institution, Fukuoka-shi, Japan; Local Institution, Kumamoto-shi, Japan; Local Institution, Matsumoto-shi, Japan
              ... and 3 more locations
----------------------------------------

195. A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
   NCT ID: NCT00358956
   Status: COMPLETED
   Phase: PHASE2
   Condition: Thyroid Cancer
   Intervention: ZD6474 (vandetanib)
   Sponsor: Genzyme, a Sanofi Company
   Start Date: 2006-08
   Completion Date: 2014-05
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00358956
   Summary: This will be a Phase II, open label study to establish the effect of once-daily oral doses of ZD6474 100mg in subjects with locally advanced or metastatic hereditary medullary thyroid cancer in whom no standard therapeutic option is available.
   Locations: Research Site, Little Rock, United States; Research Site, Boston, United States; Research Site, St Leonards, Australia
              ... and 6 more locations
----------------------------------------

196. A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma
   NCT ID: NCT00111007
   Status: COMPLETED
   Phase: PHASE3
   Condition: Melanoma
   Intervention: Sorafenib (Nexavar, BAY43-9006); Carboplatin/Paclitaxel; Placebo
   Sponsor: Bayer
   Start Date: 2005-05
   Completion Date: 2009-01
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00111007
   Summary: The objectives of this study are to compare the anti-tumor activity as measured by Progression Free Survival (PFS) and tolerability of Sorafenib in combination with Paclitaxel and Carboplatin versus Paclitaxel and Carboplatin in combination with placebo in subjects with unresectable Stage III or Sta...
----------------------------------------

197. S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma
   NCT ID: NCT00006237
   Status: COMPLETED
   Phase: PHASE3
   Condition: Melanoma (Skin)
   Intervention: interleukin-2; filgrastim; interferon alfa; cisplatin; dacarbazine; vinblastine
   Sponsor: SWOG Cancer Research Network
   Start Date: 2000-08
   Completion Date: 2012-07
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00006237
   Summary: RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells. It is not yet known whether interfer...
   Locations: Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham, Birmingham, United States; Mobile Infirmary Medical Center, Mobile, United States; Banner Thunderbird Medical Center, Glendale, United States
              ... and 293 more locations
----------------------------------------

198. Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma
   NCT ID: NCT00424515
   Status: COMPLETED
   Phase: PHASE2
   Condition: Mucosal Melanoma; Acral/Lentiginous Melanoma; Chronically Sun Damaged Melanomas
   Intervention: Imatinib
   Sponsor: Dana-Farber Cancer Institute
   Start Date: 2006-07
   Completion Date: 2011-07
   Has Posted Results: True
   Publications Count: 2
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00424515
   Summary: The purpose of this study is to evaluate how effective imatinib (Gleevec) is in treating acral/lentiginous and mucosal melanoma which has spread to other parts of the body in patients who's disease carries a c-kit mutation. Imatinib is a protein-kinase inhibitor. It is believed that imatinib may be ...
   Locations: University of Colorado at Denver Health Sciences Center, Denver, United States; H. Lee Moffitt Cancer Center, Tampa, United States; University of Chicago, Chicago, United States
              ... and 2 more locations
----------------------------------------

199. Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
   NCT ID: NCT03037385
   Status: COMPLETED
   Phase: PHASE1
   Condition: RET-altered Non Small Cell Lung Cancer; Medullary Thyroid Cancer; RET-altered Papillary Thyroid Cancer; RET-altered Colon Cancer; RET-altered Solid Tumors; Lung Neoplasm; Carcinoma, Non-Small-Cell Lung; Thyroid Diseases; Thyroid Neoplasm; Thyroid Cancer, Papillary; Carcinoma, Neuroendocrine; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Disease; Carcinoma, Bronchogenic; Bronchial Neoplasms; Endocrine System Diseases; Endocrine Gland Neoplasm; Head and Neck Neoplasms; Adenocarcinoma, Papillary; Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neuroendocrine Tumors; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Colonic Neoplasms; Colorectal Neoplasms; Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasm; Digestive System Disease; Gastrointestinal Disease; Colonic Diseases; Intestinal Disease
   Intervention: pralsetinib (BLU-667)
   Sponsor: Hoffmann-La Roche
   Start Date: 2017-03-17
   Completion Date: 2024-03-21
   Has Posted Results: True
   Publications Count: 4
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03037385
   Summary: This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of pralsetinib (BLU-667) administered orally in participants with medullary thyroid cancer (MTC), RET-alter...
   Locations: Mayo Clinic Hospital, Phoenix, United States; UC Irvine Medical Center, Orange, United States; University of Colorado Anschutz Medical Campus, Aurora, United States
              ... and 68 more locations
----------------------------------------

200. A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
   NCT ID: NCT01320085
   Status: COMPLETED
   Phase: PHASE2
   Condition: BRAF or NRAS Mutant Metastatic Melanoma
   Intervention: MEK162
   Sponsor: Pfizer
   Start Date: 2011-03-24
   Completion Date: 2023-02-06
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01320085
   Summary: The study will assess the safety and efficacy of single-agent MEK162 in adult patients with locally advanced and unresectable or metastatic malignant cutaneous melanoma, harboring BRAFV600E or NRAS mutations.
   Locations: Highlands Oncology Group, Fayetteville, United States; H. Lee Moffitt Cancer Center & Research Institute, Inc., Tampa, United States; OHSU Knight Cancer Institute, Portland, United States
              ... and 22 more locations
----------------------------------------

201. Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes
   NCT ID: NCT00509288
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma; Skin Cancer
   Intervention: autologous anti-MART-1 F5 T-cell receptor; Cyclophosphamide; Fludarabine; Aldesleukin; autologous anti-MART-1 F5 T-cell receptor gene-engineered tumor infiltrating lymphocytes
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2007-06
   Completion Date: 2012-07
   Has Posted Results: True
   Publications Count: 4
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00509288
   Summary: Background:

* Human peripheral blood lymphocytes have been engineered to express a T-cell receptor (TCR) that recognizes a blood type,HLA-A 0201 (human leukocyte antigen) derived from the gp100 protein. A retroviral vector was constructed that can deliver the T-cell receptor (TCR) to cells.
* Patie...
   Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, United States
----------------------------------------

202. Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma
   NCT ID: NCT01359956
   Status: COMPLETED
   Phase: PHASE3
   Condition: Malignant Melanoma; Recurrent Melanoma
   Intervention: Dacarbazine; Fotemustine; Interferon Alfa-2b
   Sponsor: National Cancer Institute, Naples
   Start Date: 2002-04
   Completion Date: 2011-02
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01359956
   Summary: This study evaluated two chemotherapy regimens with and without the addition of interferon in patients with advanced or recurrent melanoma.
----------------------------------------

203. Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma
   NCT ID: NCT01152788
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma
   Intervention: rIL-21; Dacarbazine
   Sponsor: NCIC Clinical Trials Group
   Start Date: 2010-08-05
   Completion Date: 2015-02-13
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01152788
   Summary: The purpose of this study is to find out what effects an experimental drug, called interleukin 21 or rIL-21, will have on malignant melanoma and whether these effects look promising compared to dacarbazine. In addition, this study will look at the side effects of rIL-21, and some special blood tests...
   Locations: The Angeles Clinic and Research Institute, Los Angeles, United States; Tom Baker Cancer Centre, Calgary, Canada; BCCA - Fraser Valley Cancer Centre, Surrey, Canada
              ... and 16 more locations
----------------------------------------

204. Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors
   NCT ID: NCT01967537
   Status: COMPLETED
   Phase: PHASE2
   Condition: Neuroendocrine Tumors; Von Hippel-Lindau Syndrome; Hippel-Lindau Disease
   Intervention: 68Gallium DOTATATE; Radio-guided surgery
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2013-10-18
   Completion Date: 2018-03-12
   Has Posted Results: True
   Publications Count: 3
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01967537
   Summary: Background:

- Neuroendocrine tumors (NETs) are rare but have been more common over the past decade. The only treatment for NETs is surgery, but most are found when they are too advanced for surgery. Researchers are looking for the best way to find NETs earlier, so that surgery can be successful. Th...
   Locations: National Institutes of Health Clinical Center, Bethesda, United States
----------------------------------------

205. A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
   NCT ID: NCT04211337
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE3
   Condition: Medullary Thyroid Cancer
   Intervention: Selpercatinib; Cabozantinib; Vandetanib
   Sponsor: Loxo Oncology, Inc.
   Start Date: 2020-02-11
   Completion Date: 2026-02
   Has Posted Results: True
   Publications Count: 2
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04211337
   Summary: The reason for this study is to see if the study drug selpercatinib is safe and more effective compared to a standard treatment in participants with rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) that cannot be removed by surgery or has spread to other parts of the body. ...
   Locations: University of Alabama at Birmingham, Birmingham, United States; City of Hope National Medical Center, Duarte, United States; UCLA Hematology/Oncology - Westwood (Building 100), Los Angeles, United States
              ... and 140 more locations
----------------------------------------

206. Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)
   NCT ID: NCT02089685
   Status: COMPLETED
   Phase: PHASE1
   Condition: Renal Cell Carcinoma; Melanoma
   Intervention: Pembrolizumab; PegIFN-2b; Ipilimumab
   Sponsor: Merck Sharp & Dohme LLC
   Start Date: 2014-03-17
   Completion Date: 2021-04-01
   Has Posted Results: True
   Publications Count: 3
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02089685
   Summary: This study is being done to analyze the safety, tolerability, and efficacy of treatment for advanced melanoma (MEL) and renal cell carcinoma (RCC) using combination regimens of pembrolizumab + pegylated interferon alfa-2b (PegIFN-2b) and pembrolizumab + ipilimumab (IPI). The primary hypothesis is th...
----------------------------------------

207. Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma
   NCT ID: NCT00084656
   Status: COMPLETED
   Phase: PHASE2
   Condition: Intraocular Melanoma; Melanoma (Skin)
   Intervention: ipilimumab; Tyrosinase/gp100/MART-1 Peptides
   Sponsor: Bristol-Myers Squibb
   Start Date: 2004-05-31
   Completion Date: 2009-10-31
   Has Posted Results: True
   Publications Count: 2
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00084656
   Summary: RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Vaccines may make the body build an immune response to kill tumor cells. Combining the vaccines with Montanide ISA-51 may cause a stronger immune res...
   Locations: H. Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa, United States
----------------------------------------

208. Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
   NCT ID: NCT00470470
   Status: COMPLETED
   Phase: PHASE2
   Condition: Acral Lentiginous Malignant Melanoma; Recurrent Melanoma; Stage IIIA Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma
   Intervention: imatinib mesylate; laboratory biomarker analysis
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2007-04
   Completion Date: 2014-10
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00470470
   Summary: This phase II trial is studying how well imatinib mesylate works in treating patients with stage III or stage IV melanoma that cannot be removed by surgery. Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
   Locations: University of California at Los Angeles (UCLA ), Los Angeles, United States; Mount Sinai Medical Center CCOP, Miami Beach, United States; Good Samaritan Medical Center, West Palm Beach, United States
              ... and 5 more locations
----------------------------------------

209. Safety Study of Adjuvant Vaccine to Treat Melanoma Patients
   NCT ID: NCT01079741
   Status: COMPLETED
   Phase: PHASE1
   Condition: Melanoma
   Intervention: NY-ESO-1 protein; Poly-ICLC; Montanide
   Sponsor: Nina Bhardwaj
   Start Date: 2010-09
   Completion Date: 2013-03-11
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01079741
   Summary: The incidence of melanoma is increasing with an estimated incidence of 59,940 cases and an annual death rate of 8110 in 2007. Although patients diagnosed with early stage disease have an excellent clinical outcome, patients diagnosed with advanced or recurrent disease, continue to have a high mortal...
   Locations: New York University Langone Medical Center, New York, United States
----------------------------------------

210. Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec
   NCT ID: NCT02014441
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma
   Intervention: Talimogene laherparepvec
   Sponsor: Amgen
   Start Date: 2014-04-07
   Completion Date: 2018-04-19
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02014441
   Summary: The primary objective was to estimate the proportion of participants with detectable talimogene laherparepvec deoxyribonucleic acid (DNA) in the blood and urine at any time after administration of talimogene laherparepvec within the first 3 cycles.
   Locations: Research Site, Tampa, United States; Research Site, Indianapolis, United States; Research Site, Louisville, United States
              ... and 11 more locations
----------------------------------------

211. A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
   NCT ID: NCT03400332
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE1
   Condition: Cancer; Melanoma
   Intervention: BMS-986253; Nivolumab; Ipilimumab; Placebo
   Sponsor: Bristol-Myers Squibb
   Start Date: 2018-02-12
   Completion Date: 2025-11-30
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03400332
   Summary: The purpose of this study is to investigate experimental medication BMS-986253 in combination with Nivolumab or Nivolumab plus Ipilimumab in participants with advanced cancers.
   Locations: Local Institution - 0059, Springdale, United States; Local Institution - 0099, Los Angeles, United States; Local Institution - 0007, Lakewood, United States
              ... and 69 more locations
----------------------------------------

212. Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist
   NCT ID: NCT00960752
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma
   Intervention: gp100; R848 gel; MAGE-3
   Sponsor: M.D. Anderson Cancer Center
   Start Date: 2010-05-20
   Completion Date: 2020-07-20
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00960752
   Summary: The goal of this clinical research study is to learn if the vaccines, gp100(g209-2M), and MAGE-3, when given in combination with resiquimod (R848), can help to stimulate the immune system against melanoma.
   Locations: University of Texas MD Anderson Cancer Center, Houston, United States
----------------------------------------

213. Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma
   NCT ID: NCT01740557
   Status: COMPLETED
   Phase: PHASE1
   Condition: Metastatic Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7
   Intervention: Aldesleukin; CXCR2-transduced Autologous Tumor Infiltrating Lymphocytes; Cyclophosphamide; Fludarabine Phosphate; Laboratory Biomarker Analysis; NGFR-transduced Autologous T Lymphocytes; Quality-of-Life Assessment
   Sponsor: M.D. Anderson Cancer Center
   Start Date: 2015-01-28
   Completion Date: 2023-04-21
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01740557
   Summary: This phase I/II trial studies how well genetically modified therapeutic autologous lymphocytes (patient's own white blood cells) followed by aldesleukin work in treating patients with stage III melanoma or melanoma that has spread to other places in the body (metastatic). Placing chemokine (C-X-C mo...
   Locations: M D Anderson Cancer Center, Houston, United States
----------------------------------------

214. A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
   NCT ID: NCT01584648
   Status: COMPLETED
   Phase: PHASE3
   Condition: Melanoma
   Intervention: Dabrafenib; Trametinib; Trametinib placebo
   Sponsor: Novartis Pharmaceuticals
   Start Date: 2012-05-04
   Completion Date: 2019-02-28
   Has Posted Results: True
   Publications Count: 8
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01584648
   Summary: This was a two-arm, double-blinded, randomized, Phase III study comparing dabrafenib and trametinib combination therapy to dabrafenib administered with a placebo (dabrafenib monotherapy). Subjects with histologically confirmed cutaneous melanoma that is either Stage IIIC (unresectable) or Stage IV, ...
   Locations: Novartis Investigative Site, Scottsdale, United States; Novartis Investigative Site, Tucson, United States; Novartis Investigative Site, Los Angeles, United States
              ... and 118 more locations
----------------------------------------

215. A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma
   NCT ID: NCT02905266
   Status: COMPLETED
   Phase: PHASE3
   Condition: Melanoma
   Intervention: Nivolumab; Ipilimumab
   Sponsor: Bristol-Myers Squibb
   Start Date: 2016-10-27
   Completion Date: 2019-10-25
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02905266
   Summary: This is a safety and efficacy study of different administration regimens of nivolumab plus Ipilimumab in subjects with previously untreated, unresectable or metastatic melanoma.
   Locations: Melanoma Institute Australia, North Sydney, Australia; Greenslopes Private Hospital, Greenslopes, Australia; Cabrini Hospital, Malvern, Australia
              ... and 13 more locations
----------------------------------------

216. Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease
   NCT ID: NCT00690430
   Status: COMPLETED
   Phase: PHASE3
   Condition: Symptomatic Refractory Resistant Carcinoid Disease
   Intervention: Pasireotide; Octreotide
   Sponsor: Novartis Pharmaceuticals
   Start Date: 2008-04
   Completion Date: 2012-04
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00690430
   Summary: The purpose of this randomized, multicenter, Phase III study was to compare the efficacy of paseriotide LAR and octreotide LAR in patients whose disease-related symptoms are inadequately controlled by currently available somatostatin analogues.
   Locations: Scottsdale Healthcare/TGen Clinical Research Service TGen Clinical Research Service, Scottsdale, United States; University of Arizona / Arizona Cancer Center, Tucson, United States; Loma Linda University Dept. of Loma Linda CancerCent, Loma Linda, United States
              ... and 59 more locations
----------------------------------------

217. Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients
   NCT ID: NCT04526730
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Melanoma
   Intervention: Tavo; Nivolumab; OncoSec Medical Electroporation Therapy System
   Sponsor: H. Lee Moffitt Cancer Center and Research Institute
   Start Date: 2020-12-22
   Completion Date: 2028-06-15
   Has Posted Results: True
   Publications Count: 2
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04526730
   Summary: This is a Phase 2 open-label, single-arm study of neoadjuvant treatment of intratumoral tavo-EP plus nivolumab IV infusion. Eligible participants will be those with pathological diagnosis of operable locally-regionally advanced melanoma.
   Locations: Moffitt Cancer Center, Tampa, United States
----------------------------------------

218. Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma
   NCT ID: NCT00397982
   Status: COMPLETED
   Phase: PHASE2
   Condition: Recurrent Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma
   Intervention: Bevacizumab; Laboratory Biomarker Analysis; Temsirolimus; Therapeutic Conventional Surgery
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2008-01
   Completion Date: 2013-07
   Has Posted Results: True
   Publications Count: 2
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00397982
   Summary: This phase II trial is studying how well giving temsirolimus together with bevacizumab works in treating patients with stage III or stage IV malignant melanoma. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for their growth. Monoclonal antibodies, such as bev...
   Locations: Fox Chase Cancer Center, Philadelphia, United States; University of Virginia Cancer Center, Charlottesville, United States
----------------------------------------

219. A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.
   NCT ID: NCT00378482
   Status: COMPLETED
   Phase: PHASE2
   Condition: Colorectal Neoplasms; Melanoma; Prostatic Neoplasms; Renal Cell Carcinoma; Neoplasms; Patients Who Have/Have Had Melanoma and Other Tumors
   Intervention: CP-675,206 (Tremelimumab)
   Sponsor: AstraZeneca
   Start Date: 2007-03-05
   Completion Date: 2023-10-27
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00378482
   Summary: This study is intended to provide access to tremelimumab for patients who have previously received tremelimumab in a clinical trial.
   Locations: Research Site, Los Angeles, United States; Research Site, Tampa, United States; Research Site, Ann Arbor, United States
              ... and 3 more locations
----------------------------------------

220. SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
   NCT ID: NCT00577382
   Status: COMPLETED
   Phase: PHASE2
   Condition: Mucosal Lentiginous Melanoma; Acral Lentiginous Malignant Melanoma
   Intervention: Sunitinib
   Sponsor: Dana-Farber Cancer Institute
   Start Date: 2007-08
   Completion Date: 2014-08
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00577382
   Summary: The purpose of this study is to evaluate how effective Sunitinib works in treating acral lentiginous and mucosal melanoma which has spread beyond the local region. Suninitib is a protein-tyrosine kinase inhibitor and acts as a c-kit inhibitor drug. It is believed to work by blocking signals on certa...
   Locations: Massachusetts General Hospital, Boston, United States; Beth Israel Deaconess Medical Center, Boston, United States; Dana-Farber Cancer Institute, Boston, United States
              ... and 2 more locations
----------------------------------------

221. Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma
   NCT ID: NCT00096382
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma (Skin)
   Intervention: aldesleukin; filgrastim; therapeutic tumor infiltrating lymphocytes; cyclophosphamide; fludarabine phosphate; radiation therapy
   Sponsor: National Institutes of Health Clinical Center (CC)
   Start Date: 2004-09
   Completion Date: 2009-01
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00096382
   Summary: RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide and fludarabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Biological therapies, such as cellular adoptive immunotherapy, work ...
   Locations: Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, United States; NCI - Surgery Branch, Bethesda, United States
----------------------------------------

222. Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour
   NCT ID: NCT00842348
   Status: COMPLETED
   Phase: PHASE3
   Condition: Non Functioning Entero-pancreatic Endocrine Tumour
   Intervention: lanreotide (Autogel formulation)
   Sponsor: Ipsen
   Start Date: 2009-02
   Completion Date: 2015-12
   Has Posted Results: True
   Publications Count: 2
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00842348
   Summary: The primary purpose of this extension study was to assess the long term safety of patients with nonfunctioning enteropancreatic neuroendocrine tumour (NET), who were treated with open label lanreotide Autogel (120 mg every 28 days) and who participated in a previous study, 2-55-52030-726 (NCT0035349...
   Locations: Cedars-Sinai Outpatient Cancer Center, Los Angeles, United States; The Johns Hopkins Hospital, Baltimore, United States; UZ Antwerpen, Antwerpen, Belgium
              ... and 22 more locations
----------------------------------------

223. Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma
   NCT ID: NCT02581930
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Metastatic Melanoma; Recurrent Cutaneous Melanoma; Stage IV Cutaneous Melanoma AJCC v6 and v7
   Intervention: Ibrutinib; Laboratory Biomarker Analysis; Pharmacogenomic Study; Pharmacological Study
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2016-08-17
   Completion Date: 2026-03-17
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02581930
   Summary: This phase II trial studies how well ibrutinib works in treating patients with stage IV melanoma of the skin that has not responded to previous treatment. Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
   Locations: Los Angeles General Medical Center, Los Angeles, United States; USC / Norris Comprehensive Cancer Center, Los Angeles, United States; University of California Davis Comprehensive Cancer Center, Sacramento, United States
              ... and 10 more locations
----------------------------------------

224. An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome
   NCT ID: NCT00774930
   Status: COMPLETED
   Phase: PHASE3
   Condition: Carcinoid Syndrome
   Intervention: Lanreotide; Placebo
   Sponsor: Ipsen
   Start Date: 2009-05
   Completion Date: 2015-12
   Has Posted Results: True
   Publications Count: 2
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00774930
   Summary: The purpose of this study was to determine whether monthly deep subcutaneous (s.c.) injections of lanreotide Autogel (Somatuline Depot) were effective and safe in controlling diarrhoea and flushing by reducing the usage of s.c. short-acting octreotide as a rescue medication to control symptoms in su...
   Locations: VA Greater Los Angeles Health Care System, Los Angeles, United States; David Geffen School of Medicine at UCLA, Los Angeles, United States; Stanford Cancer Center, Stanford, United States
              ... and 51 more locations
----------------------------------------

225. Vitamin D Supplementation in Cutaneous Malignant Melanoma Outcome
   NCT ID: NCT01748448
   Status: COMPLETED
   Phase: PHASE3
   Condition: Cutaneous Malignant Melanoma
   Intervention: Vitamin D; Placebo: Oil
   Sponsor: Universitaire Ziekenhuizen KU Leuven
   Start Date: 2012-12
   Completion Date: 2022-07
   Has Posted Results: True
   Publications Count: 4
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01748448
   Summary: To assess whether vitamin D supplementation after surgery of a first cutaneous malignant melanoma protects against relapse of the disease.
   Locations: Universitair Ziekenhuis Antwerpen, Dermatology, Edegem, Belgium; UZLeuven Gasthuisberg, Leuven, Belgium; Chef de Service du Service Universitaire de Dermatologie, Liège, Belgium
              ... and 1 more locations
----------------------------------------

226. Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes
   NCT ID: NCT03551626
   Status: COMPLETED
   Phase: PHASE3
   Condition: Malignant Melanoma
   Intervention: Dabrafenib; Trametinib
   Sponsor: Novartis Pharmaceuticals
   Start Date: 2018-08-29
   Completion Date: 2021-09-16
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03551626
   Summary: The main purpose of this study was to evaluate the impact on pyrexia-related outcomes of an adapted pyrexia adverse event (AE)-management algorithm, as well as safety, efficacy and health-related outcomes.
   Locations: Novartis Investigative Site, Rosario, Argentina; Novartis Investigative Site, Buenos Aires, Argentina; Novartis Investigative Site, Cordoba, Argentina
              ... and 97 more locations
----------------------------------------

227. Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma.
   NCT ID: NCT01416831
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Metastatic Melanoma
   Intervention: Radiation therapy and high-dose IL-2; High-dose IL-2
   Sponsor: Providence Health & Services
   Start Date: 2011-07-01
   Completion Date: 2025-12
   Has Posted Results: True
   Publications Count: 2
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01416831
   Summary: The purpose of this study is compare the response rates in patients with metastatic melanoma treated with high-dose IL-2 to patients treated with high-dose IL-2 along with radiation therapy.
   Locations: Providence Cancer Center, Portland, United States
----------------------------------------

228. Microscopic Fluorescence-guided Vestibular Schwannoma Resection Using Fluorescein Sodium and YELLOW 560
   NCT ID: NCT04351373
   Status: COMPLETED
   Phase: PHASE2
   Condition: Vestibular Schwannoma
   Intervention: Fluorescein Sodium; YELLOW560 filter
   Sponsor: Mayo Clinic
   Start Date: 2021-10-06
   Completion Date: 2022-05-25
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04351373
   Summary: The purpose of this study is to see if there is benefit to using an IV contrast called AK-Fluor® and a microscope filter called YELLOW560 when surgically removing a vestibular schwannoma, Meningioma, Head and Neck Paraganglioma, or Head and Neck Schwannoma.
   Locations: Mayo Clinic in Rochester, Rochester, United States
----------------------------------------

229. Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients
   NCT ID: NCT00525031
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma
   Intervention: Temozolomide (TMZ); Pegylated Interferon Alpha-2b (PGI)
   Sponsor: M.D. Anderson Cancer Center
   Start Date: 2006-08
   Completion Date: 2016-06
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00525031
   Summary: The goal of this clinical research study is to learn if temozolomide alone or given with pegylated interferon alpha-2b can help to control metastatic melanoma. Researchers also want to study the safety of these 2 treatments.

Objectives:

1. To determine the anti-tumor activity (pathological respons...
   Locations: University of Texas MD Anderson Cancer Center, Houston, United States
----------------------------------------

230. Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer
   NCT ID: NCT03072160
   Status: COMPLETED
   Phase: PHASE2
   Condition: Medullary Thyroid Cancer (MTC)
   Intervention: Pembrolizumab
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2017-06-16
   Completion Date: 2019-11-22
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03072160
   Summary: Background:

Medullary thyroid cancer (MTC) is a tumor of the thyroid gland. Surgery is the only current treatment to cure it. The drug pembrolizumab (MK-3475) is a new type of cancer therapy. It works by allowing the immune system to detect and kill tumor cells.

Objective:

To test how pembrolizum...
   Locations: National Institutes of Health Clinical Center, Bethesda, United States
----------------------------------------

231. A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
   NCT ID: NCT01006980
   Status: COMPLETED
   Phase: PHASE3
   Condition: Malignant Melanoma
   Intervention: Vemurafenib; Dacarbazine
   Sponsor: Hoffmann-La Roche
   Start Date: 2010-01
   Completion Date: 2015-07
   Has Posted Results: True
   Publications Count: 8
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01006980
   Summary: This randomized, open-label study evaluated the efficacy, safety and tolerability of vemurafenib (RO5185426) as compared to dacarbazine in previously untreated patients with metastatic melanoma. Patients were randomized to receive either vemurafenib 960 mg orally twice daily or dacarbazine 1000 mg/m...
----------------------------------------

232. Phase II Trial of Ontak With Metastatic Melanoma
   NCT ID: NCT00299689
   Status: COMPLETED
   Phase: PHASE2
   Condition: Malignant Melanoma
   Intervention: Denileukin diftitox
   Sponsor: James Graham Brown Cancer Center
   Start Date: 2006-03
   Completion Date: 2010-01
   Has Posted Results: True
   Publications Count: 2
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00299689
   Summary: The purpose of this study is to determine whether ONTAK is an effective treatment in patients with Stage IV Melanoma
   Locations: James Graham Brown Cancer Center, Univ. of Louisville, Louisville, United States
----------------------------------------

233. Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma
   NCT ID: NCT00121225
   Status: COMPLETED
   Phase: PHASE2
   Condition: Ciliary Body and Choroid Melanoma, Medium/Large Size; Extraocular Extension Melanoma; Iris Melanoma; Uveal Melanoma; Recurrent Intraocular Melanoma; Recurrent Melanoma; Stage IV Melanoma
   Intervention: vorinostat
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2005-09
   Completion Date: 2013-06
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00121225
   Summary: This phase II trial is studying how well vorinostat works in treating patients with metastatic or unresectable melanoma. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
   Locations: Fox Chase Cancer Center, Philadelphia, United States; Fox Chase Cancer Center, Rockledge, United States; Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Canada
              ... and 2 more locations
----------------------------------------

234. A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma
   NCT ID: NCT03470922
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE2
   Condition: Melanoma
   Intervention: Relatlimab; Nivolumab
   Sponsor: Bristol-Myers Squibb
   Start Date: 2018-04-11
   Completion Date: 2030-12-15
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03470922
   Summary: The purpose of this study is to determine whether relatlimab in combination with nivolumab is more effective than nivolumab by itself in treating unresectable melanoma or melanoma that has spread.
   Locations: Local Institution - 0010, Tucson, United States; Local Institution - 0020, Los Angeles, United States; Coastal Integrative Cancer Care, San Luis Obispo, United States
              ... and 124 more locations
----------------------------------------

235. Palonosetron for Prevention of Biochemotherapy Induced Nausea and Vomiting
   NCT ID: NCT00412425
   Status: COMPLETED
   Phase: PHASE1
   Condition: Melanoma
   Intervention: Palonosetron
   Sponsor: M.D. Anderson Cancer Center
   Start Date: 2006-11
   Completion Date: 2009-05
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00412425
   Summary: Primary Objectives:

* Safety of palonosetron administered for control of nausea and vomiting in patients with metastatic melanoma receiving biochemotherapy.
* To determine the patterns and severity of nausea and vomiting in two groups of patients with metastatic melanoma receiving biochemotherapy w...
   Locations: U.T. M.D. Anderson Cancer Center, Houston, United States
----------------------------------------

236. Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma
   NCT ID: NCT00003222
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma (Skin)
   Intervention: aldesleukin; gp100 antigen; incomplete Freund's adjuvant; sargramostim; tetanus peptide melanoma vaccine; tyrosinase peptide
   Sponsor: University of Virginia
   Start Date: 1998-04
   Completion Date: 
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00003222
   Summary: RATIONALE: Vaccines made from melanoma cells may make the body build an immune response to and kill tumor cells. Colony-stimulating factors such as GM-CSF may increase the number of immune cells found in the bone marrow or peripheral blood. Interleukin-2 may stimulate a person's white blood cells to...
   Locations: Cancer Center at the University of Virginia, Charlottesville, United States
----------------------------------------

237. Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms
   NCT ID: NCT02026063
   Status: COMPLETED
   Phase: PHASE3
   Condition: Carcinoid Syndrome
   Intervention: Telotristat etiprate
   Sponsor: Lexicon Pharmaceuticals
   Start Date: 2014-01-14
   Completion Date: 2018-09-12
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02026063
   Summary: The primary objective of this study is to evaluate the long-term safety and tolerability of orally administered telotristat etiprate.
   Locations: Lexicon Investigational Site, Mobile, United States; Lexicon Investigational Site, Stanford, United States; Lexicon Investigational Site, Iowa City, United States
              ... and 40 more locations
----------------------------------------

238. Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
   NCT ID: NCT02304458
   Status: COMPLETED
   Phase: PHASE1
   Condition: Metastatic Melanoma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Hodgkin Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Melanoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Rhabdomyosarcoma; Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Refractory Hodgkin Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Melanoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Refractory Rhabdomyosarcoma; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Melanoma
   Intervention: Ipilimumab; Laboratory Biomarker Analysis; Nivolumab; Pharmacological Study
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2015-03-30
   Completion Date: 2023-03-31
   Has Posted Results: True
   Publications Count: 2
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02304458
   Summary: This phase I/II trial studies the side effects and best dose of nivolumab when given with or without ipilimumab to see how well they work in treating younger patients with solid tumors or sarcomas that have come back (recurrent) or do not respond to treatment (refractory). Immunotherapy with monoclo...
   Locations: Children's Hospital of Alabama, Birmingham, United States; Children's Hospital Los Angeles, Los Angeles, United States; Children's Hospital of Orange County, Orange, United States
              ... and 22 more locations
----------------------------------------

239. A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
   NCT ID: NCT01028222
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma
   Intervention: Nilotinib; DTIC
   Sponsor: Novartis Pharmaceuticals
   Start Date: 2010-06
   Completion Date: 2014-12
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01028222
   Summary: The purpose of this study is to determine whether nilotinib is efficacious in the treatment of metastatic and/or inoperable melanoma harboring a c-Kit mutation.
   Locations: City of Hope National Medical Center City of Hope national Med Ctr, Duarte, United States; University of California San Diego - Moores Cancer Center UCSD Moores Cancer Center, La Jolla, United States; University of California at Los Angeles UCLA, Los Angeles, United States
              ... and 46 more locations
----------------------------------------

240. Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2
   NCT ID: NCT01419639
   Status: COMPLETED
   Phase: PHASE2
   Condition: Neurofibromatosis Type II
   Intervention: Everolimus (RAD001) , Afinitor®
   Sponsor: NYU Langone Health
   Start Date: 2011-10
   Completion Date: 2013-12
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01419639
   Summary: This trial studies whether Everolimus is efficacious in treating neurofibromatosis 2.
   Locations: New York University Medical Center, New York, United States
----------------------------------------

241. Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
   NCT ID: NCT00454363
   Status: COMPLETED
   Phase: PHASE2
   Condition: Gastrin-Producing Neuroendocrine Tumor; Lung Carcinoid Tumor; Metastatic Digestive System Neuroendocrine Tumor G1; Multiple Endocrine Neoplasia Type 1; Pancreatic Glucagonoma; Pancreatic Insulinoma; Pancreatic Polypeptide Tumor; Recurrent Digestive System Neuroendocrine Tumor G1; Recurrent Pancreatic Neuroendocrine Carcinoma; Regional Digestive System Neuroendocrine Tumor G1; Somatostatin-Producing Neuroendocrine Tumor
   Intervention: Laboratory Biomarker Analysis; Pazopanib Hydrochloride; Pharmacological Study
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2007-03
   Completion Date: 2014-12
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00454363
   Summary: This phase II trial studies how well pazopanib hydrochloride works in treating patients with advanced neuroendocrine cancer. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
   Locations: Massachusetts General Hospital Cancer Center, Boston, United States; Dana-Farber Cancer Institute, Boston, United States; M D Anderson Cancer Center, Houston, United States
----------------------------------------

242. A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma
   NCT ID: NCT01153763
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma
   Intervention: GSK2118436
   Sponsor: GlaxoSmithKline
   Start Date: 2010-08-09
   Completion Date: 2016-06-01
   Has Posted Results: True
   Publications Count: 4
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01153763
   Summary: BRF113710 is a Phase II, single-arm, open-label study to assess the efficacy, safety, and tolerability of GSK2118436 administered twice daily as a single agent in subjects with BRAF mutant metastatic melanoma. Subjects will receive 150 mg of GSK2118436 twice daily and continue on treatment until dis...
   Locations: GSK Investigational Site, Los Angeles, United States; GSK Investigational Site, Los Angeles, United States; GSK Investigational Site, San Francisco, United States
              ... and 20 more locations
----------------------------------------

243. Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver
   NCT ID: NCT03472586
   Status: COMPLETED
   Phase: PHASE2
   Condition: Metastatic Malignant Neoplasm in the Liver; Metastatic Uveal Melanoma; Stage IV Uveal Melanoma AJCC v7
   Intervention: Ipilimumab; Nivolumab; Embolization Therapy
   Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
   Start Date: 2018-05-02
   Completion Date: 2024-12-31
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03472586
   Summary: This phase II trial studies ipilimumab and nivolumab with immunoembolization in treating patients with uveal melanoma that has spread to the liver. Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with ...
   Locations: Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, United States
----------------------------------------

244. Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)
   NCT ID: NCT03820986
   Status: COMPLETED
   Phase: PHASE3
   Condition: Malignant Melanoma
   Intervention: Pembrolizumab; Lenvatinib; Placebo for lenvatinib
   Sponsor: Merck Sharp & Dohme LLC
   Start Date: 2019-03-12
   Completion Date: 2024-11-01
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03820986
   Summary: The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combined with lenvatinib (MK-7902/E7080) compared to pembrolizumab alone (with placebo for lenvatinib) as first-line treatment in adults with no prior systemic therapy for their advanced melanoma.

The primary ...
   Locations: The Angeles Clinic and Research Institute ( Site 0707), Los Angeles, United States; UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0704), San Francisco, United States; California Pacific Medical Center Research Institute ( Site 0705), San Francisco, United States
              ... and 116 more locations
----------------------------------------

245. Neoadjuvant and Adjuvant Checkpoint Blockade
   NCT ID: NCT02519322
   Status: COMPLETED
   Phase: PHASE2
   Condition: Cutaneous Melanoma; Mucosal Melanoma; Ocular Melanoma; Stage III Acral Lentiginous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIB Uveal Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IIIC Uveal Melanoma AJCC v7; Stage IV Acral Lentiginous Melanoma AJCC v6 and v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Stage IV Uveal Melanoma AJCC v7
   Intervention: Ipilimumab; Laboratory Biomarker Analysis; Nivolumab; Relatlimab; Therapeutic Conventional Surgery
   Sponsor: M.D. Anderson Cancer Center
   Start Date: 2016-02-02
   Completion Date: 2023-01-26
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02519322
   Summary: This randomized phase II trial studies how well nivolumab with or without ipilimumab or relatlimab before surgery works in treating patients with stage IIIB-IV melanoma that can be removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, and relatlimab, may help t...
   Locations: Memorial Sloan Kettering Cancer Center, New York, United States; M D Anderson Cancer Center, Houston, United States
----------------------------------------

246. Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
   NCT ID: NCT00404235
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma (Skin)
   Intervention: carboplatin; paclitaxel albumin-stabilized nanoparticle formulation
   Sponsor: Alliance for Clinical Trials in Oncology
   Start Date: 2006-10
   Completion Date: 2010-03
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00404235
   Summary: RATIONALE: Drugs used in chemotherapy, such as carboplatin and ABI-007, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

PURPOSE: This phase II tri...
   Locations: Mayo Clinic Scottsdale, Scottsdale, United States; Mayo Clinic - Jacksonville, Jacksonville, United States; Rush-Copley Cancer Care Center, Aurora, United States
              ... and 148 more locations
----------------------------------------

247. Peginterferon and TIL Therapy for Metastatic Melanoma
   NCT ID: NCT02379195
   Status: COMPLETED
   Phase: PHASE1
   Condition: Metastatic Melanoma
   Intervention: Cyclophosphamide; Fludarabine; TIL infusion; Interleukin-2; Peginterferon alfa-2b
   Sponsor: Inge Marie Svane
   Start Date: 2014-11
   Completion Date: 2018-10
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02379195
   Summary: Adoptive T cell therapy with tumor infiltrating lymphocytes (TIL) has achieved impressive clinical results with durable complete responses in patients with metastatic melanoma. The TILs are isolated from the patients own tumor tissue followed by in vitro expansion and activation for around 4-6 weeks...
   Locations: Center for Cancer Immune Therapy, Dept. of Haematology/Oncology, Copenhagen, Denmark
----------------------------------------

248. Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma
   NCT ID: NCT00110994
   Status: COMPLETED
   Phase: PHASE2
   Condition: Cancer; Melanoma
   Intervention: Sorafenib (Nexavar, BAY43-9006); Placebo; Dacarbazine
   Sponsor: Bayer
   Start Date: 2005-04
   Completion Date: 2008-03
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00110994
   Summary: This is a randomized, double blind, placebo controlled, multicenter, phase II study to compare the anti-tumor activity as measured by progression-free survival (PFS) and the tolerability of Sorafenib in combination with Dacarbazine (DTIC) versus DTIC in combination with placebo in subjects with unre...
----------------------------------------

249. To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
   NCT ID: NCT03220217
   Status: COMPLETED
   Phase: PHASE2
   Condition: Gastro-Enteropancreatic Neuroendocrine Tumor
   Intervention: Satoreotide trizoxetan 5-20μg; Satoreotide trizoxetan 30-45μg
   Sponsor: Ipsen
   Start Date: 2017-09-26
   Completion Date: 2019-08-05
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03220217
   Summary: The purpose of this clinical research is to confirm the optimal dose of 68Ga-satoreotide trizoxetan (68Ga-IPN01070), formerly 68Ga-OPS202, as a PET imaging agent to be used to detect and localize gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs). 68Ga-IPN01070 is a radiolabelled imaging agen...
   Locations: UCLA Medical Center, Los Angeles, United States; Medical University of Innsbruck, Innsbruck, Austria; University Clinic for Radiology and Nuclear Medicine, Vienna, Austria
              ... and 2 more locations
----------------------------------------

250. Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity
   NCT ID: NCT01323517
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma
   Intervention: Ipilimumab, Melphalan and Dactinomycin
   Sponsor: Memorial Sloan Kettering Cancer Center
   Start Date: 2011-02
   Completion Date: 2017-08-14
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01323517
   Summary: The purpose of this study is to see the effect of adding a systemic study drug, Ipilimumab, to two standard chemotherapy drugs, Melphalan and Dactinomycin. The study drug Ipilimumab is an antibody to a normal protein found in the body, CTLA-4. This protein normally allows the immune system (the body...
   Locations: Memorial Sloan Kettering Cancer Center, New York, United States
----------------------------------------

251. Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer
   NCT ID: NCT01767636
   Status: COMPLETED
   Phase: PHASE2
   Condition: Carcinoma of the Collecting Ducts of Bellini; Chromophobe Renal Cell Carcinoma; Kidney Medullary Carcinoma; Kidney Oncocytoma; Metastatic Renal Cell Cancer; Papillary Renal Cell Carcinoma; Recurrent Renal Cell Carcinoma; Sarcomatoid Renal Cell Carcinoma; Stage IV Renal Cell Cancer
   Intervention: Pazopanib Hydrochloride
   Sponsor: Mayo Clinic
   Start Date: 2013-05-16
   Completion Date: 2021-01-20
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01767636
   Summary: This phase II trial studies how well pazopanib hydrochloride works in treating patients with kidney cancer that has spread to other places in the body (metastatic). Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Pazopanib hydrochlor...
   Locations: Mayo Clinic in Arizona, Scottsdale, United States; Mayo Clinic in Florida, Jacksonville, United States; Mayo Clinic, Rochester, United States
----------------------------------------

252. Preoperative Alpha Blockade for Pheochromocytoma
   NCT ID: NCT03176693
   Status: COMPLETED
   Phase: PHASE3
   Condition: Pheochromocytoma; Paraganglioma
   Intervention: Phenoxybenzamine; Doxazosin
   Sponsor: University of California, Los Angeles
   Start Date: 2017-05-05
   Completion Date: 2021-10-10
   Has Posted Results: True
   Publications Count: 7
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03176693
   Summary: Pheochromocytoma is a rare, catecholamine (ex. adrenaline) secreting tumor that requires preoperative alpha blockade to minimize intraoperative hemodynamic instability, thereby reducing intra- and postoperative morbidity and mortality. Phenoxybenzamine is a non-selective alpha blocker that is signif...
   Locations: University of California, Los angeles, Los Angeles, United States
----------------------------------------

253. RFT-5-dgA in Patients With Metastatic Melanoma
   NCT ID: NCT00314093
   Status: COMPLETED
   Phase: PHASE2
   Condition: Metastatic Melanoma
   Intervention: RFT5pdgA
   Sponsor: University of Texas Southwestern Medical Center
   Start Date: 2006-04
   Completion Date: 2008-11
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00314093
   Summary: Background:

* CD4+ cells are white blood cells that regulate the immune system by controlling the strength and quality of the immune response.
* CD25+ cells are a subset of CD4+ cells that suppress or prevent immune responses.
* RFT-5-dgA is an immunotoxin (substance that kills specific cells in th...
   Locations: National Cancer Institute (NCI), Bethesda, United States
----------------------------------------

254. Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma
   NCT ID: NCT01827111
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma
   Intervention: ABI-007; Ipilimumab; Phone Call
   Sponsor: M.D. Anderson Cancer Center
   Start Date: 2013-04-25
   Completion Date: 2020-09-21
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01827111
   Summary: The goal of this clinical research study is to learn if the combination of ipilimumab and ABI-007 (abraxane) can help to control metastatic melanoma. The safety of this drug combination will also be studied.

Ipilimumab is designed to increase the immune system's ability to fight cancer.

Abraxane i...
   Locations: University of Texas MD Anderson Cancer Center, Houston, United States
----------------------------------------

255. Trial of pIL-12 Electroporation Malignant Melanoma
   NCT ID: NCT01502293
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma
   Intervention: Tavokinogene Telseplasmid (tavo); OncoSec Medical System (OMS)
   Sponsor: OncoSec Medical Incorporated
   Start Date: 2012-02-14
   Completion Date: 2016-03-21
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01502293
   Summary: This study will assess the safety and effectiveness of different dosing regimens of ImmunoPulse IL-12® in malignant melanoma. ImmunoPulse IL-12® is the combination of intratumoral interleukin-12 gene (also known as tavokinogene telseplasmid \[tavo\]) and in vivo electroporation-mediated plasmid deox...
   Locations: UCSF Helen Diller Comprehensive Cancer Center, San Francisco, United States; John Wayne Cancer Institute, Santa Monica, United States; University of Colorado Denver, Denver, United States
              ... and 3 more locations
----------------------------------------

256. Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)
   NCT ID: NCT01251978
   Status: COMPLETED
   Phase: PHASE2
   Condition: Choroidal Melanoma
   Intervention: Ranibizumab 2 mg; 0.5 mg Ranibizumab
   Sponsor: New England Retina Associates
   Start Date: 2010-07
   Completion Date: 2012-08
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01251978
   Summary: Ranibizumab has proven to be of benefit to improve the perfusion in the retina of patients with Choroidal Melanoma. The investigators consider that higher doses of Ranibizumab can help reduce the number of laser treatments that might be needed to control the tumor.
   Locations: New England Retina Associates, Hamden, United States
----------------------------------------

257. Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma
   NCT ID: NCT02403778
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma
   Intervention: VESANOID; Ipilimumab
   Sponsor: University of Colorado, Denver
   Start Date: 2015-12-17
   Completion Date: 2023-01-18
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02403778
   Summary: The purpose of this study is to assess the safety and efficacy of combined treatment with Ipilimumab and all-trans retinoic acid (ATRA) in melanoma patients.
   Locations: University of Colorado Hospital, Aurora, United States
----------------------------------------

258. Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)
   NCT ID: NCT03783078
   Status: COMPLETED
   Phase: PHASE3
   Condition: Merkel Cell Carcinoma
   Intervention: Pembrolizumab (MK-3475)
   Sponsor: Merck Sharp & Dohme LLC
   Start Date: 2019-02-25
   Completion Date: 2024-02-15
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03783078
   Summary: This is a single-arm, open-label, multicenter, efficacy, and safety study of pembrolizumab in adult and pediatric participants with previously untreated advanced Merkel Cell Carcinoma (MCC). The primary objective of the trial is to assess the objective response rate, as assessed by blinded independe...
   Locations: Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0006), New York, United States; Icahn School of Medicine at Mount Sinai ( Site 0004), New York, United States; Melanoma Institute Australia ( Site 0400), North Sydney, Australia
              ... and 19 more locations
----------------------------------------

259. Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
   NCT ID: NCT03972488
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE3
   Condition: Gastro-enteropancreatic Neuroendocrine Tumor
   Intervention: Lutathera; 30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot); 2.5% Lys-Arg sterile amino acid solution; High dose 60 mg octreotide long-acting repeatable
   Sponsor: Advanced Accelerator Applications
   Start Date: 2020-01-08
   Completion Date: 2027-10-29
   Has Posted Results: True
   Publications Count: 2
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03972488
   Summary: The aim of NETTER-2 was to determine if Lutathera in combination with long-acting octreotide prolongs progression free survival (PFS) in gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients with high proliferation rate tumors (G2 and G3), when given as a first line treatment compared to tr...
   Locations: Yale Cancer Center, New Haven, United States; USF - H. Lee Moffitt Cancer Center and Research Institute, Tampa, United States; University of Iowa Hospitals and Clinics - Oncology, Iowa City, United States
              ... and 37 more locations
----------------------------------------

260. Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)
   NCT ID: NCT01974752
   Status: COMPLETED
   Phase: PHASE3
   Condition: Metastatic; Uveal Melanoma
   Intervention: 75mg selumetinib; placebo; Dacarbazine
   Sponsor: AstraZeneca
   Start Date: 2014-04
   Completion Date: 2016-10
   Has Posted Results: True
   Publications Count: 2
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01974752
   Summary: Selumetinib therapy in patients with metastatic uveal melanoma.
   Locations: Research Site, Los Angeles, United States; Research Site, Aurora, United States; Research Site, Atlanta, United States
              ... and 28 more locations
----------------------------------------

261. Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery
   NCT ID: NCT00626405
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma (Skin)
   Intervention: bevacizumab; carboplatin; paclitaxel albumin-stabilized nanoparticle formulation; temozolomide
   Sponsor: Alliance for Clinical Trials in Oncology
   Start Date: 2008-08
   Completion Date: 2012-11
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00626405
   Summary: RATIONALE: Drugs used in chemotherapy, such as temozolomide, paclitaxel albumin-stabilized nanoparticle formulation, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, c...
   Locations: Providence Cancer Center, Anchorage, United States; Mayo Clinic Scottsdale, Scottsdale, United States; Aurora Presbyterian Hospital, Aurora, United States
              ... and 252 more locations
----------------------------------------

262. Trial of pIL-12/MK-3475 in Metastatic Melanoma
   NCT ID: NCT02493361
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma
   Intervention: Pembrolizumab; pIL-12
   Sponsor: University of California, San Francisco
   Start Date: 2015-08-17
   Completion Date: 2020-03-02
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02493361
   Summary: This is a multicenter, Phase II, open-label, 42-patient single-arm trial of intratumoral pIL-12 electroporation (EP) in combination with pembrolizumab in patients with melanoma. Patients will be evaluated in 2 parts. Part A patients will be selected using a flow cytometric assay that quantifies intr...
   Locations: University of San Francisco, California, San Francisco, United States; Huntsman Cancer Institute, University of Utah, Salt Lake City, United States
----------------------------------------

263. An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
   NCT ID: NCT00410761
   Status: COMPLETED
   Phase: PHASE3
   Condition: Thyroid Cancer
   Intervention: ZD6474 (Vandetanib)
   Sponsor: Genzyme, a Sanofi Company
   Start Date: 2006-11-30
   Completion Date: 2024-07-26
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00410761
   Summary: The purpose of this study is to learn how hereditary or sporadic medullary thyroid cancer patients, treated with ZD6474, react to the drug, what happens to ZD6474 in the human body, about the side effects of ZD6474, and if ZD6474 can decrease or prevent the growth of tumors.
   Locations: Investigational Site Number 3, Little Rock, United States; University Arkansas Site Number : 3, Little Rock, United States; Investigational Site Number 8, San Francisco, United States
              ... and 124 more locations
----------------------------------------

264. A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma
   NCT ID: NCT03635983
   Status: COMPLETED
   Phase: PHASE3
   Condition: Melanoma
   Intervention: NKTR-214; Nivolumab
   Sponsor: Bristol-Myers Squibb
   Start Date: 2018-09-21
   Completion Date: 2024-03-19
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03635983
   Summary: The purpose of the study is to test the effectiveness (how well the drug works), safety, and tolerability of the investigational drug called NKTR-214, when combined with nivolumab versus nivolumab given alone in participants with previously untreated melanoma skin cancer that is either unable to be ...
   Locations: Local Institution - 0187, Tucson, United States; Local Institution - 0014, La Jolla, United States; Local Institution - 0122, Stanford, United States
              ... and 164 more locations
----------------------------------------

265. Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)
   NCT ID: NCT01524783
   Status: COMPLETED
   Phase: PHASE3
   Condition: Advanced NET of GI Origin; Advanced NET of Lung Origin; Neuroendocrine Tumors
   Intervention: Everolimus; Placebo; Best suportive care (BSC)
   Sponsor: Novartis Pharmaceuticals
   Start Date: 2012-03-30
   Completion Date: 2020-08-07
   Has Posted Results: True
   Publications Count: 5
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01524783
   Summary: The purpose of this study is to compare the antitumor activity of everolimus plus best supportive care versus placebo plus best supportive care in patients with progressive nonfunctional neuroendocrine tumor (NET) of gastrointestinal (GI) or lung origin without a history of, or current symptoms of c...
   Locations: University of California San Diego - Moores Cancer Center Regulatory, La Jolla, United States; Scripps Clinic Regulatory, La Jolla, United States; Cedars Sinai Medical Center SC, Los Angeles, United States
              ... and 94 more locations
----------------------------------------

266. BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma
   NCT ID: NCT01512251
   Status: COMPLETED
   Phase: PHASE1
   Condition: BRAF Mutant Metastatic Melanoma
   Intervention: BKM120 Combined with Vemurafenib (PLX4032)
   Sponsor: University of California, San Francisco
   Start Date: 2012-06-09
   Completion Date: 2017-03-21
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01512251
   Summary: This is a phase 1/2 clinical trial with the goal of determining whether the addition of the investigational agent BKM120 to vemurafenib will lead to improved 6-month progression-free survival in patients with BRAFV600E/K mutant melanoma.
   Locations: University of California, San Francisco, San Francisco, United States
----------------------------------------

267. A Study of Pembrolizumab in Patients With Neuroendocrine Tumors
   NCT ID: NCT02939651
   Status: COMPLETED
   Phase: PHASE2
   Condition: Neuroendocrine Tumors
   Intervention: Pembrolizumab
   Sponsor: Fox Chase Cancer Center
   Start Date: 2016-10-26
   Completion Date: 2020-03
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02939651
   Summary: The purpose of this research study is to test if pembrolizumab is safe and effective for treating patients with metastatic high-grade neuroendocrine tumors who have failed platinum based chemotherapy.The study drug, pembrolizumab has been FDA approved for treating a type of skin cancer called melano...
   Locations: Fox Chase Cancer Center, Philadelphia, United States; MD Anderson Cancer Center, Houston, United States
----------------------------------------

268. 3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial
   NCT ID: NCT01563354
   Status: COMPLETED
   Phase: PHASE2
   Condition: Neuroendocrine Carcinoma of the Lung and Thymus
   Intervention: Pasireotide LAR; Everolimus; Pasireotide LAR and Everolimus Combination
   Sponsor: Novartis Pharmaceuticals
   Start Date: 2013-08-16
   Completion Date: 2020-02-10
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01563354
   Summary: This was a multicenter, randomized, phase II study evaluating Everolimus or Pasireotide LAR alone or in combination in adult patients with advanced (unresectable or metastatic) neuroendocrine carcinoma of the lung and thymus
   Locations: Novartis Investigative Site, Aarhus, Denmark; Novartis Investigative Site, Copenhagen N, Denmark; Novartis Investigative Site, Toulouse, France
              ... and 33 more locations
----------------------------------------

269. A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )
   NCT ID: NCT01227551
   Status: COMPLETED
   Phase: PHASE2
   Condition: Malignant Melanoma
   Intervention: Coxsackievirus A21 (CVA21)
   Sponsor: Viralytics
   Start Date: 2011-12-29
   Completion Date: 2016-04-06
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01227551
   Summary: The purpose of this study is to assess the clinical efficacy of Intratumoral (IT) CVA21 in terms of immune-related Progression-Free Survival (irPFS) at 6 months as monitored via immune-related Response Criteria \[irRECIST 1.1\] (revised Response Evaluation Criteria In Solid Tumors \[RECIST\] 1.1).
   Locations: Moores UCSD Cancer Center, La Jolla, United States; St Mary's Medical Center, San Francisco, United States; Mount Sinai Medical Center, Miami Beach, United States
              ... and 7 more locations
----------------------------------------

270. Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy
   NCT ID: NCT00363051
   Status: COMPLETED
   Phase: PHASE2
   Condition: Islet Cell Carcinoma; Neuroendocrine Carcinoma; Neuroendocrine Tumor; Pancreatic Neoplasms
   Intervention: Everolimus 10 mg; Octreotide Depot
   Sponsor: Novartis Pharmaceuticals
   Start Date: 2006-06
   Completion Date: 2012-04
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00363051
   Summary: The purpose of this study was to assess the efficacy and safety of everolimus in the treatment of advanced pancreatic neuroendocrine tumor (NET) not responsive to cytotoxic chemotherapy. All patients were treated with everolimus until either tumor progression was documented using a standard criteria...
   Locations: The University of Alabama at Birmingham, Birmingham, United States; USC Medical Center, Los Angeles, United States; Cedars-Sinai Outpatient Cancer Center/Samuel Oschin Comprehensive Cancer Inst., Los Angeles, United States
              ... and 51 more locations
----------------------------------------

271. A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors
   NCT ID: NCT02983045
   Status: COMPLETED
   Phase: PHASE1
   Condition: Melanoma; Renal Cell Carcinoma; Non Small Cell Lung Cancer; Urothelial Carcinoma; Triple Negative Breast Cancer; HR+/HER2- Breast Cancer; Gastric Cancer
   Intervention: Dose Escalation Doublet: Combination of NKTR-214 + nivolumab; Dose Expansion Doublet: Combination of NKTR-214 + nivolumab; Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab; Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab
   Sponsor: Nektar Therapeutics
   Start Date: 2016-12-19
   Completion Date: 2022-04-28
   Has Posted Results: True
   Publications Count: 3
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02983045
   Summary: In this four-part study, NKTR-214 was administered in combination with nivolumab and with/without other anticancer therapies. Part 1 considered escalating doublet (NKTR 214 + nivolumab) doses to determine the RP2D. Part 2 considered dose expansion cohorts for the doublet (NKTR 214 + nivolumab ± chem...
   Locations: UCSD, Moores Cancer Center, La Jolla, United States; UCLA, Los Angeles, United States; Stanford Cancer Institute, Stanford, United States
              ... and 55 more locations
----------------------------------------

272. Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma
   NCT ID: NCT03200847
   Status: COMPLETED
   Phase: PHASE1
   Condition: Stage IV Melanoma; Stage III Melanoma; Advanced Melanoma
   Intervention: Pembrolizumab with All-Trans Retinoic Acid
   Sponsor: University of Colorado, Denver
   Start Date: 2017-10-31
   Completion Date: 2022-10-19
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03200847
   Summary: This is a Phase I/Ib investigator-initiated open label of the combination of VESANOID and pembrolizumab treatment.
   Locations: University of Colorado Denver, Aurora, United States; Poudre Valley Hospital, Fort Collins, United States
----------------------------------------

273. Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma
   NCT ID: NCT00387751
   Status: COMPLETED
   Phase: PHASE2
   Condition: Recurrent Melanoma; Stage III Skin Melanoma; Stage IV Skin Melanoma
   Intervention: Bevacizumab; Laboratory Biomarker Analysis; Pharmacological Study; Sorafenib Tosylate
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2006-08
   Completion Date: 2010-01
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00387751
   Summary: This phase II trial is studying how well giving bevacizumab together with sorafenib works in treating patients with unresectable stage III or stage IV malignant melanoma. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to gr...
   Locations: Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, United States
----------------------------------------

274. Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma
   NCT ID: NCT01909453
   Status: COMPLETED
   Phase: PHASE3
   Condition: Melanoma
   Intervention: LGX818; MEK162; vemurafenib
   Sponsor: Pfizer
   Start Date: 2013-09-12
   Completion Date: 2024-09-03
   Has Posted Results: True
   Publications Count: 5
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01909453
   Summary: This is 2-part, randomized, open label, multi-center, parallel group, phase III study comparing the efficacy and safety of LGX818 plus MEK162 to vemurafenib and LGX818 monotherapy in patients with locally advanced unresectable or metastatic melanoma with BRAF V600 mutation. A total of approximately ...
   Locations: Retinal Consultants of Alabama P.C., Birmingham, United States; UAB Callahan Eye Hospital, Birmingham, United States; UAB Comprehensive Cancer Center, Birmingham, United States
              ... and 279 more locations
----------------------------------------

275. A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
   NCT ID: NCT00864253
   Status: COMPLETED
   Phase: PHASE3
   Condition: Malignant Melanoma
   Intervention: ABI-007; Dacarbazine
   Sponsor: Celgene
   Start Date: 2009-04-23
   Completion Date: 2014-02-12
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00864253
   Summary: The main purpose of this research study is to compare the safety, tolerability, and anti tumor activity of an investigational drug, ABI-007 versus Dacarbazine in patients with metastatic melanoma who have not previously received chemotherapy. ABI-007 is a new preparation of the active drug paclitaxe...
   Locations: University of Alabama at Birmingham, Birmingham, United States; AZ Cancer Ctr, Scottsdale, United States; Arizona Cancer Center, Tucson, United States
              ... and 109 more locations
----------------------------------------

276. Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma
   NCT ID: NCT01014351
   Status: COMPLETED
   Phase: PHASE2
   Condition: Metastatic Melanoma
   Intervention: Paclitaxel; Carboplatin; Everolimus
   Sponsor: SCRI Development Innovations, LLC
   Start Date: 2010-02
   Completion Date: 2013-08
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01014351
   Summary: Based on data demonstrating synergy between paclitaxel and mammalian target of rapamycin (mTOR) inhibition, the investigators propose that the addition of everolimus to paclitaxel with carboplatin should lead to improvements in efficacy as measured by progression-free survival and response rate.
   Locations: Florida Cancer Specialists, Fort Myers, United States; Northeast Georgia Medical Center, Gainesville, United States; Oncology Hematology of SW Indiana, Evansville, United States
              ... and 9 more locations
----------------------------------------

277. Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
   NCT ID: NCT01642251
   Status: COMPLETED
   Phase: PHASE1
   Condition: Extensive Stage Small Cell Lung Carcinoma; Large Cell Lung Carcinoma; Neuroendocrine Carcinoma; Small Cell Carcinoma; Stage IV Non-Small Cell Lung Cancer AJCC v7
   Intervention: Cisplatin; Etoposide; Veliparib; Placebo
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2012-09-28
   Completion Date: 2018-07-02
   Has Posted Results: True
   Publications Count: 2
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01642251
   Summary: This randomized phase I/II trial studies the side effects and best dose of veliparib when given together with or without cisplatin and etoposide and to see how well they work in treating patients with extensive stage small cell lung cancer or large cell neuroendocrine non-small cell lung cancer that...
   Locations: Loma Linda University Medical Center, Loma Linda, United States; Stanford Cancer Institute Palo Alto, Palo Alto, United States; Rocky Mountain Cancer Centers-Aurora, Aurora, United States
              ... and 425 more locations
----------------------------------------

278. Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain
   NCT ID: NCT02039947
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma and Brain Metastases
   Intervention: Dabrafenib; Trametinib
   Sponsor: Novartis Pharmaceuticals
   Start Date: 2014-02-21
   Completion Date: 2018-02-14
   Has Posted Results: True
   Publications Count: 2
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02039947
   Summary: This is a multi-cohort, open label, Phase II study with Dabrafenib (GSK2118436) and Trametinib (GSK1120212) combination therapy in subject with BRAF mutation-positive melanoma that has metastasized to the brain. This study will evaluate the safety and efficacy of 4 cohorts. Cohorts will consist of; ...
   Locations: Novartis Investigative Site, Birmingham, United States; Novartis Investigative Site, San Francisco, United States; Novartis Investigative Site, Aurora, United States
              ... and 44 more locations
----------------------------------------

279. Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy
   NCT ID: NCT00853047
   Status: COMPLETED
   Phase: PHASE2
   Condition: Carcinoid Syndrome
   Intervention: Telotristat etiprate; Octreotide LAR Depot; Placebo
   Sponsor: Lexicon Pharmaceuticals
   Start Date: 2009-03
   Completion Date: 2014-06
   Has Posted Results: True
   Publications Count: 2
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00853047
   Summary: The purpose of this study is to evaluate the safety and tolerability of telotristat etiprate (LX1606) versus a placebo control in participants with symptomatic carcinoid syndrome not managed by stable-dose long-acting octreotide therapy. Following determination of the maximally tolerated or effectiv...
   Locations: Hematology Oncology Services of Arkansas, Little Rock, United States; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, United States; St. Francis Medical Group Oncology and Hematology Specialists, Indianapolis, United States
              ... and 6 more locations
----------------------------------------

280. Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)
   NCT ID: NCT02155647
   Status: COMPLETED
   Phase: PHASE2
   Condition: Carcinoma, Merkel Cell
   Intervention: Avelumab
   Sponsor: EMD Serono Research & Development Institute, Inc.
   Start Date: 2014-07-03
   Completion Date: 2023-05-03
   Has Posted Results: True
   Publications Count: 15
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02155647
   Summary: This is a multicenter, international, single-arm, open-label, Phase 2 trial to evaluate the efficacy and safety of avelumab in participants with metastatic Merkel cell carcinoma (MCC).
   Locations: UCLA Medical Center, Los Angeles, United States; The Angeles Clinic and Research Institute - West LA, Los Angeles, United States; University of Colorado, Aurora, United States
              ... and 58 more locations
----------------------------------------

281. RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma
   NCT ID: NCT01252251
   Status: COMPLETED
   Phase: PHASE2
   Condition: Uveal Melanoma
   Intervention: RAD001 (Everolimus) and Pasireotide (SOM230) LAR
   Sponsor: Memorial Sloan Kettering Cancer Center
   Start Date: 2010-11
   Completion Date: 2016-06
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01252251
   Summary: The purpose of this study is to find out what effects, good and/or bad, the drugs everolimus and pasireotide have on the patient and on melanoma. Pasireotide is also called SOM-230. Pasireotide is an experimental drug and is not approved by the Food and Drug Administration. Everolimus is also called...
   Locations: Memorial Sloan Kettering Cancer Center, New York, United States
----------------------------------------

282. MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
   NCT ID: NCT00094653
   Status: COMPLETED
   Phase: PHASE3
   Condition: Melanoma; Metastases
   Intervention: MDX-010 (anti-CTLA4) monoclonal antibody; MDX-1379 (gp100) Melanoma Peptide Vaccine
   Sponsor: Bristol-Myers Squibb
   Start Date: 2004-09
   Completion Date: 2009-10
   Has Posted Results: True
   Publications Count: 10
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00094653
   Summary: The purpose of this study is to determine the safety and efficacy of MDX-010 (ipilimumab, BMS-734016) (anti-CTLA4) in combination with MDX-1379 (gp100, BMS-734019) in patients with previously treated, unresectable Stage III or IV melanoma. Survival time will be evaluated, as well as patient response...
   Locations: Arizona Cancer Center, Tucson, United States; University Medical Center, Tucson, United States; City of Hope National Medical Center, Duarte, United States
              ... and 206 more locations
----------------------------------------

283. Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery
   NCT ID: NCT00738361
   Status: COMPLETED
   Phase: PHASE2
   Condition: Intraocular Melanoma
   Intervention: nab-paclitaxel
   Sponsor: Ohio State University Comprehensive Cancer Center
   Start Date: 2008-08
   Completion Date: 2013-04
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00738361
   Summary: RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

PURPOSE: This phase II trial is studying how well paclitaxel albumin-stabil...
   Locations: Ohio State University Comprehensive Cancer Center, Columbus, United States
----------------------------------------

284. Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer
   NCT ID: NCT00328861
   Status: COMPLETED
   Phase: PHASE2
   Condition: Metastatic Melanoma; Metastatic Kidney Cancer
   Intervention: Natural Killer (NK) Lymphocytes; IL-2; Cyclophosphamide; Fludarabine
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2006-05
   Completion Date: 2009-04
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00328861
   Summary: Background:

* Natural killer (NK) cells are large lymphocytes (a type of white blood cell) that are important in the immune response to cancer.
* IL-2 (Aldesleukin) is a substance the body makes that controls the growth and function of many types of cells. The Food and Drug Administration has appro...
   Locations: National Cancer Institute (NCI), Bethesda, United States
----------------------------------------

285. Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)
   NCT ID: NCT01253161
   Status: COMPLETED
   Phase: PHASE2
   Condition: Neuroendocrine Tumors; Carcinoid Tumors
   Intervention: Pasireotide Long Acting Release (LAR)
   Sponsor: H. Lee Moffitt Cancer Center and Research Institute
   Start Date: 2011-02-01
   Completion Date: 2023-03-02
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01253161
   Summary: The goal of this clinical research study is to learn if the study drug, Pasireotide LAR can shrink or slow the growth of Metastatic Neuroendocrine Carcinomas. The safety of this drug will also be studied. The patient's physical state, changes in the size of the tumor, and laboratory findings taken w...
   Locations: Stanford Cancer Institute, Stanford, United States; H. Lee Moffitt Cancer Center and Research Institute, Tampa, United States
----------------------------------------

286. Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma
   NCT ID: NCT03047928
   Status: COMPLETED
   Phase: PHASE1
   Condition: Metastatic Melanoma
   Intervention: Nivolumab; PD-L1/IDO peptide vaccine
   Sponsor: Inge Marie Svane
   Start Date: 2018-02-22
   Completion Date: 2022-12-31
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03047928
   Summary: Combination therapy is becoming more and more general in the treatment of oncological diseases. In this clinical trial combination the standard immunotherapeutic treatment; the programmed death 1 (PD-1) regulatory antibody Nivolumab and a peptide vaccine consisting of programmed death ligand 1 (PD-L...
   Locations: Herlev Hospital, Herlev, Denmark; National Center for Cancer Immune Therapy, Dept. of Oncology, Herlev, Denmark
----------------------------------------

287. Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma
   NCT ID: NCT00109005
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma
   Intervention: Revlimid
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2005-04
   Completion Date: 2009-04
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00109005
   Summary: This study will test whether an experimental drug called Revlimid (lenalidomide) can reduce tumor size and prolong survival in patients with metastatic melanoma (melanoma that has spread beyond the original tumor site). It will also examine the toxicity and blood effects of Revlimid.

Patients 18 ye...
   Locations: National Cancer Institute (NCI), Bethesda, United States
----------------------------------------

288. Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
   NCT ID: NCT01835145
   Status: COMPLETED
   Phase: PHASE2
   Condition: Recurrent Uveal Melanoma; Stage III Uveal Melanoma AJCC v7; Stage IIIA Uveal Melanoma AJCC v7; Stage IIIB Uveal Melanoma AJCC v7; Stage IIIC Uveal Melanoma AJCC v7; Stage IV Uveal Melanoma AJCC v7
   Intervention: Cabozantinib S-malate; Dacarbazine; Laboratory Biomarker Analysis; Temozolomide
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2013-07-31
   Completion Date: 2019-11-01
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01835145
   Summary: This randomized phase II trial studies how well cabozantinib-s-malate works compared with temozolomide or dacarbazine in treating patients with melanoma of the eye (ocular melanoma) that has spread to other parts of the body and cannot be removed by surgery. Cabozantinib-s-malate may stop the growth...
   Locations: University of Alabama at Birmingham Cancer Center, Birmingham, United States; Anchorage Radiation Therapy Center, Anchorage, United States; Alaska Breast Care and Surgery LLC, Anchorage, United States
              ... and 225 more locations
----------------------------------------

289. Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).
   NCT ID: NCT01682083
   Status: COMPLETED
   Phase: PHASE3
   Condition: Melanoma
   Intervention: Dabrafenib; Trametinib; Placebos
   Sponsor: Novartis Pharmaceuticals
   Start Date: 2013-01-08
   Completion Date: 2023-07-31
   Has Posted Results: True
   Publications Count: 6
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01682083
   Summary: This was a two-arm, randomized, double-blind Phase III study of dabrafenib in combination with trametinib versus two placebos in the adjuvant treatment of melanoma after surgical resection. Patients with completely resected, histologically confirmed, BRAF V600E/K mutation-positive, high-risk \[Stage...
   Locations: Novartis Investigative Site, Birmingham, United States; Novartis Investigative Site, Tucson, United States; Novartis Investigative Site, San Francisco, United States
              ... and 207 more locations
----------------------------------------

290. A Phase II, Multi-Center, Open-Label, Uncontrolled Study to Evaluate the Efficacy and Safety of Sorafenib Given Daily in Combination With Repeated 21-Day Cycles of Dacarbazine (DTIC) Chemotherapy in Subjects With Advanced Metastatic Melanoma
   NCT ID: NCT00492297
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma
   Intervention: Sorafenib (Nexavar, BAY43-9006) + Dacarbazine (DTIC)
   Sponsor: Bayer
   Start Date: 2005-04
   Completion Date: 2008-07
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00492297
   Summary: The purpose of this study is to see whether a new type of anti-cancer drug, known as BAY 43-9006, can be given safely and with good effect in combination with dacarbazine (DTIC). DTIC is the current standard chemotherapy drug given for melanoma that has spread through the body. Although this drug ca...
----------------------------------------

291. Melanoma Vaccine With Peptides and Leuprolide
   NCT ID: NCT00254397
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma
   Intervention: Leuprolide; GP100: 209-217(210M) Peptide; MAGE-3 Peptide
   Sponsor: M.D. Anderson Cancer Center
   Start Date: 2005-11
   Completion Date: 2012-10
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00254397
   Summary: The goal of this clinical research study is to learn if the drug leuprolide will increase the level of immune cells in your body. Researchers will also want to know if this drug given together with melanoma vaccines (gp100 and MAGE-3) can improve the ability of tumor fighting immune cells (T cells) ...
   Locations: UT MD Anderson Cancer Center, Houston, United States
----------------------------------------

292. A Study of Vemurafenib in Participants With Metastatic Melanoma
   NCT ID: NCT01307397
   Status: COMPLETED
   Phase: PHASE3
   Condition: Malignant Melanoma
   Intervention: Vemurafenib
   Sponsor: Hoffmann-La Roche
   Start Date: 2011-03-01
   Completion Date: 2016-02-24
   Has Posted Results: True
   Publications Count: 2
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01307397
   Summary: This multi-center study evaluates the safety and efficacy of vemurafenib in participants with BRAF V600 mutation-positive, surgically incurable, and unresectable Stage IIIC or IV (American Joint Committee on Cancer \[AJCC\]) metastatic melanoma.
   Locations: University "Mother Theresa" Hospital Center; Oncology Department, Tirana, Albania; Hospital Britanico; Oncologia, Buenos Aires, Argentina; Fundación CIDEA, Buenos Aires, Argentina
              ... and 277 more locations
----------------------------------------

293. Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor
   NCT ID: NCT00412061
   Status: COMPLETED
   Phase: PHASE3
   Condition: Carcinoid Tumor; Malignant Carcinoid Syndrome
   Intervention: Octreotide; Placebo; Everolimus
   Sponsor: Novartis Pharmaceuticals
   Start Date: 2006-12
   Completion Date: 2013-06
   Has Posted Results: True
   Publications Count: 3
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00412061
   Summary: The purpose of this study was to evaluate whether everolimus 10 mg / day added to treatment with depot octreotide prolongs progression free survival compared to treatment with octreotide alone in patients with advanced carcinoid tumor.
   Locations: University of Arizona / Arizona Cancer Center Deptof Uof A/Arizona Cancer(2), Tucson, United States; Highlands Oncology Group The Center for Chest Care, Fayetteville, United States; Hematology Oncology Services of Arkansas, Little Rock, United States
              ... and 67 more locations
----------------------------------------

294. Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma
   NCT ID: NCT01740297
   Status: COMPLETED
   Phase: PHASE1
   Condition: Melanoma
   Intervention: Talimogene laherparepvec; Ipilimumab
   Sponsor: Amgen
   Start Date: 2013-02-07
   Completion Date: 2021-03-09
   Has Posted Results: True
   Publications Count: 5
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01740297
   Summary: Phase 1b of the study will evaluate the safety of talimogene laherparepvec in combination with ipilimumab. Phase 2 is a randomized study that will evaluate the safety and efficacy of talimogene laherparepvec in combination with ipilimumab versus ipilumumab alone.
   Locations: Research Site, Tucson, United States; Research Site, Beverly Hills, United States; Research Site, Los Angeles, United States
              ... and 37 more locations
----------------------------------------

295. Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)
   NCT ID: NCT01844505
   Status: COMPLETED
   Phase: PHASE3
   Condition: Unresectable or Metastatic Melanoma
   Intervention: Nivolumab; Ipilimumab; Placebo for Nivolumab; Placebo for Ipilimumab
   Sponsor: Bristol-Myers Squibb
   Start Date: 2013-06-11
   Completion Date: 2024-04-19
   Has Posted Results: True
   Publications Count: 8
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01844505
   Summary: The purpose of this study is to show that Nivolumab and/or Nivolumab in combination with Ipilimumab will extend progression free survival and overall survival compared to Ipilimumab alone.
   Locations: Local Institution - 0085, Gilbert, United States; University of Arizona Cancer Center, Tucson, United States; Local Institution - 0046, La Jolla, United States
              ... and 147 more locations
----------------------------------------

296. Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance
   NCT ID: NCT01100528
   Status: COMPLETED
   Phase: PHASE2
   Condition: Ciliary Body and Choroid Melanoma, Medium/Large Size; Ciliary Body and Choroid Melanoma, Small Size; Iris Melanoma; Recurrent Intraocular Melanoma
   Intervention: recombinant interferon alfa-2b; dacarbazine; laboratory biomarker analysis
   Sponsor: Case Comprehensive Cancer Center
   Start Date: 2009-11-11
   Completion Date: 2017-12-14
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01100528
   Summary: RATIONALE: Drugs used in chemotherapy, such as dacarbazine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Recombinant interferon alfa-2b may interfere with the growth of tumor cells. Giving interferon alfa-2b together with da...
   Locations: Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, United States
----------------------------------------

297. Phase IIB TL + YCWP + DC in Melanoma
   NCT ID: NCT02301611
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma
   Intervention: TLPLDC; Placebo
   Sponsor: Elios Therapeutics, LLC
   Start Date: 2015-01
   Completion Date: 2022-05-11
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02301611
   Summary: The majority of melanoma vaccines tested to date have been antigen-specific vaccines targeting melanoma-specific or associated antigens and utilizing a variety of delivery systems and immune-adjuvants. As opposed to testing an "off the shelf" vaccine that might be able to treat a subset of patients,...
   Locations: University of Alabama Birmingham (UAB) Comprehensive Cancer Center, Birmingham, United States; Mayo Clinic - Cancer Clinical Research Office, Phoenix, United States; The University of Arizona Cancer Center, Tucson, United States
              ... and 15 more locations
----------------------------------------

298. Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma
   NCT ID: NCT04099251
   Status: ACTIVE_NOT_RECRUITING
   Phase: PHASE3
   Condition: Melanoma
   Intervention: Nivolumab; Placebo
   Sponsor: Bristol-Myers Squibb
   Start Date: 2019-10-28
   Completion Date: 2027-06-29
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04099251
   Summary: The purpose of this study is to determine the effectiveness of nivolumab adjuvant immunotherapy compared to placebo in adults and pediatric participants after complete resection of Stage IIB/C melanoma with no evidence of disease (NED) who are at high risk for recurrence.
   Locations: Local Institution - 0088, Birmingham, United States; Local Institution - 0126, Tucson, United States; Local Institution - 0087, Springdale, United States
              ... and 126 more locations
----------------------------------------

299. Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
   NCT ID: NCT00060333
   Status: COMPLETED
   Phase: PHASE2
   Condition: Recurrent Melanoma
   Intervention: radiation therapy
   Sponsor: Alliance for Clinical Trials in Oncology
   Start Date: 2003-07
   Completion Date: 2016-04
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00060333
   Summary: This phase II trial is studying how well adjuvant radiation therapy works in treating patients who have undergone surgery for desmoplastic melanoma. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation therapy after surgery may kill any tumor cells remaining after surger...
   Locations: Mayo Clinic Scottsdale, Scottsdale, United States; Mayo Clinic - Jacksonville, Jacksonville, United States; Joliet Oncology-Hematology Associates, Limited - West, Joliet, United States
              ... and 36 more locations
----------------------------------------

300. Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002)
   NCT ID: NCT01704287
   Status: COMPLETED
   Phase: PHASE2
   Condition: Malignant Melanoma
   Intervention: Pembrolizumab; Carboplatin; Paclitaxel; Dacarbazine; Temozolomide
   Sponsor: Merck Sharp & Dohme LLC
   Start Date: 2012-11-20
   Completion Date: 2019-01-31
   Has Posted Results: True
   Publications Count: 9
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01704287
   Summary: This study was conducted to compare survival using pembrolizumab (SCH 900475, MK-3475) or standard chemotherapy in participants with advanced melanoma (MEL) who had progressed after prior therapy.

Initial Treatment Period:

Participants were initially randomized to receive either low-dose (2 mg/kg)...
----------------------------------------

301. Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
   NCT ID: NCT01673854
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma
   Intervention: Ipilimumab; Vemurafenib
   Sponsor: Bristol-Myers Squibb
   Start Date: 2012-09-13
   Completion Date: 2015-05-12
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01673854
   Summary: The purpose of this study is to assess the safety profile of vemurafenib, 960 mg, administered for 6 weeks, followed by ipilimumab monotherapy in patients with BRAF V600 mutated advanced/metastatic melanoma.
   Locations: Beverly Hills Cancer Center, Beverly Hills, United States; Baptist Cancer Institute, Jacksonville, United States; Orlando Health, Inc, Orlando, United States
              ... and 11 more locations
----------------------------------------

302. Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma
   NCT ID: NCT02083354
   Status: COMPLETED
   Phase: PHASE2
   Condition: Cancer; Melanoma
   Intervention: Dabrafenib; Trametinib
   Sponsor: Novartis Pharmaceuticals
   Start Date: 2014-03-18
   Completion Date: 2021-04-19
   Has Posted Results: True
   Publications Count: 2
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02083354
   Summary: This was a single-arm, open-label, multi-center, Phase II study to evaluate dabrafenib and trametinib combination therapy in subjects with BRAF V600 mutation-positive, unresectable or metastatic Acral lentiginous or cutaneous melanoma. This study evaluated the objective response rate (ORR), progress...
   Locations: Novartis Investigative Site, Guangzhou, China; Novartis Investigative Site, Kunming, China; Novartis Investigative Site, Hangzhou, China
              ... and 10 more locations
----------------------------------------

303. Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma
   NCT ID: NCT00471887
   Status: COMPLETED
   Phase: PHASE2
   Condition: Melanoma (Skin)
   Intervention: CP-675,206
   Sponsor: Jonsson Comprehensive Cancer Center
   Start Date: 2007-01
   Completion Date: 2015-03
   Has Posted Results: True
   Publications Count: 3
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT00471887
   Summary: RATIONALE: Monoclonal antibodies, such as ticilimumab (CP-675,206), can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.

PURPOSE: This phase II trial is studying how ...
   Locations: Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, United States
----------------------------------------

304. Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)
   NCT ID: NCT01207687
   Status: COMPLETED
   Phase: PHASE2
   Condition: Vestibular Schwannoma; Neurofibromatosis Type 2
   Intervention: bevacizumab; laboratory biomarker analysis; quality-of-life assessment
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2010-10
   Completion Date: 2014-03
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01207687
   Summary: People who have neurofibromatosis type 2 (NF2) can have tumors that grow on the auditory nerves and cause hearing loss. These tumors are called vestibular schwannomas (VSs), or acoustic neuromas. People with NF2 can also get schwannomas in other parts of their body, as well as tumors called meningio...
   Locations: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, United States; National Cancer Institute, Rockville, United States; Massachusetts General Hospital, Charlestown, United States
----------------------------------------

305. AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
   NCT ID: NCT01024387
   Status: COMPLETED
   Phase: PHASE2
   Condition: Neuroendocrine Tumor; Carcinoid Tumor; Pancreatic Neuroendocrine Tumor
   Intervention: AMG 479
   Sponsor: Dana-Farber Cancer Institute
   Start Date: 2010-03
   Completion Date: 2017-01
   Has Posted Results: True
   Publications Count: 1
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01024387
   Summary: The purpose of this research study is to determine the effectiveness of AMG 479 against carcinoid and pancreatic neuroendocrine tumors. AMG 479 is an antibody that is made in the laboratory. Antibodies are highly specific proteins produced by the body's immune system that recognize foreign substance...
   Locations: H. Lee Moffitt Cancer Center, Tampa, United States; Massachusetts General Hospital, Boston, United States; Dana-Farber Cancer Institute, Boston, United States
----------------------------------------

